Acquired Demyelinating Syndromes: Focus on Neuromyelitis Optica and childhood-onset Multiple Sclerosis by Pelt - Gravesteijn, E.D. (Daniëlle) van
2016
12
OCT
Acquired 
Demyelinating 
Syndromes
 Focus on Neuromyelitis Optica 
 and childhood-onset Multiple Sclerosis
Daniëlle van Pelt
D
aniëlle van Pelt
A
cquired D
em
yelinating Syndrom
es

Acquired Demyelinating Syndromes  
Focus on Neuromyelitis Optica  
and childhood-onset Multiple Sclerosis
Daniëlle van Pelt
AcknowleDgements
The research described in this thesis is supported by the Dutch MS Research Foundation. 
In addition the studies described in chapter 5 and 7 were funded by direct donations to 
MS research at the Hospital for Sick Children (Toronto, Canada) and the Canadian MS Sci-
entific Research Foundation. Besides, the study reported in chapter 9 was supported by 
a program grant provided by the EC 7th framework programme of the Marie Curie Initial 
Training Network, The United Europeans for the Development of Pharmacogenomics in 
Multiple Sclerosis, the Dutch Organization for Scientific Research (ZON—MW) and the 
Brain Foundation Netherlands.
Printing of this thesis was financially supported by the Dutch MS Research Foundation, 
Erasmus University Medical Center Rotterdam, and Sanofi Genzyme. 
 
Acquired demyelinating syndromes: focus on neuromyelitis optica
and childhood-onset multiple sclerosis
ISBN: 978-94-6169-930-5
Lay-out and cover design by Optima Grafische Communicatie, Rotterdam, 
The  Netherlands
Printed by Optima Grafische Communicatie, Rotterdam, The Netherlands
© 2016 E.D. van Pelt, Rotterdam, the Netherlands
Acquired Demyelinating syndromes:
Focus on neuromyelitis optica and childhood-onset multiple sclerosis
Verworven demyeliniserende syndromen:
focus op neuromyelitis optica en multiple sclerose op de kinderleeftijd
Proefschrift
ter verkrijging van de graad van doctor aan de
Erasmus Universiteit Rotterdam
op gezag van de
rector magnificus
Prof.dr. H.A.P. Pols
en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
woensdag 12 oktober 2016 om 9.30 uur
door
elles Daniëlle van Pelt – gravesteijn
geboren te Gouda
Promotiecommissie
Promotor: Prof.dr. R.Q. Hintzen
Overige leden: Dr. C.E. Catsman-Berrevoets
  Dr. A.M.C. van Rossum
  Prof.dr. M.A. Willemsen
Copromotor: Dr. R.F. Neuteboom
tAble oF contents
Chapter 1 General introduction 7
Part one: neuromyelitis optica spectrum disorders
Chapter 2 Incidence of AQP4-IgG seropositive neuromyelitis optica 
spectrum disorders in the Netherlands: about one in a million
33
Chapter 3 Neuromyelitis optica spectrum disorders: comparison of 
clinical and MRI characteristics of AQP4-IgG versus MOG-IgG 
seropositive cases in the Netherlands
41
Part two: Acquired demyelinating syndromes in children
Chapter 4 Application of the 2012 revised diagnostic definitions  for 
paediatric multiple sclerosis and immune-mediated central 
nervous system demyelination disorders
57
Chapter 5 Validation of MRI predictors of multiple sclerosis diagnosis in 
children with acute CNS demyelination
69
Chapter 6 Disease course after CIS in children versus adults: a prospective 
cohort study
83
Chapter 7 Risk genes associated with pediatric-onset MS but not with 
monophasic acquired CNS demyelination
95
Chapter 8 Anti-MOG antibodies plead against MS diagnosis in an ADS 
cohort
111
Chapter 9 Gray matter related proteins are associated with childhood-
onset multiple sclerosis
125
Chapter 10 General discussion 145
Chapter 11 Summary | Samenvatting 169
Chapter 12 Epilogue 177
Dankwoord 179
Authors and Affiliations 182
About the author 183
Publications 184
PhD portfolio 187
Abbreviations 189

2016
12
OCT
Chapter 1
General introduction
9General introduction
1
AcQuireD DemyelinAting synDromes oF the centrAl nerVous system
Acquired demyelinating syndromes (ADS) of the central nervous system (CNS) cover 
a broad spectrum of neurological symptoms caused by infl ammation and damage to 
the myelin sheet.1, 2 Multiple sclerosis (MS) is the most familiar diagnosis within this 
spectrum and most commonly aff ects young adults.3 Previously, CNS demyelination 
was thought to be either one event (i.e. monophasic) or included an ongoing chronic 
relapsing disease course. The latter patients were subsequently diagnosed with MS.4 In 
the past years it became clear that not all patients with relapsing CNS demyelination 
have MS, which has important therapeutic implications. Nowadays, the spectrum of ADS 
includes monophasic demyelinating events like: isolated optic neuritis (ON), transverse 
myelitis (TM), other clinically isolated syndromes (CIS), monophasic neuromyelitis optica 
spectrum disorders (NMOSD), and acute disseminated encephalomyelitis (ADEM).1, 2, 5 In 
addition the spectrum includes more chronic and relapsing types of demyelination like: 
relapsing remitting MS3, secondary progressive MS, primary progressive MS, multiphasic 
ADEM6, ADEM followed by recurrent optic neuritis (ADEM-ON)7 and relapsing NMOSD5. 
These syndromes overlap and therefore can be diffi  cult to recognize and distinguish. In 
case of a fi rst demyelinating event a careful patient history, physical examination and 
adequate diagnostics are of high importance in order to make the accurate diagnosis. 
First other causes should be excluded, like for example infectious diseases, metabolic 
disorders, and vascular diseases.3, 8 The diagnostic process is complicated by the aspect 
of time, since it is diffi  cult to identify the patients who will have a chronic and relapsing 
disease course at the fi rst event. For example, optic neuritis can stay a single event (i.e. 
MS  
NMO 
Optic 
neuritis 
CIS 
ADEM 
Transverse 
myelitis 
ADS 
Figure 1.1 The spectrum of acquired demyelinating syndromes (ADS) of the central nervous system (CNS).
ADS = acquired demyelinating syndromes, ADEM = acute disseminated encephalomyelitis, CIS = clinically iso-
lated syndrome, MS = multiple sclerosis, NMO = neuromyelitis optica.
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idiopathic ON) but also can occur in MS, NMOSD, chronic relapsing inflammatory optic 
neuropathy (CRION)9, or in other autoimmune diseases with CNS involvement.10 In other 
words, the group of ADS patients is heterogeneous and their clinical characteristics are 
dynamic. It can take several years, and in rare cases even decades, before a second and 
NMOSD or MS diagnostic event occurs.5, 11 However, accurate and early diagnoses are of 
importance for the patient for establishing their prognosis and for the correct treatment 
initiation. Figure 1.1 illustrates the spectrum of ADS and its overlap.
The first part of this thesis on ADS focuses on NMOSD and describes the incidence and 
clinical features of NMOSD in the Netherlands. The second part, and main focus of this the-
sis, is on ADS in children. The goal of our studies is to reveal the clinical spectrum of ADS 
and to find diagnostic and prognostic markers, which allow for an early and safe diagnosis.
neuromyelitis oPticA sPectrum DisorDers
Neuromyelitis optica (NMO), previously known as Devic’s disease, is a rare variant of MS, 
characterized by optic neuritis and transverse myelitis.5, 12 Classic NMO, as described by 
doctor Eugene Devic in 1894, was a monophasic illness including coincident bilateral 
optic neuritis and transverse myelitis.13 However, in current literature there are clues that 
earlier cases of NMO have been described.14 In the past years the spectrum of NMO has 
broadened and the nomenclature of Devic’s disease became insufficient and outdated.15 
At present the unifying term neuromyelitis optica spectrum disorders (NMOSD) is used.
In 2004 an important milestone in the field of NMO was reached by the discovery of 
specific antibodies directed against aquaporin-4 (AQP4-IgG), which led to the distinc-
tion of MS.16, 17 The identification of this specific antibody has led to the understanding 
of NMO pathophysiology as a B-cell mediated astrocytopathy, whereas the inflamma-
tory response causes demyelination as collateral damage.18 The timeline and growth in 
knowledge of NMOSD are illustrated in Figure 1.2. In 2006 the antibody was incorporated 
in the diagnostic criteria for NMO.19 Since then diagnostic AQP4-IgG assays have been 
improved.20 In the Netherlands the highly sensitive diagnostic AQP4-IgG cell-based 
assay (CBA) is performed at one centralized NMO expert center at Sanquin Diagnostic 
Services in Amsterdam.21 Aquaporin-4 antibodies are present in the majority of NMOSD 
patients (±77%).15 Serum AQP4 antibodies are highly specific for the disease.22 The 
presence of AQP4-IgG allowed for a broadening of the clinical NMO spectrum including 
limited forms such as isolated or recurrent optic neuritis, transverse myelitis, brainstem 
syndromes (including area postrema syndrome with intractable nausea, vomiting and 
hiccups) and cerebral syndromes (including narcolepsy and acute diencephalic clinical 
syndrome).5, 15 NMOSD diagnosis is based on clinical characteristics supported by AQP4-
IgG status and MRI findings.15 Typical MRI findings in NMO are a longitudinally extensive 
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transverse myelitis (LETM) exceeding three or more contiguous vertebra.19, 23 However 
short, sometimes even asymptomatic, spinal cord lesions can occur in a minority of 
NMOSD patients and might delay NMOSD diagnosis and treatment initiation.24, 25 MRI 
brain lesions occur in up to 70% of the NMOSD patients typically, but not solely, at sites 
with high aquaporin-4 expression.26 Current diagnostic criteria for NMOSD are presented 
in Table 1.1.15 Prior to NMOSD diagnosis other causes for the symptoms including MS, in-
fectious diseases, or systemic autoimmune disease like sarcoidosis, vasculitis or systemic 
lupus erythematosus (SLE), should be excluded. In patients with NMOSD a remarkable 
high rate of other autoimmune diseases has been observed, including thyroid diseases, 
SLE or myasthenia gravis27, which can cause a diagnostic dilemma.28, 29 Interestingly, 
AQP4-IgG can be present years before the first NMOSD attack, as described in patients 
with SLE.30 However, clinical characteristics of NMOSD patients with and without other 
autoimmune diseases seem similar.31
NMOSD represent a group of rare autoimmune diseases: worldwide reported NMO 
incidence rates range from 0.05-0.4 per 100,000 people.32 Exact incidence figures of 
NMOSD in the Netherlands were previously unknown. In most cases the disease has a 
relapsing course.5 NMO is not a genetic disease, although the high rate of autoimmune 
comorbidity in NMO patients and their families reflects a genetic predilection for auto-
immunity and amplified immune response.12 NMO frequently has been misdiagnosed 
as MS.5 In Table 1.2 definitions and characteristics, which can help to differentiate NMO 
from MS, are presented.5, 12, 15 The distinction of NMO from MS is of utmost importance for 
1894: case report 
bilateral ON and TM 
1900 - 1990: 
Monophasic disease 
bilateral ON and TM  
2000 - 2007: 
Monophasic or 
recurrent disease 
characterized by ON 
and TM 
2004: AQP4-IgG 
associated disease 
2007 - present: 
Spectrum of syndromes 
associated with AQP4-IgG 
seropositivity.  
Usually recurrent.  
Including intractable 
hiccups/ nausea and 
vomiting, narcolepsy, 
diencephalic syndrome  
Often associated with 
other autoimmune 
diseases.  
Figure 1.2 Timeline and growth in knowledge of NMOSD, from the case report of doctor Eugene Devic 
in 1894 until present.This figure is adapted from the teaching course ‘Diagnostic criteria for NMO 2014: 
update’ presented by BG Weinshenker at the 30th Congress of the European Committee for Treatment and 
Research in Multiple Sclerosis (ECTRIMS), 2014 Boston. 
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establishing the prognosis and initiating the correct treatment. The treatment of attacks 
and chronic treatment differ significantly between MS and NMOSD. In NMOSD relapses 
are more severe than in MS and cause deterioration and progression of disability.23, 33, 34 
Acute NMOSD relapses should be urgently treated with high dose intravenous methyl-
prednisolone in order to minimise disability.35-37 If corticosteroid therapy is insufficient 
patients can benefit from plasmapheresis. Escalation of the acute therapy improved the 
outcome of NMOSD patients in a large German cohort and decreased the proportion 
of non-responders.38 Preferably relapses and thus further deterioration are prevented. 
Therefore immunosuppressive treatment is indicated in relapsing NMOSD patients.35-37 
AQP4-IgG seropositive patients are at high risk for future relapses and therefore chronic 
treatment is advised in these patients after the first event. MS therapeutics can be po-
tentially harmful for NMOSD patients and should be avoided.39-42 Immunosuppressive 
therapy with azathioprine or mycophenolate mofetil is advised in NMOSD patients.35-37, 43 
table 1.1 Neuromyelitis optica spectrum disorders (NMOSD) diagnostic criteria (as defined by Wingerchuk 
et al. 2015).15
nmosD with AQP4-igg 1. At least 1 core clinical characteristic
2. Positive test for AQP4-IgG
3. Exclusion of alternative diagnoses
nmosD without AQP4-igg
or
nmosD with unknown 
AQP4-igg status
1.  At least 2 core clinical characteristics occurring as a result of one or more 
clinical attacks and meeting all of the following requirements:
 a.  At least 1 core clinical characteristic must be optic neuritis, or acute 
myelitis with LETM, or area postrema syndrome
 b. Dissemination in space (2 or more different core clinical characteristics)
 c. Fulfillment of additional MRI requirements, as applicable
2. Negative tests for AQP4-IgG, or testing unavailable
3. Exclusion of alternative diagnoses
core clinical characteristics 1. Optic neuritis (ON)
2. Acute myelitis
3.  Area postrema syndrome: episode of otherwise unexplained hiccups or 
nausea and vomiting
4.  Acute brainstem syndrome
5.  Symptomatic narcolepsy or acute diencephalic clinical syndrome with 
NMOSD-typical diencephalic MRI lesions
6.  Symptomatic cerebral syndrome with NMOSD-typical brain lesions
Additional mri 
requirements for nmosD 
without AQP4-igg and 
nmosD with unknown 
AQP4-igg status
1.  Acute ON: requires brain MRI showing (a) normal findings or only 
nonspecific white matter lesions, or (b) optic nerve MRI with T2-
hyperintense lesion or T1-weighted gadolinium enhancing lesions 
extending over > ½ optic nerve length or involving the chiasm.
2.  Acute myelitis: requires associated intramedullary MRI lesion extending 
over ≥3 contiguous segments (LETM), or ≥3 contiguous segments of focal 
spinal cord atrophy in patients with history compatible with acute myelitis
3.  Area postrema syndrome: requires associated dorsal medulla/area 
postrema lesions
4.  Acute brainstem syndrome: requires associated periependymal brainstem 
lesions
13
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In case of failure of the first-line treatments, rituximab should be considered. Future im-
munotherapeutic targets include complement proteins, the IL-6 receptor, neutrophils, 
eosinophils, CD19 and AQP4.12, 36, 44
At the Dutch NMO expert center, which includes Sanquin Diagnostic Services in 
Amsterdam and the NMO expert clinic at Erasmus MC in Rotterdam, we focus on the 
accurate diagnosis and treatment of NMOSD patients. The expert center is a referral 
center for clinicians in the Netherlands for the confirmation of NMOSD diagnosis and 
treatment advice.
table 1.2 Definitions and characteristics of MS and NMOSD (based on: Wingerchuk et al. 20075, Pittock et 
al. 201512, Wingerchuk et al. 2015.15
ms nmosD
Definition CNS symptoms and signs that 
indicate the involvement of the white 
matter tracts
Evidence of dissemination in space 
and time based on clinical or MRI 
findings
No other explanation
Core clinical characteristics (i.e. ON, 
TM, area postrema syndrome, acute 
brainstem syndrome, narcolepsy, 
diencephalic syndrome, other cerebral 
syndrome)
Supported by typical MRI findings 
and/ or AQP4-IgG seropositivity
No other explanation
Clinical course 85% relapsing remitting
15% primary progressive
Not monophasic
80-90% relapsing course
10-20% monophasic course
Median age of onset (years) 29 39
Sex (F:M) 2:1 9:1
Secondary progressive course Common Rare
MRI brain Periventricular white matter lesions Usually normal or nonspecific 
white matter lesions; 10% unique 
hypothalamic, callosal, splenial, 
periventricular, periaqueductal, 
medullary, brainstem
MRI spinal cord Short segmented peripheral lesions Longitudinally extensive (≥3 vertebral 
segments) central lesions
CSF white blood cell number 
and differential count
Mild pleocytosis
Mononuclear cells
Occasional prominent pleocytosis
Polymorphonuclear cells and 
mononuclear cells
CSF oligoclonal bands 85% 15-30%
Coexisting autoimmune 
disease
Rare Common: SLE, SS, MG, thyroid, APL
Attack prevention therapies Interferon-β, glatiramer acetate, 
fingolimod, natalizumab
Azathioprine, mycophenolate mofetil, 
rituximab, mitoxantrone
APL = antiphospholipid syndrome, AQP4 = aquaporin-4, CNS = central nervous system, CSF = cerebrospinal flu-
id, MG = myasthenia gravis, MRI = magnetic resonance imaging, MS = multiple sclerosis, NMOSD = neuromyeli-
tis optica spectrum disorders, ON = optic neuritis, SLE = systemic lupus erythematosus, SS = Sjogren’s syndrome, 
TM = transverse myelitis. 
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AcQuireD DemyelinAting synDromes in chilDhooD
ADS also occur in children and, although rare, can evolve into childhood-onset MS.8, 11 
Diagnosing childhood-onset ADS can be challenging due to unfamiliarity of clinicians 
with these rare diseases. Furthermore, children can be too young to report their 
symptoms to their caregivers. Symptoms can be mild and usually are self-limiting and 
therefore a delay can occur before a clinician is consulted. Up to 10% of all MS patients 
have their first attack during childhood, prior to their 18th birthday.8 In the Netherlands 
a nationwide prospective study was started in 2007 investigating ADS in children.45 
The main goal of the PROUDkids study (PRedicting the OUtcome of a Demyelinating 
event in children) is to identify prognostic factors, which predict a future MS diagnosis 
at the first event of ADS. Children with a first event of ADS and their families face their 
lives with uncertainty about their future.46 For this reason, adequate counselling, early 
diagnosis and treatment initiation are of utmost importance. Reported incidence rates 
of pediatric ADS range from 0.66 per 100,000 in the Netherlands to 1.66 per 100,000 
table 1.3 IPMSSG consensus definitions for acquired demyelinating syndromes in children (as defined by 
Krupp et al. 2013).51
cis
Clinically Isolated 
Syndrome
•  A first monofocal or multifocal CNS demyelinating event; encephalopathy is absent, 
unless due to fever
ADem
Acute 
Disseminated 
Encephalomyelitis
•  A first polyfocal clinical CNS event with presumed inflammatory cause
•  Encephalopathy that cannot be explained by fever is present
•  MRI typically shows diffuse, poorly demarcated, large, >1–2 cm lesions involving 
predominantly the cerebral white matter; T1 hypointense white matter lesions are rare; 
Deep gray matter lesions (e.g. thalamus or basal ganglia) can be present
•  No new symptoms, signs or MRI findings after three months of the incident ADEM
multiphasic 
ADem
New event of ADEM three months or more after the initial event that can be associated 
with new or re-emergence of prior clinical and MRI findings. Timing in relation to steroids 
is no longer pertinent.
ms
Multiple Sclerosis
Any of the following:
•  Two or more nonencephalopathic CNS clinical events separated by more than 30 days, 
involving more than one area of the CNS
•  Single clinical event and MRI features rely on 2010 Revised McDonald criteria52 for DIS 
and DIT (but criteria relative for DIT for a single attack and single MRI only apply to 
children ≥12 years and only apply to cases without an ADEM onset)
•  ADEM followed three months later by a nonencephalopathic clinical event with new 
lesions on brain MRI consistent with MS
nmo
Neuromyelitis 
Optica
All are required:
• Optic neuritis
• Acute myelitis
At least two of three supportive criteria
• Contiguous spinal cord MRI lesion ≥3 vertebral segments
• Brain MRI not meeting diagnostic criteria for MS
• AQP4-IgG seropositive status
DIS = dissemination in space, DIT = dissemination in time. 
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children per year in other cohorts.1, 45, 47-49 Approximately 5 – 10 children are diagnosed 
with MS per year in the Netherlands. In 2007 the International Pediatric MS Study Group 
(IPMSSG) first developed diagnostic criteria for childhood-onset ADS.50 In 2012 these cri-
teria were revised based on the tremendous growth in research and gain in knowledge 
of childhood-onset ADS.51 The current IPMSSG definitions of the various ADS subtypes 
are presented in Table 1.3.
A first demyelinating event in children can present with symptoms caused by a single 
lesion (monofocal) or by multiple lesions (polyfocal).52 In the Dutch ADS cohort 22% of 
the children presented with ON, 24% with ADEM and 30% with polyfocal CIS without 
encephalopathy.45 Any type of ADS can be the first presentation of MS in children. Based 
on previous cohort studies, it is estimated that 21-32% of children who presented with a 
first event of ADS will have a future diagnosis of MS.53, 54 MS percentages differ between 
the various reported pediatric ADS cohorts.53-56 This is partly explained by the introduc-
tion and revision of diagnostic criteria, differences in study design and referral bias.52
ADEM is a relatively common subtype of ADS, especially in young children.6 The acute 
event of ADEM is often preceded by viral infections and characterized by polyfocal neu-
rological deficits and encephalopathy. Encephalopathy, defined as behavioural changes 
and or alterations in consciousness not explained by fever51, is not a typical feature of 
MS.53 Children with ADEM usually have a good prognosis.57, 58 A minority of children with 
ADEM have a severe deteriorating disease course, which can lead to ICU admission and 
sometimes death.58, 59 MRI typically shows large poorly demarcated lesions in the white 
and gray matter (basal ganglia).60, 61 The symptoms and MRI findings of ADEM can fluctu-
ate within three months after the first onset of symptoms.51, 62 Fluctuations within this 
time period are considered as part of one event.51 ADEM usually is monophasic, but in 
rare cases a second event of ADEM can occur (i.e. multiphasic ADEM).57, 63 A minority of 
children with ADEM are diagnosed with MS during follow-up.51, 60 In the Dutch cohort 5 
out of 92 children with ADEM (6%) converted to MS during follow-up.58 However, one 
event of ADEM followed by a second non-ADEM event might still reflect a transient de-
myelinating disease. Therefore, children with ADEM have to fulfill strict criteria prior to 
MS diagnosis: i.e. ADEM should be followed by two non-encephalopathic events, or one 
new event with the appearance of new MS-specific MRI lesions fulfilling dissemination 
in time and space.51 In addition, a disease course with isolated relapsing optic neuritis 
can occur after the first event of ADEM (ADEM-ON).7
NMO occurs approximately in 3% of all children with ADS.45, 64 Children with NMO can 
have a very diverse clinical presentation with diffuse ADEM-like inflammatory lesions 
on first brain MRI.64-67 In one study of 88 children with AQP4-IgG seropositive NMOSD, 
45% had episodic cerebral manifestations including encephalopathy.68 Since the clini-
cal syndromes of ADEM and NMO can overlap in children, AQP4-IgG testing should be 
considered in children with an ADEM-like event including ON and LETM.51, 64, 65 A recent 
Chapter 1
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American study in 38 children with NMO demonstrated the NMOSD 2015 criteria apply 
well in the childhood setting (sensitivity 97%) and could diminish treatment delay in 
children with NMOSD.69
ms diagnosis in childhood
Prognostic factors for a future MS diagnosis in children are: female gender, age at onset 
≥ 10 years old, onset of symptoms without encephalopathy, elevated IgG index and/or 
positive oligoclonal bands in cerebrospinal fluid (CSF), presence of MS-like lesions on 
MRI.53-55 As in adults, children who had a clinical event of CNS demyelination supported 
by clinical and/or radiological evidence of dissemination in time and space can be diag-
nosed with MS.51, 70 Alternative diagnoses should be excluded. The differential diagnosis 
of MS in children is much more complex than in adults and includes a long list of other 
diagnoses like CNS infectious diseases, neoplasms, leukodystrophy, and inflammatory 
diseases.8, 71 Additional laboratory results and MRI can aid in the diagnostic workup 
and differentiation of ADS from other diseases. MRI is an important diagnostic tool in 
childhood-onset ADS by confirming demyelinating whiter matter lesions. In the past 
years several MRI criteria have been developed for early MS diagnosis and distinction 
from other ADS subtypes and alternative diagnoses in children.61, 72, 73 MRI in MS patients 
typically shows T2 lesions in locations characteristic for MS: periventricular, juxtacortical, 
infratentorial and spinal cord.70 Unique for the current 2010 McDonald diagnostic MRI 
criteria for adults is the opportunity to confirm MS diagnosis at the incident event. Sev-
eral studies have confirmed that the 2010 McDonald MRI criteria, designed for adults, 
table 1.4 MRI criteria childhood-onset MS.
2010 McDonald MRI criteria51, 52 Verhey criteria61
original 
criteria
Dissemination in space:
≥ 1 lesion in 2 of 4 characteristic areas:
- periventricular
- juxtacortical
- infratentorial
- spinal cord
Dissemination in time:
New T2 and/or gadolinium-enhancing lesion(s) on 
follow-up MRI or
Simultaneous presence of asymptomatic gadolinium-
enhancing and non-enhancing lesions*
≥1 T1 hypointense lesion and
≥1 periventricular lesion
Purpose Prognostic and diagnostic for MS in adults Prognostic for MS in a childhood-
onset ADS population
sensitivity 100%77 84%61
specificity 86%77 93%61
*at the first event this criterion applies to children ≥12 years old according to IPMSSG 2012 consensus 
definitions.51
17
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apply well in pediatric populations and led to an earlier MS diagnosis.56, 74-77 In a large 
Canadian cohort of 212 children with ADS the sensitivity of the 2010 criteria applied at 
baseline was 100%, the specificity 86%.77 Compared with adults, children with MS have 
a higher number of total T2 lesions at disease onset.78, 79 In Table 1.4 the most recent MRI 
criteria for childhood-onset MS are presented.
CSF analysis can be supportive for the MS diagnosis and for the exclusion of other 
diagnoses.80 CSF oligoclonal bands (OCB) are detected in 92% of pediatric MS patients. 
In contrast, CSF OCB are uncommon in children with ADEM.57 In a large German cohort 
including 357 children with isolated optic neuritis the presence of CSF OCB at onset was 
an independent predictor of MS diagnosis.81
course and prognosis of childhood-onset ms
Children with MS have more frequent relapses and more severe attacks than adults with 
MS.82-84 A primary progressive course (PP-MS) is extremely rare in children with MS.83, 85 
In case PP-MS is suspected in children, clinicians should carefully consider alternative 
diagnoses.8, 11 Despite a relatively higher relapse rate, disease progression is slower in 
children than in adults with MS.85, 86 A possible explanation for this could be that the de-
veloping CNS of childhood-onset MS patients has more plasticity to recover.85 However, 
children with MS reach states of irreversible disability at a younger age, approximately 
10 years earlier than adults with MS.86, 87 Indicating that there is an endpoint in the plas-
ticity of the CNS. Clinical symptoms of children with MS can be comparable with adults, 
but cognitive dysfunction and fatigue occur probably more frequently in children than 
in adults.88-93 Cognitive impairment is reported in nearly one-third of the children with 
MS and their cognitive outcome is heterogeneous.90
risk factors in childhood-onset ms
MS is a complex multifactorial disease in which environmental and genetic factors in-
teract.3, 94 However, the exact cause of MS is unknown. First degree relatives of a patient 
with MS have an increased MS risk of 2-5%.94 MS risk in monozygotic twins is approxi-
mately 25% and not 100% as would be expected if MS solely was a genetic disease.94, 95 
The presence of the major HLA-DRB1*15 MS risk allele increases MS risk in children.53, 96, 97 
It was shown in a large Canadian pediatric ADS cohort that children harbouring one or 
two HLA-DRB1*15 alleles were more likely to be diagnosed with MS than children with 
ADS lacking HLA-DRB1*15 alleles.97 Large international MS genome-wide association 
studies (GWAS) have been performed in search of novel genetic variants in adults.98, 99 
Up to now 200 MS risk single nucleotide polymorphisms (SNPs) have been identified.100 
Although there are strong genetic determinants of MS, epidemiological studies have 
shown environmental factors that are involved in the etiology of MS as well.101 Children 
with ADS are an interesting group to study these environmental risk factors for MS, since 
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children are close to the onset of the disease and are not exposed to as many different 
environmental factors as adults. Studying children with MS might reveal novel risk fac-
tors and insights in the disease mechanism of MS. Epidemiological studies have shown 
a latitude in MS prevalence, whereas MS is more prevalent in countries remote from the 
equator.101-103 This had led to the hypothesis that vitamin D deficiency is a potential risk 
factor for MS, since people who live further from the equator are less exposed to sunlight 
and have lower levels of vitamin D. In both adults and children with MS, lower serum 
vitamin D levels are associated with a higher MS risk and higher relapse rates.53, 104-106
Moreover, migration studies have shown that, children who were born in high MS 
prevalence countries and move to countries with low MS prevalence during childhood, 
adapt to the low risk of the country where they live.101, 107, 108 Suggesting exposure to spe-
cific environmental factors early in life contributes to MS risk. Previous viral infections 
have been studied as a potential risk factor for MS. Several studies have confirmed the 
significant increased frequency of Epstein-Barr virus (EBV) seropositivity in adults and 
children with MS as compared with healthy controls and patients with a monophasic 
demyelinating event.53, 109-114 There are concerns vaccinations might increase the risk of 
CNS demyelination, but in a large case-control study including 780 MS cases and 3885 
controls no associations were found between hepatitis B vaccination, human papil-
loma virus (HPV) vaccination, or vaccinations of any type and CNS demyelination.115 In 
childhood-onset MS both boys and girls are equally affected, but after puberty females 
are more often affected.11, 86 This indicates that gender and puberty enhance MS risk.116 
Smoking increases risk of adult-onset MS117, 118. A French cohort study reported the risk 
of MS is increased two-fold in children who were exposed to second hand smoking.119 
Early age obesity is associated with an increased MS risk.120, 121 An association that can 
be confounded by vitamin D status, since vitamin D levels are lower in obese people. 
However, in a large Swedish cohort an interaction was observed in obesity and HLA-
DRB1*15.122 When adjusted for vitamin D status, obesity caused an increased MS risk. 
Furthermore, higher dietary salt intake might contribute to MS severity and relapse 
rate.123 A recent American study did not find an association between higher sodium 
intake and MS risk in children.124
treatment of childhood-onset ADs
The care of children with ADS should be managed in multidisciplinary teams.11, 125 The 
Erasmus MC Sophia Children’s hospital has a national expert center for childhood-onset 
MS and variants within the spectrum of ADS. The team includes pediatric and adult MS 
neurologists, nurses, physiotherapists, occupational therapists, neuropsychologists, 
ophthalmologists, urologists and ambulatory teachers. A specialized pediatric MS 
nurse has a central role in coordinating the care and counselling of children with ADS. 
The center has expertise in the acute and chronic treatment of children with ADS. In 
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addition, it has an advisory role for pediatricians and neurologists in the Netherlands, 
who are less frequently consulted with children with ADS. The center has an important 
role in counselling, increasing the awareness of childhood-onset ADS and educating 
the school system. For example, via a special website (http://www.kindermscentrum.
nl/) and the organisation of an annually informative day, where children with MS and 
their families can meet and share their experiences. At the specialized outpatient clinic 
children are guided in the transition from pediatric to adult care.
The acute treatment of children with ADS is with intravenous corticosteroid thera-
py.11, 126, 127 The common regimen is 10-30 mg/kg/dose of methylprednisolone intrave-
nous for 3 – 5 days. In case children do not respond to the first pulse of corticosteroids, 
a second pulse could be considered. Intravenous immunoglobulins or plasmapheresis 
could be considered in the acute phase when children not tolerate or not respond to 
corticosteroids.
The effect of chronic immunomodulatory treatment on MS is well established in 
adults128, but is less proven in children.129 The small numbers of patients and more strict 
ethical concerns challenge therapeutic trials in children with MS.130 First-line treatment 
with interferon-β or glatiramer acetate have not been formally evaluated in children with 
MS.129 However, several case series report a reduction in relapse rate and an overall high 
safety-profile of those first-line therapies in children with MS.129, 131 Most notable side ef-
fect of interferon-β is a transient increase of liver transaminases.52, 131 Side effects are less 
severe in case the dose is titrated. Currently DMT is initiated at 25% of the full dose and 
titrated gradually. Long- term effects on growth, puberty and adverse effects of immu-
nomodulatory therapies for MS in children have yet to be established.127 MS is a chronic 
and ongoing disease and despite the initiation of DMT relapses can still occur. Switching 
to more aggressive second-line therapy with more severe side effects requires a care-
ful consideration of the potential risks and benefits per individual patient. The IPMSSG 
provided a definition for inadequate treatment response and recommends switching 
treatments in case children are compliant on full-dose therapy for at least 6 months and 
have an increase or no reduction in relapse rate, or new MRI lesions as compared with the 
pre-treatment period, or in case they had 2 or more relapses within a 12-month period 
or less.129 Options for switching are, change between first-line therapies, or switch to 
second-line therapy with natalizumab. An Italian study reported a cohort of 101 children 
of whom the majority tolerated natalizumab well.132 In this cohort strong MS suppres-
sion was observed with only 9 relapses during a mean follow-up of 34.2± 18.3 months. 
Long-term effects of natalizumab in children are unknown and there are concerns for 
the risk of progressive multifocal leukoencephalopathy (PML).132, 133 Patients at high risk 
of PML can be identified by serum anti-JC virus antibodies.134 Children at high risk of PML 
might switch to oral second-line therapy with fingolimod in the future. A Brazilian study 
reported no serious adverse events of fingolimod in 17 children with MS.135 The effect 
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and safety of fi ngolimod is investigated in the ongoing PARADIGMS trial: a double-blind 
randomized controlled trial which compares the safety and eff ect of fi ngolimod versus 
intramuscular interferon-β-1a.136 Recently, new oral fi rst-line therapies came available 
for adults with MS: dimethyl fumarate and terifl unomide.137, 138 First-line treatment with 
dimethyl fumarate was safe and well tolerated in a small cohort of 13 American children 
with MS.139 Novel exciting MS therapeutics are currently underway.140
seArch For new biomArkers: myelin oligoDenDrocyte 
glycoProtein AntiboDies
Current additional investigations, including laboratory fi ndings in blood (AQP4-IgG) 
and CSF (oligoclonal bands) and MRI techniques, lack sensitivity to accurately diagnose 
patients with the subtype of ADS at the fi rst event. This underscores the urgent need 
for new biomarkers, which can help to distinct monophasic ADS from chronic relaps-
ing ADS including NMOSD and MS.141, 142 Interesting markers are antibodies directed to 
myelin oligodendrocyte glycoprotein (MOG-IgG) or other myelin peptides.143 Myelin 
oligodendrocyte glycoprotein is a protein expressed exclusively in the CNS on the sur-
face of the myelin sheath and oligodendrocytes (Figure 1.3).143, 144 The protein is a minor 
component of myelin (0.05%) and is located at the outermost lamella of the myelin 
sheet. Antibodies directed to MOG (MOG-IgG) have been shown to induce or contribute 
to demyelination in various animal models. Optimization of antibody detection has 
enabled the reliable identifi cation and association of MOG-IgG with a spectrum of CNS 
demyelinating disorders, including ADEM, bilateral and recurrent ON, as well as LETM in 
both children and adults.145
Oligodendrocyte
Surface
Myelin sheath
Neuron
MOG
MOG
Figure 1.3 Schematic view of oligodendrocytes and proteins of the myelin sheath adapted from Hemmer 
et al.144
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scoPe oF this thesis
This thesis focuses on two important topics within the spectrum of acquired demyelinat-
ing syndromes (ADS): neuromyelitis optica spectrum disorders (NMOSD) and childhood-
onset ADS including MS. Both NMOSD and childhood-onset ADS, are rare variants within 
the spectrum of demyelination and can be diffi  cult to recognize. In general, early and 
correct diagnoses are of importance for both patient groups for accurate counselling 
and for early treatment possibilities. Here we aimed to reveal the spectrum of NMOSD 
in adults and of ADS in children, and to improve the diagnostic process. In addition, we 
searched for prognostic and diagnostic biomarkers in ADS.
The fi rst part of this thesis focuses on NMOSD. In chapter 2 the nationwide incidence 
of AQP4-IgG seropositive NMOSD in the Netherlands was assessed. In chapter 3 we 
investigated whether antibodies directed to MOG (MOG-IgG) are present in AQP4-IgG 
seronegative NMOSD patients, and compared the clinical features of MOG-IgG seroposi-
tive patients versus AQP4-IgG seropositive and seronegative NMOSD patients.
The second part of this thesis describes the spectrum of ADS in children and our 
search for prognostic markers. In chapter 4 we investigated the utility of the 2012 
revised International Pediatric Multiple Sclerosis Study Group (IPMSSG) diagnostic 
defi nitions for childhood-onset ADS. Furthermore, MRI predictors for MS diagnosis in 
children with a fi rst event of ADS were validated in chapter 5. In chapter 6 we studied 
the disease course after the onset of CIS in children and adults, and compared the time 
to MS diagnosis and relapse rates. We investigated whether genetic risk loci identifi ed 
in adults with MS are associated with a risk for childhood-onset MS, and if these genes 
can predict MS diagnosis in children presenting with ADS in chapter 7. In chapter 8 we 
studied if serum MOG-IgG could distinguish the diff erent subtypes of childhood-onset 
ADS and if MOG-IgG could predict the disease course after the fi rst event. In addition, we 
searched for prognostic biomarkers for MS in cerebrospinal fl uid in chapter 9.
The main fi ndings of this thesis and interpretation of our results are discussed in 
chapter 10. At the end suggestions for future research are described.
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AbstrAct
Neuromyelitis optica (NMO) is a rare autoimmune disease affecting the optic nerves 
and spinal cord. In the majority of NMO patients anti-aquaporin-4 antibodies (AQP4-
IgG) are detected. Here we assessed a nationwide incidence of AQP4-IgG seropositive 
NMO spectrum disorders (NMOSD) in the Netherlands based on results of one central 
laboratory. Data were collected since the introduction of the highly sensitive cell based 
assay for six consecutive years. Samples of 2,795 individual patients have been received, 
of them 94 (3.4%) were seropositive. Based on the Dutch population with 16,6 million 
inhabitants the mean incidence of AQP4-IgG seropositive NMOSD was calculated at 0.09 
per 100,000 people.
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introDuction
Neuromyelitis optica (NMO) is a rare autoimmune disease classically affecting the 
optic nerves and spinal cord.1 Exact incidence figures of NMO in the Netherlands are 
currently unknown. The clinical spectrum of NMO has broadened in the past years and 
besides Devic’s syndrome it includes limited forms such as isolated or recurrent optic 
neuritis, transverse myelitis, brainstem syndromes and other cerebral presentations.2, 3 
In approximately 77% of the patients with NMO spectrum disorders (NMOSD) specific 
antibodies against aquaporin-4 (AQP4-IgG) are detected.2 In the Netherlands diagnostic 
testing of these antibodies is performed in one centralised NMO expert centre. This pro-
vides a unique chance to get insight in a nationwide incidence of AQP4-IgG seropositive 
NMOSD. Epidemiological figures of NMOSD are of interest for patient care and counsel-
ing and for the estimation of the socioeconomic burden of the disease. The purpose of 
this study is to estimate a nationwide incidence of NMOSD in the Netherlands.
methoDs
Patients
This study was conducted at the Dutch national NMO expert centre which includes 
Sanquin Diagnostic Services in Amsterdam and the NMO expert clinic at the Erasmus 
university Medical Centre (Erasmus MC) in Rotterdam. We collected demographic data 
(age and gender) from serum samples sent for routine AQP4-IgG diagnostics. Data were 
collected since the introduction of the highly sensitive cell based assay (CBA) for AQP4-
IgG detection in May 2009 for six consecutive years. Samples sent in from abroad, mainly 
Belgium and the Dutch Caribbean, were excluded from this study (n=139 patients). Of 
these foreign patients 8 were AQP4-IgG seropositive. Incidence rates were calculated as 
the number of AQP4-IgG seropositive patients per year divided by the number of Dutch 
inhabitants per 100,000 people. Population figures were extracted from Statistics Neth-
erlands.4 From the patients known at the Erasmus MC in Rotterdam clinical data were 
collected. Magnetic resonance images (MRIs) were evaluated for the presence of lesions, 
longitudinally extensive transverse myelitis (LETM)3 and cerebral NMO-like lesions.5 In 
five patients known at Erasmus MC the diagnosis of NMOSD was made prior to the time 
of the AQP4-IgG assay in 2009 based on their clinical characteristics and therefore they 
were not included in the incidence calculations. This study was approved by the Medical 
Ethical Committee of the Erasmus MC in Rotterdam. All patients from the Erasmus MC 
provided informed consent.
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AQP4-igg cell based assay
We used a CBA for AQP4-IgG detection as has previously been described.6 In short, 
patient serum was incubated with HEK293 cells transiently transfected with AQP4-M23 
(final serum dilution 1:20). After washing, cells were subsequently incubated with 
goat anti-human IgG Allophycocyanin (APC) conjugated secondary antibody and 
analysed after washing using fluorescence-activated cell sorter (FACS). The cut-off was 
determined in every assay as average deltaMFI + 10 standard deviations of 8 individual 
negative control sera.
statistical analysis
Statistical analysis was performed using SPSS 21.0. The Chi-Square test and Mann-
Whitney U test were used to compare categorical and continuous data respectively.
results
During six consecutive years, from May 2009 until May 2015, 3,207 samples of 2,795 
individual Dutch patients have been received for AQP4-IgG testing. Samples were sent 
from 85 different hospitals including all 8 university hospitals. Of all included patients 94 
(3.4%) were seropositive. Two hundred and forty children and adolescents less than 18 
years old were included, of them 8 (3.3%) were AQP4-IgG seropositive. The mean age of 
AQP4-IgG seropositive patients was 47.6 years ± 18.2 compared with 41.0 years ± 16.1 in 
the seronegative group (p<0.01). Seventy-eight (83%) of the seropositive patients were 
female in contrast to 1,698 (63%) female patients in the seronegative group (p<0.01). 
The incidence rates of 6 consecutive years are presented in Table 2.1.
table 2.1 Incidence rates of 6 consecutive years of AQP4-IgG seropositive NMOSD in the Netherlands. Pop-
ulation figures were extracted from Statistics Netherlands.4
Year Number of AQP4-IgG 
seropositive NMOSD 
patients
Number of Dutch 
inhabitants
Incidence per 100.000 
people
1: May 2009 – April 2010 15 16,486,000 0.09
2: May 2010 – April 2011 15 16,575,000 0.09
3: May 2011 – April 2012 12 16,656,000 0.07
4: May 2012 – April 2013 16 16,730,000 0.10
5: May 2013 – April 2014 18 16,778,000 0.11
6: May 2014 – April 2015 13 16,829,000 0.08
mean/year 15a 16,676,000 0.09
aResults rounded to the nearest integer.
AQP4-IgG = aquaporin-4 immunoglobulin G, NMOSD = neuromyelitis optica spectrum disorders.
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The mean incidence of NMOSD during the past six years in the Netherlands was 
calculated at 0.09 per 100,000 people. Considering that approximately 77% of NMOSD 
patients has antibodies directed to AQP42, the estimated incidence of NMOSD in general 
(including AQP4-IgG seropositive and seronegative cases) is 0.12 per 100,000 people. 
Thirty-six of the 94 AQP4-IgG seropositive NMOSD patients (38%) are known at the 
Erasmus MC and their clinical data are presented in Table 2.2. Seventy-eight percent of 
table 2.2 Clinical characteristics of 36 AQP4-IgG seropositive NMOSD patients known at Erasmus MC.
AQP4-IgG seropositive NMOSD 
patients, n=36
Age at onset, mean years (SD) 41.6 (18.9)
Females, n (%) 28 (78%)
Caucasians, n (%) 27 (75%)
AID comorbidity, n ( %) 8 (22%)
Time from first onset of symptoms to AQP4-IgG assay, median 
months (range)
7.9 (0.3 – 248.8a)
Type of onset, n (%)
ON 12 (33%) 
TM 18 (50%) 
NMO 4 (11%) 
Brainstem and or cerebral syndromes 2 (6%) 
CSF elevated IgG index >0.68 and/ or positive OCB, n (%) 11/31 (35%)
MRI cerebral lesions, n (%)b 17/34 (50%)
NMO like5 4 (12%) 
Aspecific 13 (41%) 
MRI spinal cord lesions, n (%)b 30/33 (91%)
LETM 24 (73%) 
Relapse, n (%) 24 (67%)
Chronic treatment, n (%) 30 (83%)
Follow-up, mean years (SD) 5.4 (5.4)
Type at last Follow-up, n (%)
ON 3 (8%) 
TM 11 (31%) 
NMO 21 (58%) 
Brainstem and or cerebral syndromes 1 (3%) 
aThe extreme of 248.8 months from onset to sampling was caused by a patient with recurrent optic neuritis 
in 1988, 2004 and later. In this particular case NMOSD diagnosis could not have been made prior to the 
AQP4-IgG testing. bMRIs performed at onset and/or follow-up.
AID = autoimmune disease, AQP4-IgG = aquaporin-4 immunoglobulin G, CSF = cerebrospinal fluid, IgG = immu-
noglobulin G, LETM = longitudinally extensive transverse myelitis, NMO(SD) = neuromyelitis optica (spectrum 
disorders), OCB = oligoclonal bands, ON = optic neuritis, TM = transverse myelitis, MRI = magnetic resonance 
imaging.
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them were females. Twenty-four patients had LETM at some point during their disease 
course. Eventually at last follow-up 21 patients (58%) fulfilled classic NMO criteria with 
optic neuritis and transverse myelitis.3
Discussion
Here we report the incidence of AQP4-IgG seropositive NMOSD in the Netherlands, 
derived from data of the Dutch national NMO expert centre, is nearly one in a million: 
0.09 per 100,000 people. Unique for this study is that we have a nationwide coverage 
given that the CBA is performed in one central laboratory. Our incidence figure is within 
the range of previous described incidence rates which range from 0.05 – 0.4 per 100,000 
people.7 It has to be considered that epidemiological studies on NMOSD are difficult 
to compare since they are based on different selection and inclusion criteria. For ex-
ample different clinical definitions and AQP4-IgG assays were used. Also the ethnicities 
of included patients and the geographic coverage differed. Two studies performed in 
comparable geographic areas in Denmark and the United Kingdom differed essentially 
from our study, as both studies also included AQP4-IgG seronegative NMOSD patients 
and did not have nationwide coverage.8, 9
In a comparable Austrian study an incidence of 0.05 was calculated.10 The main dif-
ference with our study is that the patients they identified were all Caucasian. However 
there are indications that some ethnic groups are overrepresented in NMOSD.11 In the 
Netherlands we estimated the incidence of NMOSD is more than twice as high in 
non-Caucasians. Based on 25 percent of the patients known at Erasmus MC were non-
Caucasian and 11.9 percent of the Dutch inhabitants are non-Caucasian4 we estimated 
a mean annual incidence rate of NMOSD for non-Caucasians of 0.19 per 100,000 people 
and for Caucasians of 0.08 per 100,000 people.
We think our findings reflect the real incidence of AQP4-IgG seropositive NMOSD in 
the Netherlands. However, we cannot exclude that mild cases and forme fruste types 
of the disease2 have been missed. Fifty-eight percent of the NMOSD patients at the 
Erasmus MC fulfilled classic NMO criteria.3 Unfortunately we did not have access to the 
clinical data of all patients and therefore we could not present this figure for all NMOSD 
patients in the Netherlands. Only the clinical data of patients known at the Erasmus MC 
are presented, however covering over one third of the study population.
More awareness and better recognition of NMOSD might increase the incidence in the 
future. Further demographic studies and international collaboration in the NMO field 
would add to a better understanding of NMOSD.
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AbstrAct
background and purpose Neuromyelitis optica spectrum disorders (NMOSD) are 
a group of rare inflammatory demyelinating disorders of the CNS. The identification 
of specific antibodies directed to aquaporin 4 (AQP4-IgG) led to the distinction from 
multiple sclerosis (MS). However, up to 25% of the clinically diagnosed NMO patients 
are seronegative for AQP4-IgG. A subgroup of these patients might be identified by 
antibodies directed to myelin oligodendrocyte glycoprotein (MOG-IgG). Our objective 
was to investigate whether the clinical characteristics of these patients differ.
methods Using a cell based assay, samples of 61 AQP4-IgG seronegative patients and 41 
AQP4-IgG seropositive patients with clinically NMOSD were analysed for the presence 
of MOG-IgG. Clinical characteristics of the AQP4-IgG, MOG-IgG seropositive and double 
seronegative NMOSD patients were compared.
results Twenty of the 61 AQP4-IgG seronegative patients tested MOG-IgG seropositive 
(33%). MOG-IgG seropositive patients were more frequently males in contrast to AQP4-
IgG seropositive patients (55% versus 15%, p<0.01) and Caucasians (90% versus 63%, 
p=0.03). They more frequently presented with coincident optic neuritis (ON) and trans-
verse myelitis (TM) (40% versus 12%, p=0.02) and have a monophasic disease course 
(70% vs 29%, p<0.01). AQP4-IgG seropositive patients were 2.4 times more likely to 
suffer from relapses as compared with MOG-IgG seropositive patients (relative risk 2.4, 
95% CI 1.2 – 4.7). AQP4-IgG seropositive patients had higher EDSS levels at last follow-up 
(p<0.01).
conclusion Antibodies directed to MOG identify a subgroup of AQP4-IgG seronegative 
NMO patients with generally a favourable monophasic disease course.
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introDuction
Neuromyelitis optica spectrum disorders (NMOSD) are a group of rare inflammatory 
demyelinating disorders of the central nervous system (CNS), characterised by severe 
episodes of optic neuritis (ON) and/or longitudinally extensive transverse myelitis 
(LETM).1, 2 Antibodies directed to aquaporin 4 (AQP4-IgG) are specific for neuromyelitis 
optica (NMO) and distinguish NMO from multiple sclerosis (MS).3 Despite the devel-
opment of highly sensitive cell based assays (CBA)4 10-25% of the patients clinically 
diagnosed with NMO are AQP4-IgG seronegative.1 In the Netherlands AQP4-IgG was 
found in 74% of the recurrent NMO cases.5 The presence of antibodies directed to myelin 
oligodendrocyte glycoprotein (MOG-IgG) has been reported in a subgroup of patients 
with NMO and NMOSD6-13 and ON.14-16 These MOG antibodies are associated with CNS 
demyelinating syndromes, particularly with children with an acute-disseminated-
encephalomyelitis-like disease onset.17, 18 In case of NMOSD MOG antibodies seem to 
be associated with a male predominance and relative mild disease course.7, 9, 10 Double 
seropositive (AQP4-IgG and MOG-IgG) NMOSD patients seem to be rare and only a few 
cases have been described.6, 10, 16 In this study we investigated the presence of MOG-IgG 
in NMOSD patients referred to our clinic. Clinical characteristics of MOG-IgG seroposi-
tive patients were compared with AQP4-IgG seropositive patients, as well as MOG-IgG 
seropositive patients with double seronegative NMOSD patients.
methoDs
Patients
This study was conducted at the Dutch national NMO expert centre which includes San-
quin Diagnostic Services in Amsterdam and the NMO expert clinic at the Erasmus MC in 
Rotterdam. We included patients with NMOSD referred to the Dutch NMO expert centre 
at Erasmus MC between 2000 and 2015 retrospectively. Patients either presented pri-
marily at Erasmus MC, or were referred by ophthalmologists and neurologists in (non-) 
academic hospitals in the Netherlands. All patients fulfilled the following inclusion 
criteria: (i) age at first presentation at Erasmus MC ≥ 18 years, (ii) diagnosis of NMOSD 
according to current diagnostic criteria for NMO19, except for AQP4-IgG seropositive 
status, or limited forms of NMO defined as LETM ≥ 3 vertebral segments or bilateral 
ON or recurrent unilateral ON.1 Patients were not included in case they were diagnosed 
with MS, or a non-demyelinating inflammatory cause like other systemic autoimmune 
diseases (e.g. systemic lupus erythematous, sarcoidosis) or ophthalmologic diseases 
(e.g. Leber hereditary optic neuropathy, acute ischemic optic neuropathy). Additionally 
41 AQP4-IgG seropositive NMOSD patients from the Dutch NMO expert centre of whom 
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serum samples were available were included. Clinical characteristics were compared 
between MOG-IgG seropositive NMOSD patients and AQP4-IgG seropositive and double 
negative patients respectively. Data on auto-immune comorbidity, defined as coexisting 
clinically diagnosed auto-immune disease(s), were collected. Relapses were defined as 
new neurological symptoms lasting for at least 24 hours with objective findings at neu-
rological examination. Patients without relapses were defined as monophasic during the 
current observation period, irrespective of its duration. In order to compare the disease 
severity for patients with ON, the nadir visual acuity was retrieved from medical records. 
For all patients the expanded disability status scale (EDSS) was assessed.20 Cerebral 
and spinal cord magnetic resonance images (MRIs) were evaluated for the presence of 
specific NMO-like lesions.21 This study was approved by the Medical Ethical Committee 
of Erasmus MC in Rotterdam. All patients provided informed consent.
cell culture and cell based assays
All samples were tested blindly at Sanquin, Amsterdam. We used cell based assays (CBA) 
for MOG-IgG and AQP4-IgG detection as has previously been described.5, 17 Briefly, patient 
serum was incubated with HEK293 cells transiently transfected with AQP4-M23 (final 
serum dilution 1:20) or LN18 cells stably transfected with full length MOG (final serum 
dilution 1:200). After washing, cells were subsequently incubated with goat anti-human 
IgG Allophycocyanin (APC) conjugated secondary antibody (Jackson ImmunoResearch 
Laboratories, Brunschwig Chemie B.V., Amsterdam, The Netherlands (specific for human 
IgG)) and analysed after washing using fluorescence-activated cell sorter (FACS). The 
cut-off was determined in every assay as the average mean fluorescence intensity + 10 
standard deviations of eight individual negative control sera. Our assay has an anti-IgG 
specific detection antibody and thus no IgM anti-MOG or IgM anti-AQP4 is detected.
statistical analysis
Patients were divided in three groups: AQP4-IgG seropositive, MOG-IgG seropositive 
and double seronegative NMOSD. Statistical analyses were performed using SPSS 21.0. 
(SPSS, Chicago, IL, USA). The chi-square test and Fisher exact test were used in order 
to compare categorical data. Mann-Whitney U test and Student’s t test were used for 
continuous data when appropriate. In case p-values were < 0.05 results were considered 
significant.
results
In all, 102 NMOSD patients were included, 61 of them were AQP4-IgG seronegative and 
41 were AQP4-IgG seropositive. Twenty of the 61 AQP4-IgG seronegative patients tested 
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MOG-IgG seropositive (33%). In none of the AQP4-IgG seropositive patients MOG-IgG 
was detected. An overview of the included patients is presented in Figure 3.1. The me-
dian time to sampling was 10.7 months (0 – 401.5). Thirteen patients (12.7%) received 
chronic treatment whilst the sample was collected.
In Table 3.1 clinical characteristics are presented for MOG-IgG seropositive (n=20), 
AQP4-IgG seropositive (n=41) and double seronegative (n=41) NMOSD patients. 
Compared with AQP4-IgG seropositive patients, MOG-IgG seropositive patients were 
more frequently males (55% versus 15%, p<0.01) and Caucasians (90% versus 63%, 
Patients with opticospinal 
phenotype  
n = 102 
AQP4-IgG seropositive 
patients  
n = 41 
AQP4-IgG seronegative 
patients  
n = 61 
MOG-IgG seropositive 
patients  
n = 20 
Seronegative patients  
n = 41 
Figure 3.1 Overview of included patients.
table 3.1 Clinical characteristics of MOG-IgG seropositive (n=20) and AQP4-IgG seropositive (n=41) and 
seronegative (n=41) patients with clinically NMOSD.
mog-igg+
(n=20)
AQP4-igg+
(n=41)
seronegative
(n=41)
p-valuea p-valueb
Female, n (%) 9 (45) 35 (85) 25 (61) 0.00 0.24
Mean age at onset, years (SD) 36.2 (14.2) 42.0 (16.1) 40.4 (13.0) 0.23 0.26
Autoimmune comorbidity, n (%) 1 (5) 8 (20) 6 (15) 0.25 0.41
Familial autoimmune disease 
in fi rst and/or second degree 
relatives, n (%)
5/18 (28) 19/38 (50) 22/38 (58) 0.12 0.04
Caucasian, n (%) 18 (90) 26 (63) 34 (83) 0.03 0.70
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table 3.1 (continued)
mog-igg+
(n=20)
AQP4-igg+
(n=41)
seronegative
(n=41)
p-valuea p-valueb
Follow-up, median,
months (range)
23.9 (2.7-463.8) 61.5 (4.3-312.9) 23.9 (5.8-267.6) 0.09 0.49
Monophasic disease course 8.0 (2.7 – 463.8) 11.9 (4.3 – 61.5) 17.8 (5.8 – 202.4) 0.43 0.06 
Relapsing disease course 106.4 (30.5 – 234.3) 115.8 (14.3 – 312.9) 34.6 (17.7 – 267.6) 0.81 0.07 
Monophasic disease, n (%) 14 (70) 12 (29) 25 (61) 0.00 0.49
Phenotype at onset, n (%)
ON 8 (40) 16 (39) 15 (37) 0.94 0.80 
Bilateral ON 6/8 (75) 6/16 (38) 11/15 (73) 0.19 1.00 
LETM 4 (20) 20 (49) 15 (37) 0.03 0.19 
ON and TM 8 (40) 5 (12) 11 (27) 0.02 0.30 
Bilateral ON 7/8 (88) 4/5 (80) 8/11 (73) 1.00 0.60 
Phenotype at last follow-up, n (%)
ON 6 (30) 4 (10) 10 (24) 0.07 0.64 
LETM 3 (15) 11 (27) 12 (29) 0.35 0.34 
ON and TM 11 (55) 26 (63) 19 (46) 0.53 0.53 
CSF elevated protein >0.60, n (%) 4/14 (29) 12/32 (38) 9/32 (28) 0.74 1.00
CSF oligoclonal bands, n (%) 3/16 (19) 10/28 (36) 7/35 (20) 0.31 1.00
CSF IgG index >0.68, n (%) 4/13 (31) 13/27 (48) 15/34 (44) 0.30 0.40
EDSS at onset, median (range) 4.0 (2.0-8.0) 4.0 (1.5-9.0) 3.0 (1-9.5) 0.40 0.16
EDSS at best recovery, 
median (range)
1.0 (0-8.0) 2.0 (0-8.0) 3.0 (1.0-8.0) 0.06 0.01
EDSS at last FU, median (range) 1.0 (0-10) 3.0 (1.0-10.0) 3.0 (1.0-8.0) 0.01 0.02
Nadir visual acuity, 
median (range)
0.05 (0.003-0.7) 0.003 (0-1.0) 0.05 (0.002-1.0) 0.16 0.83
Chronic treatment, n (%)c 4 (20) 34 (83) 17 (43) 0.00 0.10
Duration, months (range) 40.3 (2.8 -79.1) 30.4 (1.3 – 152.4) 32.3 (3.5 – 213.3) 0.98 1.00 
aComparison between MOG-IgG and AQP4-IgG seropositive patients; bcomparison between seropositive 
MOG-IgG and seronegative patients; c55 patients received chronic therapy: four MOG-IgG seropositive 
patients (one azathioprine, one mycophenolate, one immunomodulatory treatment, one mycophenolate 
and rituximab), 34 AQP4-IgG seropositive patients (27 azathioprine, five mycophenolate, two rituximab), 17 
seronegative patients (11 azathioprine, four mycophenolate, one low dose oral prednisone, one mitoxan-
trone). Significant results are reported in bold.
AQP4-IgG = aquaporin-4 immunoglobulin G, CSF = cerebrospinal fluid, EDSS = expanded disability status scale, 
LETM = longitudinally extensive transverse myelitis, MOG-IgG = myelin oligodendrocyte glycoprotein immuno-
globulin G, NMOSD = neuromyelitis optica spectrum disorder, ON = optic neuritis, TM = transverse myelitis.
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p=0.03). They more frequently presented with coincident ON and transverse myelitis 
(TM) (40% versus 12%, p=0.02). AQP4-IgG seropositive patient more often presented 
with longitudinally extensive transverse myelitis (LETM) (49% versus 20%, p=0.03). In 
Table 3.2 MRI features are presented. The cerebral MRI features as recently described 
in NMOSD patients21 were only found in het AQP4-IgG seropositive patients and not 
in the MOG-IgG seropositive patients (32% versus 0%, p<0.01). An example of typical 
NMO dorsal brainstem (a) and midbrain (b) lesions of one of our patients is presented in 
Figure 3.2. Spinal cord MRI features and cerebrospinal fluid (CSF) findings were similar in 
the AQP4-IgG versus MOG-IgG seropositive groups. MOG-IgG seropositive patients more 
frequently had a monophasic disease course (Table 3.1) (70% vs 29%, p<0.01). AQP4-IgG 
seropositive patients were 2.4 times more likely to suffer from relapses as compared 
with MOG-IgG seropositive patients (RR 2.4, 95% CI 1.2 – 4.7). EDSS at last follow-up 
was higher for AQP4-IgG seropositive patients (p<0.01). Presenting phenotype was not 
predictive for a relapsing disease course. Table 3.3 shows the clinical characteristics of 
the relapsing patients. TM relapses were more frequently seen in the AQP4-IgG group 
compared with the MOG-IgG seropositive patients (76% versus 17%, p=0.01).
table 3.2 MRI features of MOG-IgG and AQP4-IgG seropositive patients with NMOSD.
mog-igg+ (n=20) AQP4-igg+ (n=41) p-value
brain
NMO specific brain lesions, n (%) 0 12/38 (32)a 0.01
Aspecific brain lesions, n (%) 4 (20) 12/37 (32) 0.32
spinal cord
Affected spinal cord segments
Cervical 9/12 (75) 31/36 (86) 0.66 
Thoracic 10/12 (83) 30/36 (83) 1.00 
Lumbar 3/12 (25) 5/36 (14) 0.66 
Whole spinal cord 3/12(25) 5/36 (14) 0.66 
Central grey matter 10/12 (83) 30/36 (83) 1.00
aMagnetic resonance imaging was reviewed for the presence of NMO specific brain lesions as recently de-
scribed.21 Five patients with diencephalic lesions surrounding the third ventricle and cerebral aquaduct, 
two patients with dorsal brainstem lesions, two patients with both diencephalic and dorsal brainstem 
lesions, one patient with a dorsal brainstem, diencephalic and periependymal lesion, one patient with a 
specific lesion of the internal capsule and one patient with an extensive confluent hemispheric lesion were 
detected.
AQP4-IgG = aquaporin-4 immunoglobulin G, MOG-IgG = myelin oligodendrocyte glycoprotein immunoglobulin 
G, MRI = magnetic resonance imaging, NMO = neuromyelitis optica, NMSOD = neuromyelitis optica spectrum 
disorder.
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a b
Figure 3.2 Transversal MRI fluid-attenuated inversion recovery images presenting typical NMO dorsal 
brainstem (a) and midbrain (b) lesions of one of our NMO patients with AQP4-IgG seropositivity.
table 3.3 Clinical characteristics of patients with relapsing NMOSD.
mog-igg+
(n=6)
AQP4-igg +
(n=29)
seronegative
patients (n=16)
p-valuea p-valueb
Phenotype at onset, n (%)
ON 4 (67) 13 (45) 9 (56) 0.40 1.00 
LETM 0 (0) 13 (45) 3 (19) 0.06 0.53 
NMO 2 (33) 3 (10) 4 (25) 0.20 1.00 
Annualised relapse rate, median 
(range)
0.46 (0.05-1.13) 0.41 (0.07-1.92) 0.67 (0.09-2.00) 0.74 0.17
Time from onset to first relapse 
median, months (range)
28 (8-219) 18 (1-192) 13 (3-96) 0.20 0.04
Relapse ON, n % 4 (67) 16 (55) 10 (63) 0.68 1.00
Relapse bilateral ON, n % 2 (33) 3 (10) 5 (31) 0.20 1.00
Relapse transverse myelitis, n % 1 (17) 22 (76) 7 (44) 0.01 0.35
Relapse simultaneous ON and TM, 
n (%)
1 (17) 4 (14) 1 (6) 1.00 1.00
Chronic therapy, n (%)c 3 (50) 26 (90) 8 (50) 0.05 1.00
Duration, months (range) 57.4 (2.8 – 79.1) 42.0 (1.8 – 152.4) 32.8 (8.7 – 213.3) 0.92 0.92 
aComparison between MOG-IgG and AQP4-IgG seropositive patients; bcomparison between seropositive 
MOG-IgG and seronegative patients; c37 patients received chronic therapy: three MOG-IgG seropositive pa-
tients (one azathioprine, one mycophenolate, one mycophenolate and rituximab); 26 AQP4-IgG seroposi-
tive patients (23 azathioprine, one mycophenolate, two rituximab) and eight seronegative patients (four 
azathioprine, two mycophenolate, one low dose oral prednisone, one mitoxantrone).
AQP4-IgG = aquaporin-4 immunoglobulin G, LETM = longitudinally extensive transverse myelitis, MOG-IgG = 
myelin oligodendrocyte glycoprotein immunoglobulin G, NMO = neuromyelitis optica, NMSOD = neuromyelitis 
optica spectrum disorder, ON = optic neuritis, TM = transverse myelitis.
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Discussion
Antibodies directed to MOG can be detected in a subgroup of children with acquired 
demyelinating syndromes.17, 18 Recently it has been reported that MOG-IgG also can be 
found in adults with clinical NMOSD phenotypes and ON.6-16 In this study we confirm that 
MOG-IgG is present in approximately one third of the AQP4-IgG seronegative NMOSD 
cases. An overview of previous studies using a CBA for MOG-IgG testing in NMO(SD) and 
this study is presented in Table 3.4. In line with previous studies we found a male and 
Caucasian predominance, frequent coincident ON and TM, more often a monophasic 
disease course and lower EDSS levels at follow-up in MOG-IgG seropositive cases.7, 9, 10 Six 
out of 8 (75%) MOG-IgG seropositive patients with coincident ON and TM had a mono-
phasic disease course as originally described as Devic’s syndrome.1 Follow-up periods 
between the MOG-IgG and AQP-IgG seropositive patients differed slightly, but not 
significantly. It cannot be excluded that upon further follow up some of the monophasic 
MOG-IgG seropositive patients will have relapses. In our study we observed a relatively 
high rate of a monophasic disease course in the AQP4-IgG seropositive patients, which 
is a result of our protocol to start immunosuppressive treatment in this group as early as 
possible, often already after the first attack.
In addition to previous studies, cerebral MRIs from MOG-IgG and AQP4-IgG seroposi-
tive patients were assessed for presence of NMO specific brain lesions.21 These lesions 
were not present in MOG-IgG seropositive NMOSD patients, which might be explained 
by different underlying disease mechanisms.
AQP4-IgG, MOG-IgG seropositive NMOSD and seronegative NMOSD seem to be simi-
lar in their clinical opticospinal phenotype, although there might be pathophysiological 
differences between these NMOSD subgroups.22, 23 Further neuropathological studies 
are needed in order to improve criteria for clinical NMOSD phenotype, since MOG-IgG 
seropositivity might reflect a separate demyelinating syndrome.
The presence of MOG-IgG further expands the spectrum of NMOSD. Although the 
presence of MOG-IgG is rare, the detection of it seems beneficial in clinical practice to 
differentiate patients with NMOSD from MS13 and may identify a subgroup of NMOSD 
patients with favourable outcome with lower EDSS levels at follow-up and less relapses. 
However it is still important to realise that some MOG IgG seropositive patients experi-
ence frequent relapses and have prominent residual neurological deficits.
MOG-IgG was found in 33% of the clinical NMOSD AQP4-IgG seronegative cases. This 
is higher than has been described in some of the previous studies (Table 3.4).8-13, 15, 16 
However, it is difficult to compare these percentages considering the different study 
protocols and inclusion criteria.
Our relative high percentage of MOG-IgG seropositivity is probably caused by the 
retrospective character of our study and selection bias of patients who have been 
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referred to our NMO expert centre at Erasmus MC Rotterdam. The scope of the current 
study was to compare clinical characteristics of MOG-IgG versus AQP4-IgG seropositive 
NMOSD patients, rather than to determine the prevalence of MOG-IgG seropositive CNS 
demyelination. Further studies are needed in order to present epidemiological figures of 
AQP4-IgG and MOG-IgG seropositivity in the Netherlands.
This study confirms MOG-IgG seropositivity in a subgroup of patients with clinically 
NMOSD in the Netherlands. Limitation of our study is a relative small sample size and 
therefore we could not make statistical corrections. Also we have not collected sequen-
tial samples.
Even though AQP4-IgG and MOG-IgG represent a considerable amount of patients 
with the clinical profile of NMOSD, there is still a group of patients without antibodies. 
Future studies are needed to gain more insight in this group of seronegative NMOSD 
patients in order to possibly detect new autoantibodies, to better customise treatment 
for individual patients and to predict their prognosis.
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AbstrAct
background Recently, the International Paediatric MS Study Group (IPMSSG) definitions 
for the diagnosis of immune-mediated acquired demyelinating syndromes (ADS) of the 
central nervous system including paediatric multiple sclerosis (MS) have been revised.
objective To evaluate the 2012 revised IPMSSG consensus definitions in a cohort of 
children with ADS prospectively followed from January 2007.
methods Children with ADS who had an MRI scan obtained within 90 days after first 
disease onset were included. The sensitivity and specificity of the 2007 and 2012 IPMSSG 
consensus definitions were assessed. The time to MS diagnosis applying the 2007 and 
2012 definitions was compared using survival analysis and log-rank test.
results Eighty-two children with ADS were included. Thirty-five children were diagnosed 
with paediatric MS, of whom 30 experienced a second clinical event. The final diagnosis 
applying either the 2007 or 2012 IPMSSG definitions corresponded. The revised 2012 
definitions had sufficient sensitivity (80%) and high specificity (100%). MS diagnosis was 
made 3.4 months earlier (Х²=8.24, p=0.004) applying the new definitions. In 14 children 
MS diagnosis was made at first MRI.
conclusions MS diagnosis can be made reliable and early using the 2012 IPMSSG 
consensus definitions. This is beneficial for adequate counseling of children and their 
families and for early treatment possibilities.
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4
introDuction
Recently, the diagnostic criteria for the diagnosis of immune-mediated acquired demy-
elinating syndromes (ADS) of the central nervous system (CNS) including paediatric mul-
tiple sclerosis (MS) have been revised by the International Paediatric Multiple Sclerosis 
Study Group (IPMSSG).1 The new definitions aim to improve consistency in terminology 
in the heterogeneous group of paediatric demyelinating disorders. They incorporate the 
in 2010 revised McDonald criteria for MS.2 Diagnosing MS earlier in the disease course is 
favourable because disease modifying treatment is also beneficial in children with MS.3 
Previous studies already showed that the 2010 McDonald magnetic resonance imaging 
(MRI) criteria, which allow diagnosis at disease onset, are useful for early MS diagnosis 
in children.4-8 But they recommended to be cautious when applying these MRI criteria 
to young children with acute disseminated encephalomyelitis (ADEM).4, 6 Therefore the 
IPMSSG included in the revised 2012 definitions that the 2010 McDonald MRI criteria for 
dissemination in time (DIT) and space (DIS) cannot be applied at first event in children 
with ADEM and children younger than 12 years old.1 In the new IPMSSG consensus 
definitions, diagnostic criteria for ADEM and neuromyelitis optica (NMO) have been 
sharpened and the term recurrent ADEM is excluded. Our aim was to evaluate the new 
2012 IPMSSG consensus definitions in our clinical cohort of prospectively included 
children with ADS.
methoDs
Patients and definitions
Children younger than 18 years, who presented with a first episode of acquired demy-
elination of the CNS between January 2007 and April 2013, were prospectively included. 
All children were identified by the Dutch Study Group for Paediatric MS, which consists 
of paediatric neurologists in 13 major paediatric neurology centres in the Netherlands, or 
the children were identified by Dutch paediatricians who participate in the NSCK (Neth-
erlands Paediatric Surveillance Unit) as has been described elsewhere.9 Children were 
eligible for this study when a cerebral MRI scan had been obtained within 90 days after 
first onset of symptoms. All patients had a minimum follow-up time of 2 years, unless 
they were diagnosed with definite MS. MS diagnosis could be made either on evidence 
of a second clinical attack at least 30 days after the initial attack, or on MRI evidence of 
DIT within 2 years. Patients were classified as MS, ADEM, clinically isolated syndrome 
(CIS), NMO, or other relapsing demyelinating disorders according to the 200710 and new 
20121 IPMSSG consensus definitions.
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standard protocol approvals, registrations and patient consents
This study was approved by the Medical Ethical Committees of the Erasmus MC in Rot-
terdam and of the other participating centres. Written informed consent was obtained 
from all children and/or their parents.
mri analysis
MRI scans were performed on 1.5-Tesla MRI scanners with slice thicknesses of 3-5 mm. 
Scans were archived as electronic images. The presence of lesions was determined on 
T2-weighted and fluid attenuated inversion recovery (FLAIR) images. All scans were 
scored blinded to clinical data by 2 experienced raters (E.D.v.P. and R.F.N.). MRI scans were 
classified as meeting the 2007 IPMSSG definitions for MS10 (based on the 2001 McDonald 
MRI criteria11) or the 2012 IPMSSG definitions for MS1 (based on the 2010 McDonald MRI 
criteria2). It should be noted that according to the 2007 IPMSSG consensus definitions, 
DIS can also be met by the combination of abnormal cerebrospinal fluid (CSF) and two 
lesions on MRI of which one must be in the brain. The 2012 IPMSSG definitions did not 
incorporate CSF findings anymore. According to the 2007 IPMSSG consensus definitions, 
MRI criteria for DIT can only be applied on a MRI scan made 3 months after disease onset 
in children ≥ 10 years old.10 In contrast, using the 2012 IPMSSG consensus definitions 
MS can be diagnosed after a single event in children ≥ 12 years old, not meeting ADEM 
criteria and meeting the 2010 McDonald MRI criteria for DIS and DIT on the baseline MRI 
scan.1
statistical analysis
Analyses were performed using SPSS version 20.0. Patient characteristics were com-
pared using Chi-Square and student’s t-test. Test characteristics of the 2007 and 2012 
diagnostic criteria (i.e. sensitivity, specificity, positive predictive value (PPV), negative 
predictive value (NPV) and accuracy) were calculated using clinical definite MS (CDMS) 
as endpoint. Children with MS diagnosis based on MRI criteria who started disease 
modifying treatment (DMT) before CDMS diagnosis (n=2) and those with a follow-up 
of <1 years (n=3) were excluded from the analysis of test characteristics. Kaplan-Meier 
survival analyses were used to analyse time to diagnosis according to the 2007 and 2012 
IPMSSG consensus definitions. The time to diagnosis was compared using a log-rank 
test. Survival analysis included all patients with a first MRI with gadolinium and either 
the presence of a follow-up scan or a diagnosis of CDMS according to the 2010 McDon-
ald MRI criteria.
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4
results
Ninety-two children presented with a first demyelinating event between January 2007 
and April 2013 and were eligible for this study. Eight patients were excluded because 
cerebral MRI was not acquired at onset (n=6 not at onset, n=2 only spinal cord MRI). One 
patient was excluded because the MRI was not of sufficient quality. One patient with 
monophasic ADS was excluded because of loss to follow-up within 2 years after onset. 
Eighty-two children were analysed of whom 41 were younger than 12 years at onset.
In Table 4.1, patient characteristics including sex, age at first onset of symptoms, type 
of onset, follow-up time in months and final diagnosis are presented. CSF data are also 
presented in Table 4.1, since the 2007 IPMSSG definitions incorporate CSF in the criteria 
for DIS, whereas CSF positivity is defined by either the presence of oligoclonal bands or 
an elevated IgG index.10
There were no discrepancies in final diagnosis according to the 2007 or 2012 IPMSSG 
criteria for paediatric MS and other CNS demyelinating disorders. Thirty-five children 
table 4.1 Patient characteristics.
multiple sclerosis (n=35) other ADs (n=47) p-value
Female/male 20/15 30/17 NS
Age at onset
Mean, SD 14.7 ± 2.8 7.5 ± 4.8 p<0.001 
Range 5.3 – 17.7 1.0 – 16.7 
Median 15.5 6.2 
Type of onset (%) p<0.001
Optic Neuritis 6 (17.1%) 10 (21.3%) 
Transverse Myelitis 1 (2.9%) 2 (4.3%) 
Other monofocal CIS 12 (34.3%) 2 (4.3%) 
Polyfocal CIS 16 (45.7%) 13 (27.7%) 
ADEM - 20 (42.6%) 
CSF analysis performed (%) 31 (88.6%) 45 (95.7%) NS
Positive CSF (valid %)* 26 (83.9%) 8 (17.8%) p<0.001 
Follow-up time months (mean, SD) 32 ± 17 38 ± 12 NS
Final diagnosis according to 
the 2007 and 2012 consensus 
definitions
CDMS 30 CIS 22
Definite MS based on 
MRI evidence 
5 ADEM 19  
NMO 4  
Other relapsing ADS 2  
*CSF positivity is defined by either the presence of oligoclonal bands or an elevated IgG index.10
ADEM = acute disseminated encephalomyelitis, ADS = acquired demyelinating syndromes, CDMS = clinical defi-
nite multiple sclerosis, CIS = clinically isolated syndrome, CSF = cerebrospinal fluid, MRI = magnetic resonance 
imaging, MS = multiple sclerosis, NMO = neuromyelitis optica, NS = non-significant.
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are diagnosed with MS according to both 2007 and 2012 IPMSSG definitions. Five of 
them did not have a second clinical event confirming CDMS during current follow-up. 
Two of these patients have started DMT, which may have suppressed a second clini-
cal event. Children with MS were older (F=18.35, p<0.001) and have a different type of 
onset (X²=27.6, p<0.001) as compared to children with monophasic or other relapsing 
demyelinating disorders. None of the children currently diagnosed with MS presented 
with ADEM, as defined by a polyfocal event with encephalopathy.1
Four patients were diagnosed with NMO according to both 2007 and 2012 consensus 
definitions.1, 10 Three of them suffered from a relapsing disease course. Anti-aquaporin-4 
antibodies were tested in 39 patients (48%) as part of their diagnostic follow-up using 
a cell based assay and fluorescence activated cell sorter (FACS).12 Two patients had anti-
aquaporin-4 IgG seropositivity, one patient with recurrent NMO and one patient who 
presented with a brainstem syndrome and was diagnosed with NMO related spectrum 
disorder.13 Two patients had a final diagnosis of other relapsing demyelinating disorders: 
one patient suffered from a relapsing optic neuritis (ON) in absence of MRI lesions fulfill-
ing DIT for MS diagnosis and aquaporin-4 antibodies for NMO spectrum diagnosis. The 
other patient suffered from a first event of ADEM followed by one event of ON without 
presence of new MRI lesions during follow-up.14 None of the children with ADEM-onset 
had a subsequent event of ADEM (multiphasic ADEM).
In Table 4.2 sensitivity and specificity of the 2007 and 2012 IPMSSG consensus defini-
tions are presented with CDMS as endpoint using only the baseline characteristics and 
using also follow-up MRI. The 2012 IPMSSG consensus definitions had better sensitivity 
(79 vs 68%), NPV (88 vs 71%) and accuracy (92 vs 82%) compared to the 2007 definitions. 
The test characteristics differed not significantly. For the calculations of DIS and DIT 2010 
McDonald MRI criteria at onset, only children who had a first MRI with gadolinium were 
included. Two patients who presented with ADEM fulfilled the 2010 McDonald MRI cri-
teria at the first MRI and one of them also fulfilled DIS and DIT 2001 and 2010 McDonald 
MRI criteria at second MRI (>3 months after onset). Both these patients had negative CSF 
at onset and did not have a second event. Follow-up time of these patients was 53 and 
58 months respectively. However, according to the 2012 IPMSSG definitions the 2010 
McDonald MRI criteria do not apply for children with an ADEM-onset and both children 
were younger than 12 years old. Therefore according to both the 2007 as 2012 IPMSSG 
consensus definitions these children cannot be diagnosed as MS. In contrast, 2 other 
patients presenting with ADS and younger than 12 years fulfilled the 2010 McDonald 
MRI criteria for DIS and DIT at baseline, but because of their age they were not diag-
nosed with MS at first MRI according to 2012 IPMSSG consensus definitions. Both these 
patients eventually showed clinical progression and thus were diagnosed with CDMS 
and turned out to have a false-negative test result at baseline. Applying the 2010 DIS 
and DIT McDonald MRI criteria at disease onset, thus irrespective of the age limit of 12 
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years, resulted in similar test characteristics (sensitivity 67%, specificity 100%, PPV 100%, 
NPV 83%) as when applied only in children older than 12 years (Table 4.2, column 5). In 
a subgroup of 41 children younger than 12 years at onset, including 4 patients with MS, 
we found a lower sensitivity (50%) but higher NPV (95%) applying the 2010 McDonald 
MRI criteria, irrespective of the age limit at first MRI, but a high sensitivity (100%) when 
a follow-up MRI is included.
Sixty-five children, including 24 children with MS, had a first MRI with gadolinium 
administration. MS was diagnosed in 14 (47%) children at first MRI (excluding 2 children 
younger than 12 years) using the 2012 IPMSSG definitions. Six (20%) of these patients 
had a spinal cord lesion contributing to DIS McDonald MRI criteria.
Twenty-seven children were eligible for the survival analysis. Kaplan Meier survival 
curves (Figure 4.1) show the time to MS diagnosis using the 2007 versus 2012 IPMSSG 
consensus definitions. MS diagnosis in children can be made significantly earlier (Х²=8.24, 
p=0.004) using the revised 2012 consensus definitions based on the 2010 McDonald 
MRI criteria, similar as in adults.15 The mean time to diagnosis was 8.5 ± 7.4 months and 
5.1 ± 7.2 months applying the 2007 and 2012 IPMSSG definitions respectively (t=6.87, 
p<0.001). The average time to MS diagnosis is 3.4 months earlier using the 2012 IPMSSG 
definitions. The mean time to a second event defining CDMS was 10.1 ± 8.7 months.
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Figure 4.1 Kaplan-Meier survival curves showing the time to MS diagnosis using the 2007 versus 2012 
International Pediatric Multiple Sclerosis Study Group (IPMSSG) consensus definitions. The 2012 IPMSSG 
definitions allow for an earlier diagnosis (χ²=8.24, p=0.004).
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Discussion
In this study the revised 2012 IPMSSG consensus definitions for paediatric MS and 
immune-mediated CNS demyelinating disorders were evaluated in a prospective na-
tionwide cohort of children aged 1.0 to 17.7 years old with the full spectrum of immune-
mediated CNS demyelination disorders. The 2010 revised McDonald MRI criteria have 
already been studied and found useful in children with CNS demyelination.4-8 In contrast 
to these previous studies, not only the revised 2010 McDonald MRI criteria were consid-
ered in the present study, but also other clinical characteristics as proposed in the 2012 
IPMSSG definitions. This means that the 2010 McDonald MRI criteria for DIT on the first 
MRI can only be applied to children of 12 years and older and having a first clinical event 
not meeting criteria for ADEM. This study showed that the 2012 IPMSSG consensus defi-
nitions allow for an equally reliable, but earlier MS diagnosis in all children, also those 
younger than 12 years. Fourteen (47%) MS patients could be diagnosed at first MRI using 
the 2012 IPMSSG definitions. Six of these patients (20%) fulfilled DIS McDonald criteria 
because of the presence of spinal cord lesion(s), confirming the importance of a spinal 
cord MRI at onset.7
An important finding in our study is that the final diagnoses corresponded applying 
either the 2007 or 2012 IPMSSG consensus definitions. However, using the 2012 defini-
tions, a diagnosis of MS can be made earlier, which is beneficial for adequate counseling 
of the children and their families, as prognosis can be uncertain after ADS, and children 
with MS may benefit from early treatment.
Test characteristics were better when applying the 2012 IPMSSG definitions compared 
to the 2007 definitions. When including follow-up MRI scans for the application of the 
2007 and 2012 IPMSSG definitions, both have a high specificity and PPV, indicating the 
absence of false positive test results. This is because the McDonald MRI criteria do not 
apply for children aged ≥ 10 years (2007 IPMSSG definitions) and ≥ 12 years at base-
line (2012 IPMSSG definitions) and for children with an onset of ADEM (2012 IPMSSG 
definitions). Test characteristics for DIT based on MRI criteria according to 2007 IPMSSG 
definitions were calculated for 39/77 patients with a follow up scan ≥ 3 months after the 
onset of clinical symptoms. This may have introduced some bias as the decision to make 
a second MRI might not be fully independent of the initial observed disease activity.
When applying the 2010 McDonald MRI criteria to all children (regardless of age) test 
characteristics are comparable although sensitivity would be higher, due to the finding 
that 2 patients ≤ 12 years old with paediatric MS tested false negative. In a subgroup of 
children aged younger than 12 years old we found lower sensitivity and NPV, indicating 
more false negative results. A second MRI increased the sensitivity. When the DIS and 
DIT 2010 criteria are not applied in children with ADEM at onset but regardless of age, 
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high specificity and PPV was found, which might warrant exclusion of the age limit. 
Further investigation of the age limit is needed.
In contrast to the study of Sadaka et al.4 we did not find 100% sensitivity and NPV for 
the 2010 McDonald MRI criteria. This is probably explained by the fact we did not use 
a standardised MRI protocol including systematic frequent follow-up MRIs. Despite the 
lack of a systematic MRI protocol, we did find earlier MS diagnosis in the Dutch cohort 
which resembles general clinical practice.
We only included patients with a minimum follow-up of 2 years (unless they were 
diagnosed with MS based on MRI criteria within 2 years (n=3)) because the time interval 
between first and second attack in paediatric MS is typically less than 12 months.16, 17 
Despite a relatively long follow-up it still might be that patients currently defined as 
monophasic will experience relapses in the future.
A first onset of ADEM is an important clinical parameter when using the 2012 consen-
sus definitions. In our prospective cohort none of the patients with a first onset of ADEM 
developed MS during follow-up, confirming its role as a negative predictor for MS. Using 
the 2012 consensus definitions, children with ADEM can be diagnosed with MS earlier if 
they experience a second non-ADEM event with new MRI lesions at least 3 months after 
onset. We did not have such patients in our current cohort. Relapse after ADEM typically 
occurs within 2 years after onset, but in a small subgroup can occur many years later.1
Using the new 2012 consensus definitions for the diagnosis of paediatric MS, CSF analy-
sis is not strictly needed. Although in clinical practice CSF analysis in children presenting 
with neurological symptoms is still of importance in order to exclude other diagnoses as 
infections and malignancies.18 It should be further investigated if CSF analysis is of use 
in doubtful cases were MRI criteria have not been completely fulfilled.
The results of our prospective multicentre cohort show that the 2012 IPMSSG consen-
sus definitions apply well for a reliable and early diagnosis of paediatric MS and ADS.
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AbstrAct
background In a recent Canadian prospective study of children with acute demyelin-
ating syndromes (ADS), we demonstrated that the presence of T2 periventricular and 
T1-hypointense lesions predicted MS diagnosis. We aimed to validate these predictors 
in a Dutch cohort of children with ADS.
methods Participants with ADS were identified from a prospective cohort or archived 
dataset. MS was diagnosed based on clinical or MRI evidence of relapsing disease. Base-
line MRI scans were evaluated for the presence of the two predictive parameters. Sen-
sitivity, specificity, positive (LR+) and negative likelihood ratios (LR-), and positive (PPV) 
and negative predictive value (NPV) were calculated to evaluate the performance of the 
MRI parameters at classifying children as having MS or monophasic demyelination.
Findings Of 115 children identified with ADS between December 1993 and December 
2009, MRI scans from 87 children (45 prospective; 47 archived) were evaluated; scans of 
28 children were excluded due to incomplete or poor quality imaging. Mean duration 
of observation was longer in the archived group (7.1 years, SD 3.5) than the prospective 
cohort (3.3 years, SD 1.4). Thirty children were diagnosed with MS. Performance of the 
parameters was not statistically different between the prospective cohort (sensitivity 
93.3% [68.1-99.8]; specificity 86.7% [69.3-96.2]; LR+ 7.0 [2.8-17.6]; LR- 0.08 [0.01-0.5]; 
PPV 77.8% [52.4-93.6]; NPV 96.3% [81.0-99.9]) and archived group (sensitivity 66.7% 
[38.4-88.2]; specificity 85.2% [66.3-95.8]; LR+ 4.5 [1.7-11.9]; LR- 0.4 [0.2-0.8]; PPV 71.4% 
[41.9-91.6]; NPV 82.1% [63.1-93.9]).
interpretation In an independent Dutch cohort, we confirm that the presence of ≥1 T2 
periventricular and ≥1 T1-hypointense lesions reliably identifies children with MS.
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introDuction
The ability of magnetic resonance imaging (MRI) to aid in identifying children at risk 
for multiple sclerosis (MS) is important for early diagnosis and prompt initiation of MS-
targeted therapies. With treatment trials for pediatric-onset MS currently being planned, 
tools to stratify children with acute demyelinating syndromes (ADS) of the central ner-
vous system (CNS) into groups at highest risk for MS and those at low risk for recurrent 
demyelination has become increasingly valuable. We recently proposed MRI parameters 
associated with MS diagnosis in children with incident ADS. The presence of at least one 
T2 periventricular lesion and one or more T1-hypointense lesions at onset were predic-
tive of MS diagnosis (sensitivity 84%, specificity 93%).1 In collaboration with the Dutch 
Study Group for Pediatric MS, our aim was to validate the predictive MRI parameters in 
an independent cohort of children with ADS.
methoDs
Participants and definitions
We included patients younger than 17 years of age with ADS. Participants were identi-
fied from either an archived group or a prospective cohort under the Dutch Study 
Group for Pediatric MS, a nationwide network of 13 pediatric healthcare centers in the 
Netherlands.
Archived group
Children less than 17 years of age who presented with an ADS, based on clinical features, 
between 1990 and 2007 inclusive were identified from hospital records by pediatric 
neurologists at 11 participating centers. These centers are located in nine large cities 
with complete geographic coverage of the Netherlands. Demographic, clinical and 
laboratory data collected at onset of ADS and at any follow-up assessments were 
extracted from health records by a trained individual using standardized case report 
forms, and subsequently entered into a centralized database. Duration of follow-up was 
determined based on the last clinic visit or telephone contact with the site neurologist 
or pediatrician. MRI scans acquired at onset, and any serial scans were retrieved from 
each hospital for centralized analysis.
Prospective Group
Beginning in 2008, children with incident ADS are being consecutively enrolled into 
a nationwide prospective study at each of the 13 participating centers (8 academic 
pediatric hospitals and 5 regional hospitals). To confirm nationwide inclusion of chil-
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dren with ADS, email surveys were sent out to pediatricians through the Netherlands 
Pediatric Surveillance Unit (response rate: 85%) in which they reported suspected cases 
of ADS. Uniform definitions for ADS2 and clinical assessments are conducted at onset 
and annually by trained neurologists at each site using standardized case report forms. 
In the instance that patients are unable to attend a clinic visit, neurologists at the lead 
site perform a telephone interview with the patient and site neurologist. MRI scans are 
not acquired according to a standardized research protocol at all sites; however, recom-
mended sequences and scanner settings were provided to each site to increase the 
consistency of image acquisition. MRI scans are acquired at the time of incident ADS, 
at three months following ADS, and annually. Acute demyelinating syndromes were 
defined according to International Pediatric Multiple Sclerosis Study Group consensus 
definitions,2 and included optic neuritis (ON), transverse myelitis (TM), monofocal 
neurological deficits other than ON or TM, polyfocal deficits, and acute disseminated 
encephalomyelitis (ADEM) – defined by the presence of polyfocal neurological deficits 
and encephalopathy. Eligible children had a brain MRI scan acquired within 90 days 
of incident demyelinating attack. Each participant had at least two years of clinical 
observation following acute demyelination. Children with neuromyelitis optica were 
excluded.3 Participants or their guardians in the prospective cohort provided written 
informed consent. This study was conducted under research ethics approvals obtained 
previously at each participating center for the archived group and prospective cohort.
The outcome was defined as MS diagnosis, which was adjudicated by neurologists 
with expertise in demyelinating disorders (RFN, CEC-B, RQH) independently of the indi-
vidual (LHV) who performed the analyses of baseline MRI scans. MS diagnosis was based 
on either a confirmed second demyelinating attack occurring at least 28 days after the 
incident episode,4 or on the accrual of new lesions according to the 2005 McDonald 
criteria for dissemination in time (DIT) in patients who had not yet experienced a second 
attack at the time of data analysis.5 To adjudicate whether participants met MRI criteria 
for DIT, available serial scans were evaluated by neurologists at the lead site (RFN, CEC-B, 
RQH). Children initially diagnosed with ADEM were diagnosed with MS if they had two 
or more non-ADEM attacks, provided that the subsequent events occurred at least 90 
days after their initial ADS and the two subsequent attacks were separated by at least 28 
days.2 Participants not meeting clinical or MRI criteria for MS diagnosis were classified as 
having monophasic demyelination at the time of data analysis.
mri analysis
MRI scans were acquired at each participating site on 1.0 or 1.5 Tesla scanners in the 
archived group and 1.5 Tesla scanners in the prospective study. Scans were archived as 
either electronic images or hardcopy films at Erasmus MC or Sophia Children’s Hospital 
(Rotterdam, the Netherlands). For inclusion, T1-weighted and T2-weighted or fluid at-
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tenuated inversion recovery (FLAIR) images acquired at the time of ADS were required 
for each patient. An individual (LHV) with expertise in neuroimaging excluded MRI scans 
with artifact due to patient motion or dental hardware, inadequate coverage of the 
whole brain, or poor grey matter–white matter contrast, according to pre-defined qual-
ity criteria.1 The MRI scan acquired at the time of incident ADS for each participant was 
evaluated by a trained rater (LHV) blinded to clinical data. Lesions were evaluated, mea-
sured, and localized according to a priori rules previously described.1 Two parameters 
were scored on each baseline scan as described in our original work:1 i) T1-hypointense 
lesions were defined as lesions hypointense relative to cortical grey matter and nonen-
hancing on post-contrast T1-weighted imaging, and ii) T2 periventricular lesions were 
defined as lesions hyperintense on T2-weighted images abutting any portion of the 
lateral ventricles (including lesions in the corpus callosal white matter, but excluding 
deep grey matter lesions). Each scan was classified as meeting the MRI parameters when 
at least one T2 periventricular and one or more T1-hypointense lesions were present.
statistical analysis
Categorical data were summarized as frequency (%) and continuous data as mean 
(standard deviation, SD) or median (interquartile range, IQR). Univariate statistics were 
computed using Fisher’s exact tests, Χ2 tests, t tests and Mann-Whitney U tests as ap-
propriate. We evaluated the performance of the MRI parameters against confirmed 
MS diagnosis by calculating sensitivity, specificity, positive predictive value (PPV), and 
negative predictive value (NPV).6 In addition, we also calculated likelihood ratios for a 
positive test (LR+) and negative test (LR-) in order to evaluate our parameters using a 
metric that is independent of the prevalence of the outcome of interest,6 although the 
relative proportion of children diagnosed with MS following an ADS event was actually 
similar in the Canadian and Dutch cohorts (approximately 30% during the periods of 
observation).1, 7-9 For the estimates of diagnostic performance, 95% confidence intervals 
were computed from the binomial distribution. We performed a sensitivity analysis to 
assess whether the performance of the MRI parameters was influenced by method of 
MS diagnosis (based on occurrence of a second clinical attack4 or MRI evidence of DIT 
alone5). Statistical analyses were conducted using Stata version 11 (College Station, 
Texas, USA).
results
Of 115 children and adolescents presenting with an incident ADS between December 
1993 and December 2009 who were eligible, 87 were analyzed (Figure 5.1). Twenty-eight 
children were excluded because one or more of the required brain MRI sequences was 
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not acquired at onset (n=9), or one or more of T1-weighted, T2-weighted, and FLAIR 
sequences were not of sufficient quality (n=19). As detailed in Supplementary Table 5.1, 
the 28 children excluded from the present analysis did not differ from the 87 participants 
retained in the study with respect to sex (p=0.2307), ADEM versus non-ADEM presenta-
tions (p=0.4833), mean age at onset (p=0.7691), or proportion of patients diagnosed 
with MS (p=0.1951).
Mean duration of clinical observation was longer for the 42 children in the archived 
group (7.1 years, SD 2.5) than for the 45 participants enrolled in the prospective cohort 
(3.3 years, SD 1.4; p<0.0001) (Table 5.1). Serial MRI scans were evaluated only for evi-
dence of MRI DIT. At least one serial scan was acquired in 59 (69%) of the 87 patients 
115 assessed for eligibility 
57 prospective cohort 
58 retrospective cohort 
30 multiple sclerosis 
 24 ≥ 2 attacks§ 
12 prospective cohort 
12 retrospective cohort 
 6 MRI dissemination in time only* 
3 prospective cohort 
3 retrospective cohort 
57 monophasic ADS 
30 prospective cohort 
 1 recurrent ON‡ 
27 retrospective cohort 
 1 multiphasic ADEM‡ 
87 analyzed 
45 prospective cohort 
42 retrospective cohort 
28 exclusions  
 12 prospective group 
 2 brain MRI not acquired at onset 
 2 T1-weighted sequence not acquired at onset 
4 brain MRI failed pre-determined quality 
requirements¶ 
4 T1-weighted sequence failed pre-determined quality 
requirements¶ 
 16 archived group 
2 only spine MRI scans acquired 
1 no MRI scan acquired at ADS 
Figure
Figure 5.1 Description of cohort:
¶ MRI scans do not pass quality control if they are degraded by motion or dental hardware artifact, and if 
images have poor grey matter-white matter contrast or in adequate coverage of the brain.
§ Attacks separated by at least 28 days and localize to distinct regions of the central nervous system.4
*Gadolinium enhancement at least 3 months after clinical onset if not at site corresponding to initial event, 
or a new T2 lesion at any time compared with a reference scan done at least 30 days after clinical onset.5
‡ Two children had relapsing demyelinating episodes, but did not meet criteria for MS in the following 
circumstances: (1) recurrence of optic neuritis in the absence of T2 lesions in the brain; (2) occurrence of a 
second episode of ADEM six years after a first attack of ADEM, with no subsequent non-ADEM attacks or 
accrual of new lesions on MRI.2
MRI = magnetic resonance imaging, ADS = acute demyelinating syndrome, ON optic neuritis.
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(24 had one serial scan, 23 had two, and 12 had at least three); the remaining 28 (32%) 
children did not have any serial imaging acquired.
Of 87 children, 30 (34%) children were diagnosed with MS, and 57 (66%) have ex-
perienced monophasic ADS to date (Table 5.1). Of the 30 children diagnosed with MS, 
24 (80%) experienced two or more clinical attacks,4 whereas the remaining 6 (20%) 
patients were diagnosed with MS based on MRI evidence of DIT5 alone. The median time 
from incident demyelination to MS diagnosis was shorter in the prospective group (3.6 
months, IQR 2.4-8.4) than the archived group (14.4 months, IQR 6.0-20.4; p=0.019). One 
child in the archived group, who presented with transverse myelitis, was diagnosed with 
table 5.1 Clinical and demographic characteristics of participants.
Archived group Prospective group
overall
(n=42)
ms
(n=15)
monophasic 
ADs (n=27)
overall
(n=45)
ms
(n=15)
monophasic 
ADs (n=30)
p-value*
Length of clinical 
observation (years)
7.1 (3.5) 8.0 (3.5) 6.6 (3.4) 3.3 (1.4) 3.3 (1.3) 3.3 (1.5) <0.0001
Age at onset (years) 9.5 (4.9) 12.1 (3.5) 8.0 (5.0) 9.1 (5.5) 15.1 (1.9) 6.1 (4.1) 0.734
Age at onset
<10 years 19 (45%) 4 (27%) 15 (56%)  26 (58%) 1 (7%) 25 (83%) 0.286 
≥10 years 23 (55%) 11 (73%) 12 (44%)  19 (42%) 14 (93%) 5 (17%)  
Female 22 (52%) 10 (67%) 12 (44%) 27 (60%) 7 (47%) 20 (67%) 0.521
Female : male ratio 1.1 2.0 0.8 1.5 0.9 2.0 --
Age at MS diagnosis 
(years)
-- 13.8 (3.9) -- -- 15.6 (1.8) -- 0.121§
Time to MS diagnosis 
(years)
-- 1.2 (0.5-1.7) -- -- 0.3 (0.2-0.7) -- 0.019§
2nd clinical attack -- 12 (80%) -- -- 12 (80%) -- 1.0§
ADS phenotype
ADEM 13 (31%) 1 (7%) 12 (44%)  15 (33%) 0 (0%) 15 (50%) 0.605 
Transverse myelitis 5 (12%) 1 (7%) 4 (15%)  2 (4%) 1 (7%) 1 (3%) 
Optic neuritis 5 (12%) 2 (13%) 3 (11%)  4 (9%) 1 (7%) 3 (10%) 
Monofocal – other 8 (19%) 7 (47%) 1 (4%)  7 (16%) 5 (33%) 2 (7%) 
Polyfocal 11 (26%) 4 (27%) 7 (26%)  17 (38%) 8 (53%) 9 (30%) 
Abnormal MRI scan 34 (81%) 14 (93%) 20 (74%) 38 (84%) 15 (100%) 23 (77%) 0.779
*Comparison between the overall archived and prospective groups. §Comparison between children with 
MS in the archived group and those with MS in the prospective group. MS diagnosis based on either a 
confirmed second clinical attack at least 28 days after incident demyelination4, or 2005 McDonald criteria 
for MRI dissemination in time: gadolinium enhancement occurred at least 3 months after clinical onset if 
not at the site corresponding to the initial event, or a new T2 lesion was seen at any time compared with a 
reference scan acquired at least 30 days after clinical onset.5
Data are mean (standard deviation, SD), median (interquartile range, IQR) or number (%).
MS = multiple sclerosis, ADS = acute demyelinating syndrome, ADEM = acute disseminated encephalomyelitis. 
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MS after 8 years and has subsequently experienced three relapses. Five (17%) children 
with MS experienced their first attack prior to ten years of age. Of the 28 children who 
met criteria for ADEM at onset, only one was diagnosed with MS after experiencing two 
non-ADEM attacks.2 Of the 27 children with clinically monophasic ADEM, 17 had serial 
MRI scans and none had new lesions.
T2 lesions were present in 73 (84%) children; 14 (16%) had normal brain imaging at 
onset (1 with ADEM, 5 with monofocal ON, 5 with monofocal TM, and 3 with polyfocal 
neurological deficits). Of the 30 children with MS, 29 had T2-weighted lesions present on 
brain MRI at ADS. The one child without brain lesions presented with transverse myelitis, 
but subsequently developed clinical and MRI evidence of brain involvement.
Table 5.2 demonstrates the performance of the MRI parameters. Comparing the pro-
spective cohort to the archived group with regards to performance of the MRI param-
eters at correctly identifying children diagnosed with MS according to the occurrence of 
a second clinical attack or MRI evidence of DIT, sensitivity (93.3% vs. 66.7%; p=0.0686), 
specificity (86.7% vs. 85.2%; p=0.8706), PPV (77.8% vs. 71.4%; p=0.6783), and NPV (96.3% 
vs. 82.1%; p=0.0915) were not statistically different. Similarly, the 95% confidence inter-
vals overlapped considerably when comparing positive and negative likelihood ratios 
of the prospective cohort (LR+ 7.0, 95% CI 2.8-17.6; LR- 0.08, 95% CI 0.01-0.5) to the 
archived group (LR+ 4.5, 95% CI 1.7-11.9; LR- 0.39, 95% CI 0.2-0.8).
In total, MRI scans of six patients with MS (5 in the archived group; 1 in the prospective 
cohort) did not demonstrate the MRI parameters on baseline images (20% false negative 
rate). Of these, one child who presented with transverse myelitis did not have brain le-
sions at onset. Of the remaining five children (three of whom were under ten years of age 
at ADS), three children had T2 brain lesions, but no T2 periventricular or T1-hypointense 
lesions, and two had T2 periventricular lesions but no T1-hypointense lesions.
Eight children (4 in the archived group; 4 in the prospective cohort) were predicted to 
have MS based on presence of both MRI parameters, but to date have not experienced 
MRI or clinical evidence of relapsing disease (14% false positive rate). Of the eight par-
ticipants, 6 were female and 6 were less than 10 years of age at onset. Three children 
presented with ADEM, 2 with monofocal deficits, and 3 with polyfocal neurological 
deficits.
We performed a sensitivity analysis to evaluate the effect of method of MS diagnosis 
on the performance of the MRI parameters. As illustrated in Table 5.2, when MS diagnosis 
was defined on the basis of clinical relapses only4, estimates of diagnostic performance 
were not significantly different from the estimates obtained when MS was diagnosed 
on the basis of a second attack or MRI evidence of DIT (statistical analyses not shown).
In a post hoc analysis, we evaluated the performance of the MRI parameters at cor-
rectly classifying children with ADEM as having monophasic demyelination. Of the 28 
children with monophasic ADEM, 25 were correctly classified as not having MS and three 
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children were incorrectly predicted to have MS. Of the 25 children with ADEM who were 
correctly classified as having a monophasic illness, 15 had neither T2 periventricular nor 
T1-hypointense lesions, 8 had T2 periventricular but no T1-hypointense lesions, and 2 
had T1-hypointense but no T2 periventricular lesions. Three children with clinically and 
radiographically monophasic ADEM had both T1-hypointense and T2 periventricular 
lesions at onset, and therefore were falsely classified as having MS. All three children 
were female, less than ten years of age at onset, and have been followed clinically for 4.9 
years, 3.2 years, and 2.4 years.
Discussion
We confirm the high sensitivity and specificity of T1 hypointense lesions and T2 peri-
ventricular lesions as predictive of MS outcome in children with ADS, supporting our 
initial work.1 That the presence of periventricular lesions – a characteristic location for 
MS lesion formation, and T1-hypointense lesions at ADS – an indicator of established 
tissue injury – are robust early predictors of MS diagnosis is in line with current concepts 
of MS pathobiology.
table 5.2 Performance of MRI parameters for predicting MS diagnosis.
ms diagnosis according to occurrence 
of 2nd attack4 or 2005 mcDonald Dit5
ms diagnosis according to occurrence of 
2nd attack4 alone
Archived 
Group
(N=42)
Prospective 
Group
(N=45)
p-value Archived 
Group
(N=42)
Prospective 
Group
(N=45)
p-value
True Positives, n 10 14 8 11
True Negatives, n 23 26 24 26
False Negatives, n 5 1 4 1
False Positives, n 4 4 6 7
Sensitivity,
% (95% CI)
66.7
(38.4-88.2)
93.3
(68.1-99.8)
0.0686 66.7
(34.9-90.1)
91.7
(61.5-99.8)
0.1314
Specificity,
% (95% CI)
85.2
(66.3-95.8)
86.7
(69.3-96.2)
0.8706 80.0
(61.4-92.3)
78.8
(61.1-91.0)
0.8988
Positive Predictive 
Value, % (95% CI)
71.4
(41.9-91.6)
77.8
(52.4-93.6)
0.6783 57.1
(28.9-82.3)
61.1
(35.7-82.7)
0.8192
Negative Predictive 
Value, % (95% CI)
82.1
(63.1-93.9)
96.3
(81.0-99.9)
0.0915 85.7
(67.3-96.0)
96.3
(81.0-99.9)
0.1717
Positive Likelihood 
Ratio (95% CI)
4.5
(1.7-11.9)
7.0
(2.8-17.6)
3.3
(1.5-7.6)
4.3
(2.2-8.5)
Negative Likelihood 
Ratio (95% CI)
0.39
(0.2-0.8)
0.08
(0.01-0.5)
0.42
(0.2-0.9)
0.1
(0.02-0.70)
DIT = dissemination in time, CI = confidence interval.
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The first aspect of our validation study was performed in the Dutch prospective cohort, 
an independent but methodologically similar study population to the Canadian Demy-
elinating Disease program7 from which the MRI parameters were originally developed.1 
Specifically, both studies utilized the International Pediatric MS Study Group consensus 
definitions2 to characterize ADS phenotype and MS diagnosis, both studies utilized 
the same standardized clinical reporting form, and the MRI protocols utilized were suf-
ficiently similar to permit consistency in evaluation of commonly acquired sequences. 
The Dutch and Canadian cohorts are also similar clinically: (i) the proportion of children 
with ADS subsequently diagnosed with MS was 36% in the Dutch prospective cohort 
and 20% in Canadian prospective study; and (ii) the diagnosis of MS in children with an 
initial ADEM presentation was extremely rare in both cohorts (none in the Dutch cohort 
and one in the Canadian). Thus, in cohorts of children with typical ADS, we demonstrate 
robust sensitivity (Dutch cohort 93%, Canadian study 84%) and specificity (Dutch cohort 
87%, Canadian study 93%) of the MRI parameters.
We then applied the MRI parameters to a dataset of archived scans of children with 
ADS in the Netherlands, in order to evaluate the MRI parameters in patients not enrolled 
in prospective research protocols. MRI scans in this archived group were obtained at 
either 1.0 or 1.5 Tesla, and were not obtained according to a consistent protocol. The 
estimate of sensitivity (67%), although not statistically significantly different, is lower 
than that from the prospective cohort (93%). Although all MRI scans analyzed were con-
sidered to be of sufficient quality for scoring, the increased number of false negatives in 
the archived cohort may be due to image quality and variable sequence acquisition in 
the archived dataset compared with the prospective cohort. Specifically in the archived 
set, FLAIR imaging was either less frequently acquired or acquired in the coronal rather 
than axial plane, whole brain coverage was not achieved, and the contrast between grey 
matter and white matter on T1-weighted imaging was poorer, rendering detection of T2 
lesions in the periventricular region and T1-hypointense lesions more challenging. Since 
common practice as well as a published MRI protocol for MS10 includes axial FLAIR and T2 
sequences with contiguous three millimeter slices, we anticipate that these sequences 
will enhance sensitivity of our MRI parameters.
The ability to predict whether children with incident CNS demyelination will be diag-
nosed with MS is important for counseling of families and for planning of patient care. A 
key challenge in pediatric demyelination is the ability to predict MS diagnosis across the 
full range of ADS presentations, particularly in the context of ADEM. Given that ADEM 
is particularly more common in children than adults11-13, MRI parameters that effectively 
stratify unselected groups of children with ADS, including those with ADEM, into high 
and low likelihood for MS diagnosis have significant clinical value.
Eight children (14% false positive rate) would have been predicted by our MRI param-
eters to be diagnosed with MS, yet have experienced a clinically monophasic disease 
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course to date (three with ADEM, three with polyfocal and two with monofocal ADS). 
Whether these eight children are particularly likely to reach a diagnosis of MS in the 
future remains to be determined as standardized serial imaging is not performed in 
the Dutch study, and thus MRI evidence of DIT was potentially underappreciated. Thus, 
while the ability to predict MS diagnosis based on initial MRI has obvious value to the 
immediate care of the child, it remains important to emphasize that long-term monitor-
ing of children with ADS is essential to capture either new lesions on serial MRI scans or 
a second clinical attack.
Evaluation of the predictive validity of the MRI parameters at baseline is influenced 
by the method of MS diagnosis. As expected, given that MRI evidence of new lesions is 
often independent of clinical relapses14, 15, when restricting our analysis to only children 
with confirmed clinical relapses, the positive predictive value of the MRI parameters 
was slightly but not significantly reduced. A further confound is that six children in the 
current study initiated MS-targeted therapy after MRI confirmation of DIT, four of whom 
have not had a second clinical attack to date.
Our study has several limitations. In the archived collection of MRI scans, acquisition 
orientation, slice thickness, interslice gap and image contrast were not consistent, and 
images were acquired on 1.0 T and 1.5 T scanners. The children enrolled in the prospec-
tive Dutch program were imaged with more consistent protocols, and were all imaged at 
1.5 T. Our primary goal was to devise a predictive tool suited to application in the clinical 
context, and across variable imaging protocols. While the results of our predictive model 
performed better when applied to more rigorously acquired MRI scans, our parameters 
remained valid even within the limits of variable sequence parameters or quality. We also 
acknowledge the limitation of including both a retrospective and prospective patient 
sample in our present analysis. For the retrospective pediatric MS patients, MS diagnosis 
was made largely on the basis of confirmed relapsing clinical disease, given that consis-
tent serial MRI studies were not available for earlier diagnostic confirmation of MS. In 
contrast, for the prospectively enrolled children, MRI studies were more frequently and 
consistently obtained, and thus new lesions on MRI were more likely to be detected, 
as reflected by the shorter time from first attack to MS diagnosis in this group. For our 
purposes, however, the outcome was not time to MS diagnosis; rather, we focused only 
on whether our MRI parameters correctly distinguished children with MS from those 
with monophasic disease. Finally, as is true for all predictive models, it is imperative to 
acknowledge that some children currently considered to have monophasic disease, may 
ultimately experience new disease activity leading to a diagnosis of MS.
Overall, we confirm that T2 lesions in the periventricular white mater (a region well-
recognized as targeted in MS) and the presence of T1-hypointense lesions (suggestive 
of established pathology) are robust predictors of a future diagnosis of MS in children 
with ADS.
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 suPPlementAl mAteriAl
supplementary table 5.1 Demographic and clinical characteristics of excluded patients (n=28).
Patient 
number
group reason for 
exclusion
sex ADs Age at 
onset, years
Diagnosis
1 Prospective Failed QC F ADEM 3.9 Monophasic ADS
2 Prospective No MRI scan F TM 3.3 Monophasic ADS
3 Prospective Failed QC F Polyfocal 12.4 Monophasic ADS
4 Prospective Failed QC M ON 10.3 Monophasic ADS
5 Prospective No T1 scan F ADEM 8.9 Monophasic ADS
6 Prospective Failed QC F ON 14.6 MS
7 Prospective Failed QC F Polyfocal 16.8 MS
8 Prospective Failed QC M ADEM 2.8 Monophasic ADS
9 Prospective Failed QC M ADEM 3.5 Monophasic ADS
10 Prospective Failed QC F ON 16.3 MS
11 Prospective No T1 scan F Monofocal 13.7 Monophasic ADS
12 Prospective No MRI scan M TM 12.5 MS
13 Archived Failed QC M Polyfocal 7.2 Relapsing ADS*
14 Archived No MRI scan F Monofocal 14.8 Monophasic ADS
15 Archived Failed QC M ADEM 4.3 Monophasic ADS
16 Archived No MRI scan M TM 8.1 Monophasic ADS
17 Archived Failed QC M TM 3.6 Monophasic ADS
18 Archived Failed QC M Polyfocal 5.9 Monophasic ADS
19 Archived Failed QC M ADEM 7.6 Monophasic ADS
20 Archived Failed QC M TM 6.8 MS
21 Archived Failed QC F ADEM 4.2 Monophasic ADS
22 Archived Failed QC F Polyfocal 12.4 MS
23 Archived No MRI scan F TM 15.4 Monophasic ADS
24 Archived Failed QC M Monofocal 8.1 Monophasic ADS
25 Archived Failed QC M ADEM 4.3 Monophasic ADS
26 Archived Failed QC M Monofocal 13.0 Monophasic ADS
27 Archived Failed QC M Polyfocal 5.7 Monophasic ADS
28 Archived Failed QC M Polyfocal 10.9 Monophasic ADS
summary statistics F: 12(43%) non-ADem:
21 (75%)
mean (sD):
9.0 (4.5)
ms: 6 (21%)
*This child presented with an “ADEM-like” incident demyelinating episode, and subsequently has had mul-
tiple episodes of optic neuritis; brain MRI does not meet criteria for multiple sclerosis. The child has been 
treated with intravenous immunoglobulins, and has not experienced further clinical or MRI evidence of 
relapse. Until present, the child does not meet criteria for neuromyelitis optica.
QC = quality control, MRI = magnetic resonance imaging, F = female, M = male, ADS = acute demyelinating 
syndrome, ADEM = acute disseminated encephalomyelitis, TM = transverse myelitis, ON = optic neuritis, MS = 
multiple sclerosis
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AbstrAct
background Clinically isolated syndrome (CIS) is a first demyelinating event of the 
central nervous system (CNS) and can be a single event. After CIS a chronic disease 
course with ongoing inflammation and relapses might occur, resulting in a diagnosis 
of multiple sclerosis (MS). Whether children and adults with CIS have the same disease 
course has not been prospectively explored yet.
methods Patients with CIS, whose age ranged from 1-50 years, were prospectively fol-
lowed. We divided the patients in four different age groups: patients 1-10, 11-16, 17-29, 
and 30-50 years old. Among these groups demographic data, disease course, time to MS 
diagnosis and annualized relapse rates (ARR) were compared.
results We included 383 CIS patients, of whom 218 (56.9%) were diagnosed with MS. 
11-16 year-old children had the highest rate of MS conversion (85% versus 51% in the 
other age groups together, p<0.01) and the shortest time to MS diagnosis (median time 
2.6 months (IQR: 0.62-5.94) versus 7.8 months (IQR: 2.0-25.5) in the other age groups 
together, p<0.01). Highest ARR were found in 1-10 year-old children with MS (ARR: 0.79), 
followed by 11-16 year-old children with MS (ARR: 0.62). In 30-50 year-old adults with 
MS the ARR was 0.41.
conclusion Children with CIS tend to have a more inflammatory disease course appear-
ing from the high relapse rate in all children, and the highest rate of MS conversion 
in 11-16 year-old children. This supports early initiation of first-line disease modifying 
therapy in children with CIS who are at high risk for a future MS diagnosis.
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introDuction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central 
nervous system (CNS) which can cause a broad spectrum of neurological deficits.1 
Worldwide over 2.5 million people suffer from MS.1 MS mostly affects young women 
in their early twenties or thirties, and although rare, MS can also occur in children.2 MS 
can be diagnosed when a first event of CNS demyelination, a so-called clinically isolated 
syndrome (CIS), is followed by a new clinical event.3-5 In addition, MS can be diagnosed 
after CIS when new lesions, which fulfill MS diagnostic criteria for dissemination in time 
and space, are detected on Magnetic Resonance Imaging (MRI).4, 5 However CIS can be 
a single event. Whether childhood-onset versus adulthood-onset CIS and MS reflect the 
same disease is unknown.6-8 Previous studies focused on MS and did not compare the 
disease course between children and adults after the onset of CIS.9-15 Despite existing 
parallels in childhood-onset and adulthood-onset MS, there are fundamental differ-
ences in presentation and disease course. Several studies have reported a higher relapse 
rate and MRI lesion load in children than in adults with MS.10, 12, 13, 16, 17 On the other 
hand, the progression of disability is slower in children with MS.14, 15 It should be noted, 
however, that some of the previous studies included retrospective cohorts11, 14, 15, 17, and 
some were conducted before the immunomodulatory treatment era in children.9-11, 14, 15 
Current recommendation and use of disease modifying therapies (DMT) in children with 
MS likely influenced their disease course and relapse rate.18 Several studies have shown 
initiation of first-line DMT (interferon or glatiramer acetate) in adults with CIS delays MS 
diagnosis and disability accumulation.19-21 In children with CIS it is not common practice 
yet to offer first-line DMT prior to MS diagnosis. Here, we performed a clinical prospec-
tive follow-up study of 383 patients with CIS, whose age ranged from 1 - 50 years, in 
order to report a comparison of childhood-onset versus adulthood-onset CIS and MS.
methoDs
Patients and definitions
Patients with CIS were included between April 2006 and August 2015, either in our pro-
spective cohort of adults with CIS (PRedicting the Outcome of a Demyelinating event, 
PROUD study)22, or in our prospective cohort study of children with a first episode of 
acquired demyelination of the CNS (PROUDkids).23 Both studies are ongoing multicenter 
observational studies conducted at Erasmus MC in Rotterdam, the Netherlands, and 
study protocols have been described previously.22, 23 Patients younger than 51 years 
old were included within 6 months after the first onset of their clinical symptoms. At 
baseline, a MRI scan was performed and routine laboratory tests were done. Patients 
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with alternative diagnoses other than CIS were excluded. After baseline patients were 
reassessed at least annually.
We used a prediction rule for defining children with CIS at high risk of MS when they 
fulfilled two out of three criteria at onset: more than nine T2 white matter lesions, and/
or at least one gadolinium-enhancing lesion on MRI, and/or positive oligoclonal bands 
(OCB) in cerebrospinal fluid.24, 25 MS was diagnosed in adults according to the 2010 
McDonald criteria.5 Children were diagnosed with CIS and MS according to the diag-
nostic criteria from the International Pediatric Multiple Sclerosis Study Group (IPMSSG).4 
Clinically definite multiple sclerosis (CDMS) was defined as two attacks with (para)clinical 
evidence of two separate lesions as described by Poser26 and should include two non-
encephalopathic events.4 The expanded disability status scale (EDSS scale) was used to 
define disability.27 EDSS scores were obtained at least 2 months after a relapse occurred. 
Secondary progressive MS is defined as a history of gradual worsening after an initial 
relapsing-remitting disease course, with or without exacerbations during the progres-
sive course.28 This study was approved by the medical ethical committees of Erasmus 
MC in Rotterdam and of the other participating centers. Written informed consent was 
provided for all patients.
Data analysis
Statistical analysis was performed using SPSS v20 (SPSS Inc., Chicago, Illinois, USA) and 
GraphPad Prism 5 (GraphPad., San Diego, USA). We divided the patients in four different 
age groups of clinical interest, based on evidence that puberty enhances CNS autoim-
munity in females29: i.e. pre-puberty, puberty, young adults and adults (patients 1-10, 
11-16, 17-29, and 30-50 years old). Among these groups we compared demographic 
data, disease course, time to MS diagnosis and annualized relapse rate (ARR). We used 
the Kolmogorov-Smirnov test to assess normal distribution of the data. For the compari-
son of continuous data between two groups we applied a two-tailed t-test, or when the 
data were not normally distributed a Mann-Whitney U test. For the analysis of multiple 
groups, we used the one-way-ANOVA for normally distributed data, and Kruskal-Wallis 
test for not normally distributed data. Categorical data were analyzed using the Chi-
square or Fisher’s exact test. Kaplan-Meier survival analyses were used to analyse the 
time to MS diagnosis. Univariate and multivariable Cox proportional hazard regression 
models were used to obtain hazard ratios for MS diagnosis and EDSS 4.0 respectively. 
Patients who were not diagnosed with MS, or did not reach EDSS 4.0 during follow-up 
respectively, were considered as censored observations in those analyses. Negative 
binomial regression, with the natural logarithm of follow-up years after MS diagnosis as 
offset, was used to analyse ARR after CIS. This offset was used to correct for the different 
follow-up times between patients. We used a generalized estimating equations (GEE) 
model to compare ARR with and without disease-modifying treatment. This GEE model 
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includes the effect and interaction of treatment and age group and accounts for the 
correlation within patients.
results
characteristics of patients with cis
We included 383 patients who met our inclusion criteria. The youngest included patient 
had CIS at the age of 1 year, and the oldest included patient was 50 years at the time of 
CIS. 218 patients (56.9%) were diagnosed with MS during follow-up. Patient characteris-
tics for the four different age groups are shown in Table 6.1.
CIS patients in the age group 11-16 had the highest rate of MS conversion (85% versus 
51% in the other age groups together p<0.01) and the shortest time to MS diagnosis 
(median time 2.6 months (IQR: 0.62-5.94) versus 7.8 months (IQR: 2.0-25.5) in the other 
age groups together, p<0.01).The time to MS diagnosis is presented in Figure 6.1. Hazard 
ratios for future MS diagnosis for the different age groups are shown in Table 6.2.
Disease course after ms diagnosis
ARR corrected for follow-up were higher in children than in adults with MS (mean ARR 
0.66 vs 0.43, p<0.01). ARR in MS patients per age group, and ARR with and without DMT 
are presented in Table 6.3.
The time to reach EDSS 4.0 in patients who were diagnosed with MS was shorter in 
30-50 year-old adults than in the other groups, hazard ratio 3.0 (p=0.04). Using a mul-
tivariable COX regression model including MRI and CSF features (n=119), in which we 
corrected for optic neuritis at CIS, the presence of gadolinium enhancing lesions and 
positive OCB in CSF, the hazard ratio was 4.5 (p=0.03). Kaplan-Meier curves for time to 
EDSS 4.0 in MS patients are demonstrated in Figure 6.2. Eight patients in the age group 
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Figure 6.1 Kaplan-Meier curves 
for time to MS diagnosis for pa-
tients in different age catego-
ries. (Log Rank test p<0.01).
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30-50 were diagnosed with secondary progressive MS (SPMS), and none of the younger 
patients were diagnosed with SPMS during follow-up (p<0.01).
Using a prediction rule at onset (methods), 42 out of 94 (45%) 1-16 year-old children 
with CIS were defined at high risk for a future MS diagnosis. Of them 25 ≥12 year-old 
children were diagnosed with MS at the first event.4 The other 17 children were diag-
nosed with MS during follow-up based on new relapses or on MRI-criteria. None of the 
children with CIS who remained monophasic during follow-up were defined as having a 
high risk for MS by using this prediction rule (sensitivity 68%, specificity 100%).
table 6.2 Hazard ratios for MS diagnosis, univariate cox regression analysis.
Age groups (years) Number of patients Number of events Hazard ratio (95% CI) p-value
1-10 28 6 0.4 (0.2-0.9) 0.03
11-16 66 56 3.6 (2.6-5.1) <0.01
17-29 115 72 1.5 (1.1-2.1) 0.01
30-50 174 84 1(ref )
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Figure 6.2 Kaplan-Meier curves 
for time to EDSS 4.0 for MS pa-
tients in age groups 1-29 and 
30-50. Legend: We merged 
the younger age groups (1-10, 
11-16, 17-29) since the patient 
numbers were small and their 
KM-curves overlapped.
table 6.3 ARR corrected for follow-up in MS patients per age group.
Age group Total years at 
risk after MS 
diagnosis
Total 
number of 
relapses
Overall ARR
(95% CI)
ARR 
with-
outDMT
ARR 
with 
DMT
p-valuea Interaction 
coefficient 
of DMT
p-valueb
0-10 (n=6) 15.4 12 0.79 (0.42-1.48) 5.22 0.43 <0.01 5.64 0.033
11-16 (n=56) 154.3 94 0.62 (0.49-0.77) 2.13 0.47 <0.01 2.08 0.040
17-30 (n=72) 200.6 104 0.52 (0.42-0.65) 1.16 0.45 <0.01 1.19 ns
30-50 (n=84) 283.6 114 0.41 (0.34-0.51) 0.81 0.37 <0.01 Ref. Ref.
a Presented p-values for the comparison of ARR with and without DMT within the different age groups.
b Presented p-values for the interaction coefficient of DMT for the different age groups.
ARR = annualized relapse rate, DMT = disease modifying therapies, CI = confidence interval
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Discussion
The purpose of our study was to report a comparison of childhood-onset versus 
adulthood-onset CIS and MS in a large prospective cohort during the current immuno-
modulatory treatment era. The results of our study suggest a more inflammatory disease 
course, rather than a neurodegenerative disease course, in 11-16 year-old children with 
CIS, as this group had the highest rate of MS conversion and the shortest time to MS 
diagnosis, higher ARR, higher MRI lesion load and a more inflammatory CSF profile. A 
secondary progressive MS disease course, which reflects a more neurodegenerative in-
stead of an inflammatory phase of MS, was found in eight 30-50 year-old adult patients. 
However, secondary progression in MS is age dependant and probably therefore has 
not been observed yet in our younger patients with the current follow-up.30 In addition, 
we found higher EDSS progression rates in adults than in children. Previous studies on 
childhood-onset MS versus adulthood-onset MS, have already reported a higher relapse 
rate in children than in adults.10, 12, 13 In our unique prospective study we followed 
children and adults after the first attack. Since we collected a large cohort, we could 
compare subgroups and draw conclusions for different age groups of clinical interest. 
Overall, we found a female predominance both in patients with CIS and MS, except in 
young children who were diagnosed with MS before puberty, of whom four out of six 
MS patients were boys. The difference in sex distribution in children diagnosed with MS 
before and after puberty and the higher rates of MS diagnoses after puberty suggests 
that sex hormones contribute to the onset of MS.2, 23, 29 A remarkable high rate of non-
Caucasian ethnicities was observed in 11-16 year-old children with CIS. Higher rates of 
non-Caucasian ethnicities have been reported in childhood-onset MS and might reflect 
a higher vulnerability of developing MS at a younger age.23, 31, 32 A possible explanation 
for this might be that non-Caucasians miss certain protective genes since their ances-
tors were born in countries with a low prevalence of MS.23 In the lowest age group of 
1-10 years old, 28.6% of the children with CIS were non-Caucasians, while 83.3% of the 
children with MS were non-Caucasians.
The shorter time to MS diagnosis in 11-16 year-old children is partly explained by the 
current diagnostic MRI criteria which allow for an early MS diagnosis in a subgroup of 
the patients at first MRI, however not in children younger than 12 years of age.4, 5 Still, 
we observed a high rate of CDMS and short time to CDMS diagnosis in 11-16 year-old 
children.
Early initiation of DMT in adults with CIS might have influenced their disease course. 
However, a relatively small proportion of adults (12.5%) started with DMT before MS 
diagnosis and in a subanalysis (data not shown) we found similar results when we ex-
cluded these patients. Relapse rates decrease after the initiation of DMT in both children 
and in adults with MS. It is unlikely our observed differences in ARR are only caused by 
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early initiation of DMT, since a small proportion of CIS patients started with DMT prior to 
the MS diagnosis and pre-treatment ARR differed significantly. First-line DMT is already 
offered to adults with CIS who are at high risk for a future MS diagnosis, but not to chil-
dren with CIS. However, DMT especially reduce MS relapse rates and have been shown 
beneficial in children with MS.18 In addition, DMT might prevent disability progression. 
Therefore early initiation of first-line DMT in children with CIS who are at high risk for MS 
seems logical. By using a prediction rule at onset, we found that 42 out of 94 (45%) 1-16 
year-old children with CIS were defined as at high risk for MS, and could have started 
with first-line DMT at onset, since all 42 children were diagnosed with MS during follow-
up. The utility of this prediction rule should be validated in other prospective cohorts 
for its usefulness and safety. A limitation of our study is that the follow-up is limited 
and relatively shorter in children with CIS since our prospective study in adults started 
prior to our prospective study in children. With the current follow-up, however, we 
could already demonstrate important differences in rates of MS diagnosis and relapses. 
It would be interesting to follow our cohort in order to compare the clinical outcome 
and disease progression over several decades. Another limitation of our study is a selec-
tion bias since we only included patients with CIS, while in children it is known that 
MS can present with a spectrum of acquired demyelinating events, including ADEM.4 
However, it is not expected that this influences our results much, since it is uncommon 
that children are diagnosed with MS after ADEM, using the current diagnostics criteria.4 
In addition, there could have been a selection in patients who were reported for our 
prospective studies by physicians from other hospitals. Furthermore, we do not have a 
standard MRI protocol, gadolinium was not administered to all patients at the first event, 
nor was a lumbar puncture performed in all patients. Nevertheless, our data resemble 
clinical practice. In summary, we found a more inflammatory disease course of CIS and 
MS in children. This could argue for early initiation of first-line disease modifying therapy 
in children with CIS who are at high risk for a future MS diagnosis.
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Risk genes associated with pediatric-onset MS but 
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AbstrAct
objective To investigate whether 57 genetic risk loci recently identified in a large-scale 
genome-wide association study (GWAS) in adult MS patients are also associated with 
a risk for pediatric-onset MS and whether they can predict MS diagnosis in children 
presenting with acquired demyelinating syndromes (ADS).
methods We included 188 children with ADS, of which 53 were diagnosed with MS, 466 
adult-onset MS patients and 2046 adult controls in our cohort study. Weighted genetic 
risk scores (wGRS) were calculated to evaluate genetic effects.
results Mean wGRS was significantly higher for pediatric-onset MS patients (7.32 ± 0.53) 
as compared with monophasic ADS patients (7.10 ± 0.47, p=0.01) and controls (7.11 ± 
0.53, p<0.01). We found no difference in mean wGRS of participants with monophasic 
ADS (7.10 ± 0.47) and controls (7.11 ± 0.53). The ability of the wGRS for the 57 SNPs to 
discriminate between children with MS and those with monophasic ADS was moderate 
(AUC =0.64), but improved with the addition of sex and HLA-DRB1*15 (AUC =0.70). The 
combined effect of 57 SNPs exceeded the effect of HLA-DRB1*15 alone in our risk models 
for pediatric- and adult-onset MS.
conclusion The previously reported 57 SNPs for adult-onset MS also confer increased 
susceptibility to pediatric-onset MS, but not to monophasic ADS.
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introDuction
Multiple sclerosis (MS) is being increasingly diagnosed in childhood.1 In children, an ini-
tial attack of central nervous system (CNS) demyelination (acquired demyelinating syn-
drome or ADS) frequently remains monophasic. Approximately 21-32% of the children 
with ADS will display further MRI or clinical evidence of inflammatory CNS demyelination 
meeting diagnostic criteria for MS.2, 3 This is in contrast with adults, where the majority 
of patients are diagnosed with MS after an initial event of acute CNS demyelination.4 
Pediatric-onset MS has been proposed as a unique time window for the study of early 
MS disease mechanisms. However, it is not known whether pediatric- and adult-onset 
MS share the same genetic risk factors. A recent Canadian study of a large ADS cohort 
reported that children harboring one or more HLA-DRB1*15 alleles were more likely to 
be confirmed to have MS, compared to ADS children lacking HLA-DRB1*15 alleles.5 While 
HLA alleles thus contribute to the risk of both pediatric- and adult-onset MS6, large-scale 
genome-wide association studies (GWAS) recently identified 57 non-HLA genetic risk 
loci in adult MS patients compared to controls.7 Whether these 57 single nucleotide 
polymorphisms (SNPs) also contribute to the risk of either MS in children, or childhood-
onset ADS more generally is not known. The objective of this study was to investigate 
whether the 57 SNPs identified in adult-onset MS are associated with increased risk 
of pediatric-onset MS, and whether such SNPs distinguish children with MS from chil-
dren with monophasic ADS. We utilized a previously published approach to generate 
compound-weighted genetic risk scores8, and compared the predictive value of the 57 
SNPs with the predictive value of HLA-DRB1*15 alone, in distinguishing children with MS 
from children with monophasic ADS and controls from the general population.
methoDs
Patients and definitions
Children younger than 16 years 0 days (Canadian cohort) and 17 years 0 days (Dutch 
cohort) of age who presented with ADS between 2001 and 2009 were enrolled in either 
the prospective Canadian Pediatric Demyelinating Disease Study or the Dutch Study 
group for Pediatric MS study. The Canadian National Pediatric Demyelinating Disease 
Study Group consists of 23 participating pediatric health care centers across Canada. 
The Dutch Study Group for Pediatric MS consists of 13 participating pediatric healthcare 
centers in the Netherlands. Initial phenotypes were characterized by clinical history and 
physical examination as clinically monofocal optic neuritis (ON), clinically monofocal 
transverse myelitis (TM), other clinically monofocal disease, clinically polyfocal disease, 
or acute disseminated encephalomyelitis (ADEM9). Children were diagnosed with MS 
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based either on evidence of a second clinical attack after at least 30 days or MRI evi-
dence of dissemination in time.9, 10 The recent 2010 iteration of the McDonald criteria for 
MS diagnosis was not available at the time of clinical classification, and was not used for 
this work. All participants had a minimum follow-up of 2 years from initial ADS. A total 
of 466 adult-onset (> 18 years) MS patients with either whole blood or saliva available 
to extract DNA were identified through the Rotterdam MS center. DNA from a control 
group of 2046 unrelated European adults from the general population was obtained 
from individuals enrolled in the longitudinal Rotterdam Study.11 In order to control the 
effect of genetic variation due to ancestry, only participants with self-reported European 
ancestry were included in the analyses presented in the paper. Potential stratification 
was corrected for by genomic control and principal component analysis.
standard protocol approvals, registration and Patient consents
Institutional ethical approval by an ethical standard committee on human experimenta-
tion was obtained at all 23 sites participating in the Canadian National Pediatric Demy-
elinating Disease Study and all 13 sites participating in the Dutch national study and for 
the Rotterdam study. Written informed consent for genetic analysis was obtained from 
all participants and/ or their families.
snP selection and genotyping
DNA isolation and purification from saliva (Oragene DNA Purification kit, DNA Genotek 
®) or whole blood samples12 was performed. Genotyping was performed using the Il-
lumina Human610-Quad Bead array and the 57 risk SNPs of interest were extracted.7 
An overview of these 57 risk SNPs and their odds ratios (ORs) obtained from a recent 
GWAS7 are presented in Supplementary Table 7.1. A tagging SNP (rs9271366) for the 
HLA-DRB1*15 locus was used. This SNP is in linkage disequilibrium (LD) (r2 =0.957)13 with 
the most often described HLA-DRB1*15 tagging SNP (rs3135388)14 in MS and is strongly 
correlated with the presence of HLA-DRB1*15 itself.15 We confirmed this linkage with 
HLA-DRB1*15 in our pediatric patients with an overlap of 97.4% for HLA-DRB1*15 allele 
typed using PCR amplification5 and the tagging SNP rs9271366 (r² =0.95, p<0.01). All 
genotyping was carried out blinded to clinical data.
genetic risk score computation
Unweighted genetic risk scores (uwGRS) were calculated by adding the total number 
of risk alleles for the 57 non-HLA SNPs carried by each individual. Weighted genetic risk 
scores (wGRS) were calculated by multiplying the number of risk alleles for each SNP 
with the effect size (log odd ratios) obtained from the literature7, 15 (Supplementary Table 
7. 1) and then taking the sum across all 57 risk SNPs.8, 16 To assess the additional effect of 
HLA-DRB1*15 status (as determined by presence of the rs9271366 tagging risk SNP), we 
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also calculated the wGRS for the 57 risk SNPs with and without including HLA-DRB1*15 
status. To determine how well our genetic risk scores discriminated between children 
with MS and monophasic ADS we constructed receiver operating characteristic (ROC) 
curves by plotting the sensitivity of the continuous wGRS scores against ‘1 -specificity’ 
and calculated the area under the ROC curve (AUC). AUC is a measure of how well the 
model is able to distinguish between patients and non-patients and varies between 0.5 
(no discrimination) and 1 (perfect discrimination). Sex, a known risk factor in MS1, 17, 18, 
was also included in the final adjusted models. For comparative purposes, we tested 
the performance of the wGRS using a risk model for our adult-onset MS patients and 
controls. This study was reported based on the guideline for the Reporting of Genetic 
Risk Prediction Studies (GRIPS).19
statistical analysis
Statistical analyses were performed using R software.20 The Welch two-sample t-test was 
used to compare the means of the GRS. PredictABEL package21 was used to compute 
univariate ORs. For the construction of the ROC curves and computation and compari-
son of the AUC values, we used PredictABEL21 and ROCR22 packages for the R software. 
SPSS Statistical Software (IBM Company, version 20) was used to analyze categorical 
and continuous variables (ex: sex and mean age) using Chi-Square and one-way-ANOVA 
tests and to calculate Spearman’s Rank Correlation Coefficient for HLA-DRB1*15 allele 
and tagging SNP rs9271366.
results
We identified 209 children with European background and with ADS. We excluded 8 
patients with relapsing diseases that were not MS (multiphasic / recurrent ADEM n=2, 
optic neuritis after ADEM n=1, and recurrent ON n=5). Two patients with neuromyelitis 
optica (NMO) and 5 patients with other alternative diagnoses (vasculitis n=1, cerebel-
litis n=1, CNS infection n=2 and one patient with progressive unexplained visual loss) 
were excluded. Three patients withdrew from the Canadian prospective study within 
6 months of ADS and were excluded. Two patients were excluded because poor DNA 
quality did not permit accurate genotyping and one patient was excluded because data 
for one risk SNP was missing. A total of 188 children with ADS were therefore included 
in this study. Of these 188 pediatric ADS patients, 53 children were diagnosed with 
MS during a mean overall follow-up period of 8.1 months (range 1.1 – 37.0 months, 
median 5.4 months, 90th percentile 17.6 months). The mean age at ADS (13.1 years ± 
3.08) of children subsequently diagnosed with MS was higher than the mean age (9.0 
years ± 4.57) of those who remained monophasic (F =21.82, p<0.01). There was a greater 
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proportion of females in the MS group as compared to the monophasic ADS group (χ² 
=7.880, p<0.01). Of the 135 children who had monophasic ADS, 52 had ADEM as their 
ADS phenotype. Patient and control characteristics are presented in detail in Table 7.1. 
We did not find any clinical differences between the children from the Canadian and the 
Dutch cohort (appendix 1).
There was modest population stratification (inflation factor 1.07). However, exclusion 
of outliers regarding genomic kinship had no influence on the results. Univariate ORs of 
the 57 risk SNPs for our patients with pediatric-onset and adult-onset MS are presented 
in Supplementary Table 7.1. We calculated the wGRS to investigate whether there is 
implication of the 57 risk SNPs in pediatric-onset MS risk, and if so, whether it is similarly 
implicated as in adults. The mean wGRS was similar between pediatric-onset MS and 
adult-onset MS (7.32 ± 0.53 vs. 7.40 ± 0.52, p=0.29). The mean wGRS differed signifi-
cantly between both MS groups and general population controls (p<0.01). We found a 
significantly higher mean wGRS in pediatric-onset MS patients as compared to children 
with monophasic ADS (7.32 ± 0.53 vs. 7.10 ± 0.47, p=0.01) and as compared to controls 
(7.32 ± 0.53 vs. 7.11 ± 0.53, p<0.01). In contrast, there was no difference in mean wGRS 
of participants with monophasic ADS (7.10 ± 0.47) and controls (7.11 ± 0.53).We did not 
find differences in mean GRS between children from the Canadian and the Dutch cohort 
(appendix 1). As an exploratory analysis, we were also interested in whether mean wGRS 
differed between children with an ADEM (n=52) presentation at ADS and controls or 
children with pediatric-onset MS. Since ADEM reflects a specific ADS presentation with 
encephalopathy and typical MRI features and often is post-infectious.9 No difference 
was found in mean wGRS between children with ADEM (7.06 ± 0.45) and controls, while 
table 7.1 Characteristics of patients and controls.
Pediatric-onset 
MS
Pediatric-onset 
Monophasic ADS
Controls Adult-onset 
MS
Total, n 53 135 2,046 466
Sex, % female 68 45 56 72
Age at onset, y, mean ± SD 13.1 ± 3.1 9.0 ± 4.6 NA NA
Type of onset
Optic Neuritis 10 (18.9%) 26 (19.3%) NA NA 
Transverse Myelitis  4 (7.5%) 28 (20.7%) 
Clinically monofocal disease 17 (32.1%) 11 (8.1%) 
Clinically polyfocal disease 19 (35.8%) 18 (13.3%) 
ADEM  3 (5.7%) 52 (38.5%) 
Follow-up time, months (range) 63.5 (25-115) 66.0 (24-160) NA NA
ADEM = acute disseminated encephalomyelitis, ADS = acquired demyelinating syndrome, MS = multiple sclero-
sis, NA = not available or not applicable.
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the mean wGRS was higher in children with MS as compared to the children with ADEM 
(7.32 ± 0.53 vs. 7.06 ± 0.45, p<0.01). Similar results were found for all comparisons us-
ing the unweighted GRS. In Figure 7.1A the distribution of the number of risk alleles in 
pediatric-onset MS patients and children with monophasic ADS is presented. Figure 7.1B 
displays the distribution of wGRS values as plot boxes for children with MS, children with 
monophasic ADS, adults with MS and controls from the general population.
We next examined how well the wGRS values were able to discriminate between 
children with MS and monophasic ADS or controls, as well as between adults with MS 
and controls. To do this, we created ROC-curves and calculated AUC-values, including 
the effects of HLA-DRB1*15 and sex. AUC values and their confidence intervals are pre-
sented in Table 7.2. The ability of the wGRS for the 57 non-HLA risk SNPs to discriminate 
between children with MS and those with monophasic ADS was moderate (AUC =0.64), 
but improved with the addition of sex and HLA-DRB1*15 (AUC =0.70). Comparable AUCs 
of the wGRS for the 57 risk SNPs (AUC =0.66) and for the 57 risk SNPs combined with 
sex and HLA-DRB1*15 (AUC =0.73) were found in our adult-onset MS patients when 
A B
Figure 7.1 Distribution of genetic parameters in patients and controls.
(A) Distribution of the number of risk alleles in children with multiple sclerosis (MS) (black) and monophasic 
acquired demyelinating syndrome (ADS) (green). It should be noted that patients can harbor 0, 1, or 2 al-
leles for each risk single nucleotide polymorphism (SNP). (B) Box plots present the distribution of weighted 
genetic risk score (wGRS) values in patients and controls. The distribution of wGRS is presented for children 
with MS, children with monophasic ADS, adults with MS, and controls from the general population using 
box plots. We found a significantly higher mean wGRS in patients with pediatric onset MS as compared to 
children with monophasic ADS (7.32 ± 0.53 vs 7.10 ± 0.47, p=0.01) and as compared to controls (7.32 ± 0.53 
vs 7.11 ± 0.53, p=0.01). The mean wGRS in patients with adult-onset MS was significantly higher compared 
with controls (7.40 ± 0.52 vs 7.11 ± 0.53, p=0.01). The mean wGRS was similar between pediatric-onset MS 
and adult-onset MS (7.32 ± 0.53 vs 7.40 ± 0.52, p=0.29).
HLA = human leukocyte antigen.
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Figure 7.2 Receiver operating characteristic curve for models identifying diagnosis of pediatric-onset mul-
tiple sclerosis among children with acquired demyelinating syndrome.
The results for 4 separate models to identify pediatric-onset multiple sclerosis (MS) cases among children 
with acquired demyelinating syndrome (ADS): weighted genetic risk score (wGRS) with HLA-DRB1*15 
(black); wGRS with 57 non-HLA risk loci (red); wGRS with HLA-DRB1*15 and 57 non-HLA risk loci (green); and 
wGRS with HLA-DRB1*15, including 57 non-HLA risk loci and sex (blue).
AUC = area under the curve, HLA = human leukocyte antigen, SNP = single nucleotide polymorphism.
table 7.2 AUC values for risk models for pediatric-onset MS versus monophasic ADS and adult-onset MS 
versus controls from the general population.
Pediatric-onset MS Adult-onset MS
AUC 95% CI AUC 95% CI
HLA-DRB1*15 0.60 0.52 - 0.67 0.63 0.60 - 0.65
HLA-DRB1*15 and sex 0.66 0.58 - 0.74 0.67 0.64 - 0.69
57 non-HLA SNPs 0.64 0.54 - 0.73 0.66 0.63 - 0.68
57 non-HLA SNPs and HLA-DRB1*15 0.66 0.58 - 0.75 0.71 0.69 - 0.74
57 non-HLA SNPs, HLA-DRB1*15 and sex 0.70 0.62 - 0.79 0.73 0.71 - 0.76
AUC = area under the receiver operating characteristic curve, CI = confidence interval, HLA = human leukocyte 
antigen, MS = multiple sclerosis, SNP = single nucleotide polymorphism.
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compared with controls. The combined effects of the 57 risk SNPs exceeded the effect 
of HLA-DRB1*15 alone in both models. In Figure 7.2, we present the ROC-curves for our 
model predicting pediatric-onset MS in children with ADS. In contrast, the same model 
using wGRS of the 57 non-HLA SNPs had no ability to discriminate between individuals 
with monophasic ADS and controls (AUC =0.50).
Discussion
We report a unique analysis of the 57 non-HLA SNPs recently found to confer risk for 
adult-onset MS, in a large prospective pediatric ADS cohort including children ascer-
tained to have MS and children with monophasic ADS. Using a compound weighted 
genetic risk score of the 57 SNPs, we found that mean wGRS significantly differs between 
pediatric-onset MS patients and controls and between children with MS and those with 
monophasic ADS. Our results indicate that the 57 non-HLA risk SNPs implicated in adult-
onset MS, also contribute to risk of MS in children. These SNPs do not appear to confer 
a general risk of CNS inflammation in children since wGRS of children with monophasic 
ADS and controls did not differ.
Disease onset during childhood may represent a heightened genetic susceptibility (a 
greater “genetic load”) or a particularly powerful interaction between genetic factors and 
childhood environmental risk exposures. We found no significant differences between 
the GRS of the 57 non-HLA risk SNPs in children and adults diagnosed with MS, suggest-
ing a similar cumulative genetic contribution to disease risk in both pediatric-onset and 
adult-onset disease. However, whether the very same loci make the same contributions 
to the pathophysiology of pediatric- and adult-onset MS remains to be fully elucidated, 
and would require large sample sizes to distinguish individual SNP contributions.
While mean wGRS was higher in the pediatric-onset MS group as compared to both 
the monophasic ADS and control group, our AUC modeling indicated only a modest 
ability to discriminate between children with MS and monophasic ADS (AUC =0.70 
for final adjusted model). The same model applied to adult-onset disease was compa-
rable in its ability to distinguish between MS patients and controls (AUC =0.73 for final 
adjusted model) and its discriminatory ability was similar to other published models 
using a compound genetic risk score in adult-onset MS.8,16 For comparison, the AUC of 
LDL-cholesterol as a risk predictor of coronary heart disease was 0.74 in men and 0.77 in 
woman in a large prospective study.23
As we expected, presence of HLA-DRB1*15 alone had a high contribution to the overall 
predictive ability of the model (AUC =0.60). However, a surprising finding of our study 
was that the predictive value as reflected in AUCs of the 57 non-HLA risk SNPs together 
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(AUC =0.64) was larger than the predictive value of the major MS risk allele HLA-DRB1*15 
(AUC =0.60) alone. We found a similar result in our adult MS patients.
There are several limitations in our study. While our pediatric MS cohort is relatively 
large given the rarity of this condition, our overall numbers still limit comparisons be-
tween groups. Future studies would be aided by large-scale multinational collaborations 
to facilitate the inclusion of more patients. Despite a mean duration of follow-up of 66.0 
months (range 24 – 160), it remains possible that some of the children currently classified 
as having monophasic disease will be diagnosed with MS in the future. We do not expect 
that this number will be very high, since pediatric MS studies have demonstrated a high 
early relapse rate24 and given that the time interval between incident attack and second 
event is typically less than 12 months.2, 25 In order to study a genetically homogenous 
group as possible, our study focused on individuals of European ancestry. Replication 
studies including individuals of mixed ethnicities will be valuable, though the field is 
currently hampered by differences in the distribution and linkage disequilibrium of the 
genetic variants. Other areas of future study include the generation of more complex 
prediction models that incorporate not only genetic susceptibility but also known en-
vironmental factors such as serum 25-hydroxyvitamin D levels and viral exposures.26 As 
has been seen in models for adult-onset MS and other autoimmune diseases, it is likely 
that the incorporation of non-genetic risk factors to the current genetic risk model will 
lead to improved predictive ability for pediatric-onset MS.27
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Appendix 1. supplementary statistical analysis
Appendix 1:  supplementary statistical analysis
Canadian and Dutch cohorts 
There were no overt clinical differences between the children from the Canadian and the 
Dutch cohort (mean age at onset, sex, type of onset, mean time of follow-up).  
Mean age at onset: one-way ANOVA F = 5.17, df = 35, p = 0.68 
Sex: Chi Square χ² = 2.7, df = 1, p = 0.10 
Type of onset: Chi Square χ² = 9.1, df = 4, p = 0.06 
Mean time of follow-up: one-way ANOVA F= 27.3, df = 30, p = 0.83 
We also did not find differences in the Genetic Risk Scores between children from the 
Canadian and the Dutch cohort. 
uwGRS 57 SNPs: Welch two-sample t-test  p = 0.49 
wGRS 57 SNPs: Welch two-sample t-test p = 0.55 
wGRS 57 SNPs + HLA: Welch two-sample t-test p = 0.14 
Controlling for possible population stratification 
In order to control the effect of genetic variation due to ancestry, only participants with self-
reported European ancestry were included in the analyses presented in the paper. Potential 
stratification was corrected by genomic control and principal component (PC) analysis. There 
was modest population stratification (inflation factor 1.07). However, exclusion of outliers 
regarding genomic kinship had no influence on the results. 
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AbstrAct
background Acquired demyelinating syndromes (ADS) in children are a group of dis-
tinct first immune-mediated demyelinating events of the central nervous system (CNS). 
Predictive biomarkers for future diagnosis are lacking. A putative target antigen is myelin 
oligodendrocyte glycoprotein (MOG). We analysed the presence of MOG-antibodies in 
a cohort of ADS patients.
methods 117 children with ADS form a nationwide cohort were analysed with a cell-
based assay, divided in 5 groups: optic neuritis (ON; n=20), transverse myelitis (TM; n=7), 
other monofocal ADS (n=22), polyfocal ADS without encephalopathy (n=44) and polyfo-
cal ADS with encephalopathy (n=24). Additionally, 13 children with other neurological 
diseases (OND), 31 healthy children and 29 adult ADEM patients were tested.
results Twenty-one of the 117 children with ADS tested anti-MOG seropositive (18%). 
The group of patients with polyfocal ADS plus encephalopathy (ADEM) had the highest 
prevalence of anti-MOG seropositivity (42% versus 18% in non-encephalopathic polyfo-
cal ADS patients). Forty-seven ADS children had a final diagnosis of multiple sclerosis 
(MS). In only one of them MOG-antibodies were detected (2%), with only borderline 
positivity. Only 1 out of 29 adult ADEM patients tested anti-MOG seropositive.
conclusions MOG-antibodies are strongly skewed towards ADS children that present 
with an ADEM-like disease-onset. The presence of such antibodies pleads against a 
future diagnosis of MS.
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introDuction
Acquired demyelinating syndromes (ADS) in children are first immune-mediated 
demyelinating events of the central nervous system (CNS).1, 2 The clinical spectrum is 
very heterogenic, including optic neuritis (ON), transverse myelitis (TM), other clinically 
isolated syndromes, acute disseminated encephalomyelitis (ADEM) and neuromyelitis 
optica (NMO). These distinct disease entities may be challenging to diagnose accurately 
at the first event. Disease course and prognosis are also variable and all these different 
subtypes of ADS can represent a first episode of multiple sclerosis (MS). It is essential to 
distinguish monophasic disease forms from a chronic relapsing disease like MS early in 
the disease course, because prompt initiation of disease-modifying treatment has been 
recommended for children with MS.3
Clinical evidence suggests that ADS includes several distinct disorders with different 
underlying pathophysiology. Preferably, certain subsets of ADS patients characterized 
by humoral autoimmunity might be identified through the use of disease-specific au-
toantibodies. For example, NMO is now considered to be an antibody-mediated disease 
that is distinct from MS, on account of the discovery of the disease-specific autoantibody 
against aquaporin-4 (AQP4).4, 5
In the search for disease-specific autoantibodies in ADS, myelin oligodendrocyte 
glycoprotein (MOG) is a putative target antigen. This protein is expressed on the surface 
of myelin sheaths and oligodendrocytes, and thus specific to the CNS. Previous studies 
already showed that MOG-antibodies can cause demyelination in vitro and can induce 
experimental autoimmune encephalomyelitis (EAE).6, 7 Based on the current knowledge, 
antibodies to MOG have been detected in a subgroup of patients presenting with CNS 
demyelinating diseases8, 9 and are especially present in patients with ADEM10, 11, in chil-
dren with very early-onset MS12, and with higher titers in the youngest children and 
children with ADEM.11, 13-15 But the sensitivity of MOG-antibody assays to discriminate 
patients with CNS demyelinating disease varies and is reported to be only as high as 
46%.16 This is in part due to the patient population that is included, since the antibod-
ies are more prevalent is the ADEM subgroup of ADS10-15 and might not be a sensitive 
marker for ADS in general. Previous studies focused mainly on specific subgroups of 
ADS patients based on diagnosis, like paediatric onset MS10-12, 14, 16, ADEM10, 11, 13, 14, 17 
and CIS.11, 13, 14 Recently MOG-antibodies were also detected in patients with anti-AQP4 
negative NMO or NMO spectrum disorders such as bilateral or recurrent ON and longi-
tudinally transverse myelitis.18-26
To date, it is unsure which subgroup the children with MOG-antibodies represent 
within the spectrum of ADS.16 In the current study we investigated the presence of MOG-
antibodies in a cohort comprised of all ADS subtypes and compared their presence 
between the different ADS subtypes based on clinical presentation. We hypothesized 
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that the MOG-antibodies are prevalent in the younger ADS children who are more likely 
to have a polyfocal onset with encephalopathy, which is the strict definition for ADEM.27
mAteriAls AnD methoDs
Patients and controls
Children with a first demyelinating event of the CNS (ADS), younger than 18 years, en-
rolled in the nationwide cohort of the Dutch pediatric MS study2, 28, were consecutively 
included in this study. At first event, patients were divided into five groups, based on 
clinical presentation: ON, TM, other monofocal disease-onset (mono ADS), polyfocal 
disease-onset without encephalopathy (poly ADS –) and polyfocal disease-onset with 
encephalopathy (poly ADS +). Encephalopathy was defined as altered consciousness or 
change in behaviour, which cannot be explained by fever, systemic illness or postictal 
symptoms.2 A diagnosis of MS could be made when a second demyelinating attack oc-
curred, with clinical and/or MRI evidence of dissemination in time and space at least one 
month after onset.29 After a first attack with encephalopathy, a second event without 
encephalopathy at least three months after onset and a third event with clinical or 
MRI evidence of dissemination in time are needed for a diagnosis of MS.27 Follow-up 
information was provided by the clinical physician and by telephone interview of the 
parents. As control groups we included healthy children and children with other neuro-
logical diseases (OND). Furthermore we tested a group of adult patients with a clinical 
diagnosis of ADEM. This study was approved by the Medical Ethical Committees of the 
Erasmus University Medical Centre in Rotterdam and of the other participating centres.
cell culture
Human MOG-transfected and untransfected LN18 cells were cultured in IMDM medium 
(Bio Whittaker, Verviers, Belgium) containing 10% fetal calf serum (Bodinco, Alkmaar, The 
Netherlands), penicillin 100 U/ml / streptomycin 100 ug/ml (Gibco, Merelbeke, Belgium), 
and 50 μM 2-mercaptoethanol (Sigma-Aldrich, Steinheim, Germany).
cell-based assay
In order to detect antibodies to native intact MOG we used a glial LN18 cell line (a kind 
gift of Prof. B. Hemmer, Technical University of Munich, Germany) that stably expressed 
full-length MOG tagged with eGFP (GeneCopeia, Inc., OmicsLink Clone, Cat.# EX-M0097-
M03). For the detection and quantification of antibodies binding to MOG expressed on 
the cell surface a fluorescence activated cell sorter (FACS, LSRII and FCS 3.0 software, 
Becton Dickinson) was used. MOG-LN18 and untransfected LN18 cells were harvested by 
trypsinization and washing into ice-cold PBAE buffer (PBS/0.5% BSA (vol/vol, Celliance, 
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Kanakee, Illinois, USA) /0.1% azide /1 mM EDTA (all from Sigma)). Equal numbers of MOG-
transfected LN18 cells and untransfected LN18 cells were mixed to a final concentration 
of 100000 cells per well and incubated with patient or control samples (1:50 in PBAE) in 
96 wells round-bottom microtiter plates (Greiner Bio-One, Alphen a/d Rijn, The Nether-
lands) for 30 min on ice. After three times washing with PBAE cells were incubated with 
goat anti-human IgG- Allophycocyanin (APC) conjugated secondary antibody (Jackson 
ImmunoResearch Laboratories, BrunschwigChemie B.V., Amsterdam, The Netherlands) 
at 1:500 in PBAE containing containing 10% (vol/vol) normal goat serum (NGS, Sanquin, 
Amsterdam, The Netherlands) for 25 min on ice. Cells were than washed 4 times in PBAE 
and analyzed immediately by FACS. Binding of human IgG was determined by measur-
ing APC fluorescence after setting an acquisition gate of 10,000 events on GFP-positive 
cells. In each assay we tested 8 individual negative control sera (apparently healthy lab 
workers), one strongly positive and one low positive control serum. Quantitative levels 
of antibody titers were expressed as difference in median fluorescence intensity (ΔMFI) 
between MOG transfected and untransfected LN18. The assay cut-off was based on the 
average ΔMFI+3xSD of healthy and diseased control patients.
statistical analysis
Statistical analysis was performed using SPSS 20.0. Chi-square test was used to compare 
categorical data and Kruskal-Wallis and Mann-Whitney U tests to compare continuous 
data. Differences in continuous data between two groups were compared using Stu-
dent’s t-test. Results were considered significant if p-values were <0.05. Bonferroni 
corrections were made when appropriate.
results
We included 117 patients with ADS, 13 children with other neurological disorders (OND) 
and 31 healthy children. The OND group consisted of patients with epilepsy (n=4), viral 
encephalitis (n=4), other autoimmune diseases (n=2: opsoclonus myoclonus syndrome 
and cerebral vasculitis), migraine (n=1), trauma (n=1) and hypertensive encephalopathy 
(n=1). In addition, 29 adult ADEM patients were tested. Demographic characteristics are 
shown in Table 8.1. MOG-antibodies were present in 21 of the 117 children with ADS 
(18%) and in none of the healthy or OND control children (Chi-Square=9.082, p=0.003). 
Eighteen anti-MOG seropositive patients had a polyfocal disease-onset. Two children 
had isolated ON as the initial event, one had right-sided hemiparesis, whereas all other 
46 patients with a monofocal onset were seronegative.
Figure 8.1 shows the anti-MOG titers in the 5 separate clinical subgroups, healthy 
controls, children with other neurological diseases and adults with ADEM. The group of 
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children with a polyfocal disease-onset plus encephalopathy had the highest frequency 
of anti-MOG seropositivity (42%). Also 18% of children presenting with polyfocal ADS 
without encephalopathy had MOG-antibodies. Most of them had an ADEM-like onset 
according to the International Paediatric MS Study Group (IPMSSG) criteria defined as 
table 8.1 Demographics of patients and controls.
ADS
children
OND 
children
Healthy control 
children
Adult ADEM 
patients
Number 117 13 31 29
Female, n (%) 61 (52) 6 (46) 12 (39) 17 (59)
Mean age, years (range) 10.7 (0.5 - 17.5) 9.8 (1 - 16) 8.7 (2 – 16) 40 (18 – 82)
Mean time disease onset – sampling, years (range) 1.2 (0 – 13.5) 2.24 (0 – 11) 1.3 (0 – 14.1)
Sampling < 3 months, n (%) 73 (62) 5 (62) 19 (66)
ADEM = acute disseminated encephalomyelitis, ADS =  acquired demyelinating syndromes, OND =  other neu-
rological diseases.
Figure 8.1 MOG-antibody titers in ADS patients (divided by clinical presentation) and control groups.
 * p<0.05 ** p<0.01, dotted line represents the assay cut-off (ΔMFI 360)
ADS = acquired demyelinating syndrome, ΔMFI = median fluorescence intensity (delta is the change in this), 
MOG = myelin oligodendrocyte glycoprotein, mono ADS = monofocal ADS, ON: = optic neuritis, OND = other 
neurologic disorders, poly ADS - = polyfocal ADS without encephalopathy (negative), poly ADS + = polyfocal 
ADS with encephalopathy (positive), TM = transverse myelitis.
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a first polyfocal clinical CNS event with encephalopathy and a presumed inflammatory 
cause and usually diffuse poorly demarcated lesions on cerebral MRI, although they 
presented without encephalopathy, and did not qualify as suffering from MS.27 The 
clinical presentation and disease course of individual MOG-antibody positive children 
are outlined in Table 8.2. The characteristics of the MOG-antibody positive and negative 
paediatric patient groups are shown in Table 8.3. The MOG-antibody positive patients 
were 4.4 years younger on average than the MOG-antibody negative patients (p<0.001).
In the ADS cohort, 47 children had a final diagnosis of MS (mean follow-up time of 
4.7 years) and except for one they were all seronegative. In contrast, of the 70 patients 
without MS diagnosis (mean follow-up time of 5 years) 29% was seropositive (p<0.001). 
Eleven of these 70 children developed a relapsing disease without fulfilling diagnostic 
criteria for MS. In eight of these 11 children MOG-antibodies could be detected (Table 
8.2). Figure 8.2 shows the disease course of the 8 seropositive children with clinical re-
lapsing disease without MS diagnosis. There were no significant differences between the 
monophasic and relapsing MOG-antibody seropositive patients in length of follow-up 
(4.02 vs 6.75 years) and in treatment (75% vs 67% were treated with Methylprednisolone 
after disease presentation).
Clinical recovery of the MOG-antibody positive patients at last follow-up was complete 
in 12 patients. Eight patients had only mild residual symptoms, like fatigue, attention or 
behavioural deficits or mild persisting visual loss. One patient who initially presented 
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Figure 8.2 Disease courses of the 8 MOG-antibody positive children with relapsing disease.
ADEM = acute disseminated encephalomyelitis, BG = basal ganglia, CC = corpus callosum, MOG = myelin oli-
godendrocyte glycoprotein, MRI = magnetic resonance imaging, ON = optic neuritis, TM = transverse myelitis.
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with optic neuritis had a subsequently progressive disease course and she died of com-
plications (aspiration pneumonia) 9 years after disease onset (Table 8.2).
table 8.2 Clinical presentation and disease course of MOG-antibody positive children.
Patient Sex Disease onset Clinical diagnosis Relapse(s) Recovery Remarks
1 F Poly ADS - ADEM ON Incomplete Not meeting MS 
diagnostic criteria
2 M ON Bilateral ON ON Complete Not meeting MS 
diagnostic criteria
3 F Poly ADS - NMO ON+TM Incomplete AQP4-antibody negative; 
Not meeting MS 
diagnostic criteria
4 M Poly ADS + ADEM ON Incomplete
5 M Poly ADS + ADEM ON Complete
6 F Poly ADS - ADEM ON Incomplete Not meeting MS 
diagnostic criteria
7 F ON ON TM Died 9 years after 
onset
Subsequently 
progressive disease 
course
8
9
M
M
Poly ADS -
Mono ADS
ADEM
CIS
ADEM
MS
Complete
Complete
10 F Poly ADS - Bilateral ON and 
TM
Basal 
ganglia 
lesions on 
follow-up 
brain MRI
Complete AQP4-antibody negative; 
Not meeting NMO or MS 
diagnostic criteria
11 F Poly ADS + ADEM Incomplete
12 M Poly ADS + ADEM Complete
13 F Poly ADS + ADEM Complete
14 F Poly ADS - ADEM Complete
15 M Poly ADS + ADEM Complete
16 M Poly ADS + ADEM Complete
17 M Poly ADS - ADEM Complete
18 F Poly ADS - ADEM Incomplete
19 M Poly ADS + ADEM and LETM Incomplete AQP4-antibody positive
20 M Poly ADS + ADEM Complete
21 M Poly ADS + ADEM Incomplete
ADEM = acute disseminated encephalomyelitis, ADS = acquired demyelinating syndrome, AQP4-antibody = 
aquaporin-4 antibody, F = female, LETM = longitudinally extensive transverse myelitis, M = male, MOG = myelin 
oligodendrocyte glycoprotein, MRI = magnetic resonance imaging, MS = multiple sclerosis, NMO = neuromy-
elitis optica, ON = optic neuritis, Poly ADS - = polyfocal disease-onset without encephalopathy, Poly ADS+ = 
polyfocal disease-onset with encephalopathy, TM = transverse myelitis.
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In only one adult patient with ADEM we were able to detect MOG-antibodies (3% 
versus 42% of the children with poly ADS +; Pearson Chi-Square, p=0.002). This man was 
37 years old at disease-onset. The sample was obtained within 1 month after onset and 
he had a monophasic disease.
In 11 children follow-up samples were tested, 9 patients were anti-MOG seronegative 
at onset and remained negative (including 6 children with MS, one with mono ADS, one 
with ON, one with poly ADS +). A second sample was obtained in 2 anti-MOG seroposi-
tive children (patients 4 and 7 in Table 8.2). In both patients MOG-antibodies remained 
detectable, respectively 3 months and 7 months after last relapse.
Discussion
It is now widely accepted that antibodies to MOG are specific for demyelinating CNS 
diseases in children10-14, 17 and also in adults with NMO and NMO-spectrum disorders.19-26 
However, this biomarker appears to lack sensitivity to discriminate (subgroups of ) chil-
dren with ADS from healthy children or children with other neurological diseases. In this 
study we investigated MOG seropositivity amongst the complete spectrum of acquired 
demyelinating syndromes. We used a cell-based assay in a glial cell-line to maintain 
optimal natural conformation and glycosylation of the MOG molecule, as such assays 
discriminate best between clinical sub-groups.16
We here observed that antibodies were almost exclusively detected in children with 
a polyfocal disease-onset. MOG-antibodies were more frequently present in children 
with a polyfocal disease-onset plus encephalopathy (42% positivity in this group fulfill-
ing ADEM criteria according to the IPMSSG definitions)27 when compared to all other 
patient groups. Also a significant part of the children with a polyfocal onset but without 
encephalopathy tested positive (18%). This group fulfilled the IPMSSG criteria for ADEM, 
except for the lack of encephalopathy at onset.
Of the total set of 21 anti-MOG seropositive patients, only 5 did not have a typical ADEM 
presentation. One of them had recurrent ON. This is in line with a previous study show-
table 8.3 Characteristics of MOG-antibody positive and negative paediatric patients.
MOG Ab + patients 
(n=21)
MOG Ab – patients 
(n=96)
p-value
Female, n (%) 9 (43) 52 (54) 0.48
Mean age, years ± SD 7.1 ± 4.5 11.5± 4.6 <0.001
Mean time disease onset – sampling, years ± SD 2.7± 4.2 0.9 ± 2.1 0.06
Sampling < 3 months, n (%) 13 (62) 60 (63) 0.95
Mean follow-up time, years ± SD 5.2 ± 4.3 4.8 ± 4.5 0.72
MOG Ab = myelin oligodendrocyte glycoprotein antibody
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ing that MOG-antibodies in paediatric patients with ON are predominantly detected in 
children with recurrent disease.18 Three anti-MOG positive girls had a NMO (spectrum) 
disorder, but without detectable AQP4-antibodies, confirming previous studies showing 
that a subgroup of AQP4-antibody negative NMO patients do have MOG-antibodies.19-26
An interesting observation is that the four children in this cohort with a clear ADEM 
onset followed by multiple episodes of ON only, all tested anti-MOG seropositive. As this 
phenomenon has already been described by Huppke et al, we suggest that this may 
represent a newly identified disease entity.30
Only one of the children with MS in our cohort was anti-MOG seropositive, which is in 
contrast to former studies.9-12, 14, 17, 19, 21 It has been discussed that if these antibodies can 
be measured in MS patients, the titers are lower in comparison to ADEM patients.11, 13, 14 
This is in line with our observation in this child, as he had a very low antibody titer (ΔMFI 
395) just above the cut-off value of our assay (ΔMFI 360). Another explanation may be 
a different application of the diagnostic criteria for paediatric MS. In the current study 
children only with 2 non-ADEM episodes were diagnosed with MS, whereas in another 
study only a second non-ADEM attack or clinically silent new lesions on MRI were already 
sufficient for MS diagnosis.14
It is still unclear whether MOG-antibodies have demyelinating activity or whether 
they represent an epiphenomenon of myelin destruction. However, it is unlikely that 
these antibodies merely reflect fulminant white matter damage, as MOG-antibodies 
were virtually absent in adult ADEM patients. Similarly, we never encountered an anti-
MOG positive adult MS patient (data not shown).
MOG polymorphisms vary among patients31 and genetic factors affect conformation, 
glycosylation or expression of the MOG protein. The cell-based assay used here has the 
highest chance of finding naturally occurring, relevant auto-antibodies. It will be of 
interest to investigate in the future if some polymorphisms are associated with the rise 
of anti-MOG antibodies or even protect against the recognition of certain epitopes.16, 32
Some studies showed that these antibodies may remain detectable during the disease 
course10, 12, 18, whereas two longitudinal studies showed that MOG-antibodies in some 
ADEM patients disappear over time.11, 14 We did not obtain sequential samples routinely. 
In two of the anti-MOG positive children a second sample was tested and the antibodies 
remained detectable long after disease activity. Furthermore in 6 of the 21 anti-MOG 
positive patients, their sample was obtained during remission instead of during the 
active stage of the disease. Despite the small numbers in our study, this may contradict 
the observation that antibodies are only present as a kick-off of the disease or reflect the 
presence of a chronic active disease.8, 14
The main limitation of the study is that in 38% of ADS patients the samples were ob-
tained during remission of this first attack instead of close to attack onset. Still, time of 
sampling does not seem to be of pivotal importance, otherwise it would be more likely 
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for the MS patients to be anti-MOG positive, as they have a chronic recurrent disease. 
The study is further limited by the lack of serial sampling, although the few samples we 
tested showed no difference in seropositivity in the follow-up sample.
This study is the first to describe the presence of MOG-antibodies in an unbiased co-
hort encompassing all clinical ADS subtypes in children and with relatively long follow 
up (over 4 years). ADS are a heterogeneous group of clinical phenotypes and diagnosis 
can be inaccurate, partly because substantial clinical overlap between the subgroups 
can exist. Here we zoomed in on the clinical features at disease-onset of MOG-antibody 
positive patients. Most of these seropositive patients had an ADEM-like disease and only 
one was diagnosed with MS. In our study the presence of MOG-antibodies in children 
with a first attack of CNS demyelination strongly pleads against future diagnosis of MS. 
We expect that the future value of testing for MOG-antibodies in a clinical setting will 
depend on international collaboration, on assay standardization and on consensus 
about the proper cut-off values. Such studies are underway.
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AbstrAct
objective To identify CSF biomarkers for multiple sclerosis (MS) in children with an 
initial acquired CNS demyelinating syndromes (ADS).
methods CSF was collected from a cohort of 39 children with initial ADS, of them 18 
were diagnosed with MS and 21 had a monophasic disease course. Proteomic analysis 
of trypsinised CSF (20 µl) was performed by nano liquid chromatography Orbitrap mass 
spectrometry. Univariate statistical analysis was used to identify differentially abundant 
proteins between childhood-onset MS and monophasic ADS.
results A total of 2260 peptides corresponding with 318 proteins were identified in the 
total set of samples. Of these 2260 peptides, 88 were identified as most distinctive be-
tween MS and ADS. 53 peptides, corresponding to 14 proteins, had higher abundance in 
children with MS as compared to monophasic ADS. Twelve out of these 14 proteins were 
linked to neuronal functions and structures such as synapses, axons and CNS proteases 
(example: neurofascin, carboxypeptidase E, brevican core protein, and contactin-2). The 
other two were functionally related to immune function. The 35 peptides identified with 
decreased abundance in children with MS corresponded to seven proteins. Six of them 
linked to innate immune function (example: haptoglobin, haptoglobin-related protein, 
c4b-binding protein alpha chain and monocyte differentiation antigen CD14) and one 
to cellular adhesion (protein diaphanous homolog 1).
conclusion At first onset of ADS, CSF of children diagnosed with MS showed increased 
abundance of CNS gray matter related proteins, whereas CSF of children with a mono-
phasic disease course showed increased abundance of innate immunity related proteins.
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introDuction
A few percent of all MS patients experience their first event in childhood.1 In children, 
such a first event can present with a spectrum of clinical features of acquired demy-
elinating syndromes (ADS) including optic neuritis (ON), transverse myelitis (TM), 
acute disseminated encephalomyelitis (ADEM), neuromyelitis optica (NMO), and other 
clinically monofocal or polyfocal symptoms.2 In most children with ADS, the disease 
course remains monophasic. However approximately 21% to 32% of these children will 
subsequently be diagnosed with MS.3, 4 Current MS diagnosis is based on a combination 
of clinical features, CSF findings and MRI-criteria for dissemination in time and space.1, 3, 5 
These factors are insufficient to predict the disease course at first event. The availability 
of a biomarker that helps to differentiate between children with monophasic ADS, and 
those subsequently diagnosed with MS is needed. Moreover, identification of CSF pro-
teins that are associated with childhood-onset MS can provide further insight into the 
disease pathophysiology. So far, one study was published that compared CSF of children 
with MS and monophasic ADS which suggested disturbed axoglial biology during early 
MS events.6 In the present study, we investigated CSF, a body fluid that reflects ongoing 
CNS pathology7 in a fully unbiased manner. Samples were analyzed by high resolution, 
and sensitive nano-liquid chromatography Orbitrap mass spectrometry (LC-MS).8 Our 
aim was to find CSF protein markers expressed during first event of CNS demyelination 
that can help to distinguish children with monophasic ADS (n=21) from children with 
MS (n=18).
methoDs
Patients
Children younger than 18 years old who presented with a first acquired demyelinating 
event were identified by the Dutch Study Group for Pediatric MS, which includes 13 
major pediatric neurology centers in the Netherlands as described earlier.9 Children 
were diagnosed with MS in case they had a second demyelinating attack of the CNS 
and/or MRI evidence of a new lesion at least one month after onset.1 Clinical features 
and physical examination defined initial clinical phenotypes of the children. This study 
included 41 children with ADS of them 22 had a monophasic disease course and 19 
were diagnosed with MS. The CSF samples were collected at first clinical presentation. 
Children were symptomatic at time of sampling. Children were not on immunomodula-
tory treatment at time of sampling. CSF samples were collected, processed and stored 
following previously described protocols.8, 10
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standard Protocol Approvals, registrations, and Patient consents
The study was approved by the Clinical Research Ethics Board of the Erasmus University. 
Written informed consent was obtained from all patients and/or their families.
sample preparation and lc-ms measurements
CSF samples (20 µL) were digested using an in-solution trypsin digestion protocol fol-
lowed as previously described.11 Prepared samples were analyzed by LC-MS/MS using 
an Ultimate 3000 nano RSLC system (Thermo Fischer Scientific, Germering, Germany) 
online coupled to a hybrid linear ion trap/Orbitrap mass spectrometer (LTQ Orbitrap XL; 
Thermo Fisher Scientific, Bremen, Germany) using data - dependent acquisition method. 
LC-MS data were analyzed using the Progenesis LC-MS software package (version 3.6, 
Nonlinear Dynamics Ltd, Newcastle - upon - Tyne, United Kingdom). Detailed LC-MS 
measurements, protein identification and quantification, are available in the e-methods 
at Neurology.org/nn.
statistical analysis
The Wilcoxon test (unpaired, two tailed) was used to analyze the differences in the 
abundance of peptides between children with MS, and monophasic ADS. p-values <0.01 
were considered statistically signiﬁcant. Relative quantitative differences of peptide 
abundances between samples of children with MS and monophasic ADS samples were 
calculated as log2 ratio between median abundances of both groups. A set of signifi-
cantly distinct peptides and proteins was determined by applying following stringent 
criteria: (a) peptides that had at least 1.5 fold difference in expression at a p-value <0.01; 
(b) protein identified by at least 2 peptides, and (c) at least 40% differentially abundant 
peptides (p<0.01) per protein, whereby peptides of a given protein were required to 
have representation in the same direction (increased or decreased abundance in 
MS). In the above dataset we also excluded those proteins that had only one peptide 
differentially abundant out of a total two. To verify these findings and to determine 
the statistical background level, we performed a permutation analysis on the entire 
dataset (2260 peptides) between samples of children with MS (n=18) and monophasic 
ADS (n=21) sample groups included with the above mentioned criteria. Whereby, we 
determined the statistical background level on a set of significantly distinct peptides. 
The random permutation test, on the dataset with randomized sample group assign-
ment, was repeated 1000 times through which, the resulting thresholds were saved. For 
all calculations and graphics, we used the R software package (R version 3.0.2, http://
www.R-project.org, accessed on February 4th, 2014).12 For other calculations SPSS 15.0 
(SPSS, Chicago, IL, USA) and Microsoft Excel 2010 were used.
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results
Patient characteristics
We have analyzed CSF samples of 18 children with MS and 21 with monophasic ADS 
patients. One MS and one monophasic ADS patients were excluded because of <200 
required alignment vectors (weak alignment) found during Progenesis LC-MS analysis. 
From 18 children diagnosed with MS, five had ON, two had TM, three had clinical mono-
focal, and eight had clinical polyfocal symptoms as their presenting symptoms of onset. 
From the 21 children with monophasic ADS, two had experienced ON, two had TM, eight 
had clinical polyfocal symptoms and nine had ADEM. No significant differences were 
observed between the two groups in terms of gender, CSF levels of total protein, albu-
min, albumin CSF/serum quotient, leukocyte and IgG concentration. The mean age at 
onset of children diagnosed with MS (14.17 ± 1.5) was found to be significantly higher in 
comparison to children with monophasic ADS (6.89 ± 4.9), reflecting the epidemiology 
of these phenotypes. In addition, CSF elevated IgG index and positive OCB were more 
frequently present in children with MS (p ≤ 0.01). Patients characteristics are shown in 
Table 9.1.
identification of proteins that discriminates ms from monophasic ADs
We have detected 50,119 peptide precursors from Progenesis label-free analysis LC-MS 
experiment from all trypsin digested protein in CSF samples. A Mascot database search 
in the human subset of the Uniprot database resulted into 2260 unique peptides that 
corresponded with 318 proteins (listed as a supplementary Table e-1). The total protein 
concentrations of digested peptide samples quantified (integrated UV area at 214 nm) 
during LC–MS measurements did not show any significant difference (p=0.54) between 
CSF samples of children with MS and monophasic ADS group. To check technical vari-
ability, at regular interval we measured 12 reference samples (pooled CSF samples from 
all patients). Here, also the total protein concentrations of digested peptide samples 
quantified (integrated UV area at 214 nm) during LC – MS measurements between Refer-
ence group 1 (n=6) and 2 (n=6) did not show any difference (Reference group 1 (n=6) 
=382.94 ± 153.28; versus Reference group 2 (n=6), 429.34± 661.90, p=0.3). In addition, 
a number of MS/MS fragmentation spectra also did not show any significant difference 
between samples of children with MS and monophasic ADS. In particular, the measured 
MS/MS fragmentation spectra for MS, and monophasic ADS samples were 16796 ± SD 
1795 and 16971 ± 1153 (p=0.72) respectively. Moreover, the database identified MS/MS 
spectra for MS and monophasic ADS samples were 1607 ± 280 and 1626 ± 256 (p=0.83) 
respectively.
Comparing abundance of identified peptides (n=2260) from CSF samples of children 
with MS and monophasic ADS patients and using the stringent criteria as described in 
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table 9.2 Identification of proteins differentially abundant in CSF samples of children with MS (n=18) and 
samples of children with monophasic ADS (n=21).
Trend 
in MSa
Description Sign./
totalb
Fold change
mean (Min-Max)c
p Valued
mean (Min-Max)
In
cr
ea
se
d 
ab
un
da
nc
e 
in
 M
S
(n
=1
4)
Amyloid-like protein 2 2/2 3.8 (2-5.5) 0.006 (0.003-0.008)
Neurofascin 3/3 2.5 (2.1-3) 0.002 (0.001-0.002)
Carboxypeptidase E 2/3 2.4 (2.1-2.6) 0.0004 (0.0002-0.0005)
Neuronal growth regulator 1 2/3 2.3 (2.1-2.5) 0.0008 (0.0008-0.0009)
Contactin-2 4/9 2.3 (1.5-3.2) 0.002 (0.0005-0.003)
Amyloid beta A4 protein 6/11 2.2 (1.8-2.6) 0.002 (0.00003-0.008)
Brevican core protein 5/7 2.1 (1.7-2.6) 0.002 (0.0001-0.005)
Disintegrin and metalloproteinase domain-
containing protein 22
2/2 1.9 (1.7-2.1) 0.0004 (0.0001-0.0006)
Tyrosine-protein phosphatase non-receptor type 
substrate 1
3/4 1.9 (1.5-2.1) 0.003 (0.001-0.006)
Dickkopf-related protein 3 6/11 1.8 (1.6-2) 0.002 (0.00004-0.006)
Neuronal cell adhesion molecule 9/18 1.8 (1.6-2.1) 0.004 (0.001-0.009)
Ig kappa chain V-III region POM 2/2 1.8 (1.7-1.8) 0.002 (0.0009-0.003)
Ig gamma-1 chain C region 5/11 1.7 (1.5-1.8) 0.0016 (0.0002-0.005)
Kallikrein-6 4/7 1.7 (1.5-1.9) 0.001 (0.0006-0.004)
D
ec
re
as
ed
 a
bu
nd
an
ce
 in
 
M
S 
(n
=7
)
Apolipoprotein B-100 7/17 661 (3.5-3930) 0.0026 (0.00002-0.01)
C4b-binding protein alpha chain 2/4 8.1 (2.9-13.4) 0.008 (0.007-0.008)
Haptoglobin 18/29 3.7 (2-12.1) 0.002 (0.00004-0.01)
Haptoglobin-related protein 2/4 3.3 (3.1-3.5) 0.0002 (0.00001-0.0005)
Leucine-rich alpha-2-glycoprotein 2/3 2.6 (2.3-3) 0.008 (0.007-0.009)
Monocyte differentiation antigen CD14 3/3 1.9 (1.8-2) 0.006 (0.004-0.009)
Protein diaphanous homolog 1 2/2 1.8 (1.7-1.9) 0.005 (0.001-0.009)
The table shows 21 proteins, of which 14 were identified with increased abundance in CSF samples of 
children with MS and 7 were identified with decreased abundance in CSF samples of children with MS. The 
table includes the direction of difference (trend) in MS, name of the protein (description), fold expression 
difference, and p value. All proteins given in the table were identified with at least 2 unique peptides; dif-
ferentially abundant peptides (p < 0.01) had at least 1.5-fold difference in expression (median) between 
groups; and for the same protein, 40% of identified peptides were differentially abundant with the expres-
sion in the same direction (i.e., either higher or lower in MS) of the same protein. Details of each peptide of 
the indicated proteins are listed in Tables e-2 and e-3.
a Protein abundance is either significantly increased or decreased in children with MS compared to children 
with monophasic ADS.
b Number of differentially identified peptides p < 0.01/total number of identified peptides for the same 
protein.
c Fold expression difference calculated based on median abundance from 18 patients with MS and 21 pa-
tients with ADS. Shown is the average of fold difference for all peptides of the same protein. Minimum and 
maximum range for the same is indicated.
d Calculated by Wilcoxon test. Given in the table is the mean p value and range for all differentially abundant 
peptides of the same protein.
ADS = acquired demyelinating syndrome; MS = multiple sclerosis.
Chapter 9
132
Figure 9.1 Volcano plot.
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statistical analysis, we found a total of 88 differentially abundant peptides (supplemen-
tary Table e-2 and e-3). Of these 88 peptides, 53 were significantly increased (Table 9.2 
and supplementary Table e-2) and 35 decreased in CSF samples of children with MS 
(Table 9.2 and supplementary Table e-3) as compared with monophasic ADS. Peptides 
with increased abundance (n=53) in the MS group corresponded with 14 proteins and 
peptides with decreased abundance (n=35) corresponded with 7 proteins. An inventory 
of these 21 proteins is given in Table 9.2.
Moreover, fold expression difference between MS and monophasic ADS groups groups 
and statistical significance are plotted simultaneously for our entire data set (n=2260 
peptides) as a Volcano plot (Figure 9.1). This permutation analysis resulted in 20 ± 41 
(median 9) false positive peptide markers, which indicated that our observations are not 
due to chance alone, because more than 90% of the permutations yielded 0-4 significant 
hits i.e. in 900. Only 4 times out of 1000 more than 88 hits with low p-value were detected 
(FDR: 0.4%). Whereas, contrasting to this mere background chance, from the actual data 
set (true hits) 88 peptides were identified. Therefore, comparison of permutated data 
with the real data indicated that the occurrence of differentially abundant peptides 
related to MS or monophasic ADS was highly significant (p<0.001). The outcome of the 
permutation test is shown as a histogram (supplementary Figure e-1).
Identified proteins with increased abundance (n=14) in MS (Table 9.2 and supple-
mentary Table e-2) were: amyloid-like protein 2 (2/2, 2 significant peptides for a total 
of 2 peptides), neurofascin (3/3), carboxypeptidase E (2/3), neuronal growth regulator 1 
(2/3), contactin-2 (4/9), amyloid beta A4 (6/11), brevican core protein (5/7), disintegrin 
and metalloproteinase domain-containing protein 22 (2/2), tyrosine-protein phospha-
tase non-receptor type substrate 1 (3/4), dickkopf-related protein 3 (6/11), neuronal cell 
adhesion molecule (9/18), Ig kappa chain V-III region POM (2/2), Ig gamma-1 chain C 
region (5/11) and kallikrein-6 (4/7). Proteins identified with decreased abundance (n=7) 
in MS (Table 9.2 and supplementary Table e-3) were: apolipoprotein B-100 (7/17), c4b-
binding protein alpha chain (2/4), haptoglobin (18/29), haptoglobin-related protein 
(2/4), leucine-rich alpha-2-glycoprotein (2/3), monocyte differentiation antigen CD14 
← Figure 9.1 Volcano plot.
Peptides (n=2,260) showing distribution of fold change and statistical significance. In this plot each point 
represents a peptide, and shows the ratio between CSF samples of children with MS (n=18) and monopha-
sic ADS (n=21) plotted against the level of statistical significance. Y-axis shows p-values, obtained (plotted 
at log10) from a Wilcoxon tests performed between abundances of peptides. X-axis shows the ratio of the 
median between MS and monophasic ADS samples (plotted on log2). (a) Above the dashed horizontal line, 
red points (n=53 peptides) were found with increased in abundance (right side of the vertical line), green 
points (n=35 peptides) decreased in abundance (at the left side of the vertical dashed line) in the MS group 
(compared to monophasic ADS). (b) Peptides shown in gray color point below the dashed horizontal line 
did not pass stringent statistical criteria for identification of a candidate peptide.
Chapter 9
134
ta
bl
e 
9.
3 
Fu
nc
tio
n 
of
 p
ro
te
in
s 
id
en
tifi
ed
 w
ith
 in
cr
ea
se
d 
ab
un
da
nc
e 
in
 C
SF
 s
am
pl
es
 o
f c
hi
ld
re
n 
w
ith
 M
S 
co
m
pa
re
d 
w
ith
 s
am
pl
es
 o
f c
hi
ld
re
n 
w
ith
 m
on
op
ha
si
c 
A
D
S.
Pr
ot
ei
ns
 (A
cc
es
si
on
 n
o.
)
Fu
nc
ti
on
s 
an
d 
ex
pr
es
si
on
s
D
ha
un
ch
ak
 e
t a
l.6
sc
hu
tz
er
 e
t a
l.1
3
A
m
yl
oi
d-
lik
e 
pr
ot
ei
n 
2 
(Q
06
48
1)
A
m
yl
oi
d 
pr
ec
ur
so
r p
ro
te
in
 fa
m
ily
, m
em
or
y 
pr
oc
es
se
s, 
co
nc
en
tr
at
ed
 in
 
sy
na
ps
es
18
, r
eg
ul
at
es
 n
eu
ro
na
l s
te
m
 c
el
l d
iff
er
en
tia
tio
n 
du
rin
g 
co
rt
ic
al
 
de
ve
lo
pm
en
t
×
**
 V
ar
ia
nt
N
eu
ro
fa
sc
in
 (O
94
85
6)
Sy
na
ps
e 
fo
rm
at
io
n,
 lo
ca
te
d 
at
 C
N
S 
pa
ra
no
da
l d
om
ai
n 
an
d 
ex
pr
es
se
d 
by
 
ol
ig
od
en
dr
oc
yt
es
20
, t
ar
ge
t f
or
 a
ut
oa
nt
ib
od
y-
m
ed
ia
te
d 
ax
on
al
 in
ju
ry
 in
 
M
S2
1
N
S
×
Co
nt
ac
tin
-2
 (Q
02
24
6)
A
xo
n 
co
nn
ec
tio
n,
 m
aj
or
ly
 e
xp
re
ss
ed
 o
n 
CN
S 
ju
xt
ap
ar
an
od
al
 d
om
ai
n1
9,
 2
0
N
S
**
*
A
m
yl
oi
d 
be
ta
 A
4 
pr
ot
ei
n 
(P
05
06
7)
Co
m
po
ne
nt
 o
f a
m
yl
oi
d 
pl
aq
ue
s 
(A
lz
he
im
er
 b
ra
in
s)
35
, n
eu
ro
na
l a
dh
es
io
n
×
×
Br
ev
ic
an
 c
or
e 
pr
ot
ei
n 
(Q
96
G
W
7)
M
aj
or
 p
ro
te
og
ly
ca
n 
in
 p
er
is
yn
ap
tic
 e
xt
ra
ce
llu
la
r m
at
rix
 o
f b
ra
in
, i
nh
ib
its
 
ne
ur
ite
 o
ut
gr
ow
th
 fr
om
 c
er
eb
el
la
r g
ra
nu
le
 n
eu
ro
ns
23
N
S
D
ec
re
as
ed
 e
xp
re
ss
io
n 
in
 fi
rs
t a
tt
ac
k 
CI
S-
M
S 
re
la
tiv
e 
to
 e
st
ab
lis
he
d 
RR
-M
S 
an
d 
co
nt
ro
ls
Ca
rb
ox
yp
ep
tid
as
e 
E 
(P
16
87
0)
Fo
un
d 
in
 b
ra
in
 a
nd
 th
ro
ug
ho
ut
 n
eu
ro
en
do
cr
in
e 
sy
st
em
, i
nv
ol
ve
d 
in
 
sy
nt
he
si
s 
of
 m
os
t n
eu
ro
pe
pt
id
e3
6
Sa
m
e 
tr
en
d
(4
 s
ig
n.
/2
1 
to
ta
l, 
p=
0.
00
4)
×
N
eu
ro
na
l g
ro
w
th
 re
gu
la
to
r 1
 
(Q
7Z
3B
1)
Pr
om
ot
es
 o
ut
gr
ow
th
 a
nd
 e
xp
re
ss
ed
 o
n 
re
ac
tiv
e 
as
tr
oc
yt
es
 a
ft
er
 
en
to
rh
in
al
 c
or
te
x 
le
si
on
 (i
n 
m
ic
e)
37
N
S
×
Ty
ro
si
ne
-p
ro
te
in
 p
ho
sp
ha
ta
se
 n
on
-
re
ce
pt
or
 ty
pe
 s
ub
st
ra
te
 1
 (P
78
32
4)
Su
pp
or
ts
 a
dh
es
io
n 
of
 c
er
eb
el
la
r n
eu
ro
ns
, n
eu
rit
e 
ou
tg
ro
w
th
 a
nd
 g
lia
l c
el
l 
at
ta
ch
m
en
t2
8
×
×
N
eu
ro
na
l c
el
l a
dh
es
io
n 
m
ol
ec
ul
e 
(Q
92
82
3)
Lo
ca
liz
ed
 a
t t
he
 n
od
e 
of
 R
an
vi
er
 a
nd
 in
 u
nm
ye
lin
at
ed
 a
xo
ns
, P
ar
an
od
al
 
re
gi
on
 o
f C
N
S,
 a
xo
-g
lia
l c
on
ta
ct
19
N
S
**
D
is
in
te
gr
in
 a
nd
 m
et
al
lo
pr
ot
ei
na
se
 
do
m
ai
n-
co
nt
ai
ni
ng
 p
ro
te
in
 2
2 
(Q
9P
0K
1)
Ex
pr
es
se
d 
in
 th
e 
ju
xt
ap
ar
an
od
al
 c
om
pl
ex
19
N
ot
 s
am
e 
tr
en
d
(2
 s
ig
n.
/1
0;
 
p=
0.
01
,0
.0
2)
×
D
ic
kk
op
f-r
el
at
ed
 p
ro
te
in
 3
 (Q
9U
BP
4)
Ex
pr
es
se
d 
in
 th
e 
br
ai
n 
an
d 
sp
in
al
 c
or
d,
 s
yn
ap
se
 fo
rm
at
io
n1
3
×
**
Ka
lli
kr
ei
n-
6 
(Q
92
87
6)
El
ev
at
ed
 in
 a
ct
iv
e 
M
S2
6 , 
re
gu
la
te
s 
ea
rly
 C
N
S 
de
m
ye
lin
at
io
n 
in
 a
 v
ira
l 
(m
ou
se
) m
od
el
 o
f M
S2
6
×
**
135
CSF proteome analysis in children with ADS
9
ta
bl
e 
9.
3 
(c
on
tin
ue
d)
Pr
ot
ei
ns
 (A
cc
es
si
on
 n
o.
)
Fu
nc
ti
on
s 
an
d 
ex
pr
es
si
on
s
D
ha
un
ch
ak
 e
t a
l.6
sc
hu
tz
er
 e
t a
l.1
3
Ig
 g
am
m
a-
1 
ch
ai
n 
C 
re
gi
on
 (P
01
85
7)
El
ev
at
ed
 in
 a
du
lt 
M
S 
an
d 
CI
S 
as
 c
om
pa
re
d 
to
 n
on
-in
fla
m
m
at
or
y 
ne
ur
ol
og
ic
al
 d
is
ea
se
s3
8
×
×
Ig
 k
ap
pa
 c
ha
in
 V
-II
I r
eg
io
n 
PO
M
 
(P
01
62
4)
El
ev
at
ed
 in
 a
du
lt 
M
S 
as
 c
om
pa
re
d 
to
 n
on
-in
fla
m
m
at
or
y 
an
d 
in
fla
m
m
at
or
y 
ne
ur
ol
og
ic
al
 d
is
ea
se
s3
8
×
×
N
od
es
, p
ar
an
od
es
, j
ux
ta
pa
ra
no
de
s 
(b
eg
in
s 
at
 th
e 
in
ne
rm
os
t a
xo
gl
ia
 ju
nc
tio
n 
of
 p
ar
an
od
e)
, a
nd
 in
te
rn
od
es
 a
re
 s
tr
uc
tu
ra
l p
ar
ts
 o
f a
 m
ye
lin
at
ed
 a
xo
n.
Su
m
m
ar
y 
of
 t
he
 fu
nc
tio
n 
of
 d
iff
er
en
tia
lly
 a
bu
nd
an
t 
in
cr
ea
se
d 
pr
ot
ei
n 
m
ar
ke
rs
 in
 M
S 
an
d 
th
ei
r 
ov
er
la
p 
w
ith
 p
re
vi
ou
s 
st
ud
ie
s. 
M
os
t 
of
 t
he
 p
ro
te
in
s 
w
er
e 
as
si
gn
ed
 a
s 
ei
th
er
 n
eu
ro
na
l o
r i
m
m
un
e-
re
la
te
d 
m
ol
ec
ul
es
 b
as
ed
 o
n 
pr
ev
io
us
 re
po
rt
s 
an
d 
da
ta
ba
se
 s
ea
rc
he
s. 
Th
e 
fir
st
 c
ol
um
n 
sh
ow
s 
th
e 
na
m
e 
of
 th
e 
pr
ot
ei
n 
an
d 
U
ni
pr
ot
 a
cc
es
si
on
 
nu
m
be
r. 
Th
e 
se
co
nd
 c
ol
um
n 
sh
ow
s t
he
 fu
nc
tio
n 
of
 th
e 
pr
ot
ei
ns
. T
he
 th
ird
 c
ol
um
n 
sh
ow
s c
om
pa
ris
on
 w
ith
 a
 p
re
vi
ou
s s
tu
dy
 o
n 
ch
ild
re
n 
w
ith
 M
S 
(D
ha
un
ch
ak
 e
t a
l.)
 u
si
ng
 
A
D
S-
M
S 
(n
=8
, m
ea
n 
ag
e 
12
 y
ea
rs
) v
s 
m
on
op
ha
si
c 
A
D
S 
(n
=1
1,
 m
ea
n 
ag
e 
10
 y
ea
rs
). 
Th
e 
fo
ur
th
 c
ol
um
n 
sh
ow
s 
ov
er
la
p 
w
ith
 th
e 
w
or
k 
of
 S
ch
ut
ze
r e
t a
l.,
 w
ho
 u
se
d 
CI
S-
M
S 
(n
=9
, a
ge
 1
8–
42
 y
ea
rs
) a
nd
 e
st
ab
lis
he
d 
M
S 
an
d 
co
nt
ro
ls
 (n
=6
, a
ge
 3
1–
54
 y
ea
rs
).
× 
= 
pr
ot
ei
n 
w
as
 n
ot
 id
en
tifi
ed
; *
* 
va
ria
nt
 =
 v
ar
ia
nt
 o
f s
am
e 
pr
ot
ei
n 
w
as
 fo
un
d 
w
ith
 in
cr
ea
se
d 
ex
pr
es
si
on
 in
 fi
rs
t-
at
ta
ck
 C
IS
-M
S 
gr
ou
p 
co
m
pa
re
d 
to
es
ta
bl
is
he
d 
RR
M
S 
an
d 
co
nt
ro
ls
; *
* 
= 
in
cr
ea
se
d 
ex
pr
es
si
on
 in
 fi
rs
t-
at
ta
ck
 C
IS
-M
S 
gr
ou
p 
co
m
pa
re
d 
to
 e
st
ab
lis
he
d 
RR
M
S 
an
d 
co
nt
ro
ls
; *
**
 =
 p
ro
te
in
 w
as
fo
un
d 
w
ith
 in
cr
ea
se
d 
ex
pr
es
si
on
 in
 fi
rs
t-
at
ta
ck
 C
IS
-M
S 
re
la
tiv
e 
to
 R
RM
S 
bu
t w
ith
 d
ec
re
as
ed
 e
xp
re
ss
io
n 
in
 fi
rs
t-
at
ta
ck
 C
IS
-M
S 
vs
 c
on
tr
ol
s;
 N
S 
= 
pr
ot
ei
n
w
as
 d
et
ec
te
d 
in
 p
ed
ia
tr
ic
 C
SF
 s
am
pl
es
 b
ut
 n
o 
st
at
is
tic
al
 d
iff
er
en
ce
 in
 th
ei
r a
bu
nd
an
ce
 w
as
 re
po
rt
ed
 b
et
w
ee
n 
M
S 
an
d 
m
on
op
ha
si
c 
A
D
S 
gr
ou
p 
co
m
pa
ris
on
;
sa
m
e 
tr
en
d 
(t
re
nd
 is
 th
e 
di
re
ct
io
n 
of
 d
iff
er
en
ce
 in
 M
S)
 =
 w
he
n 
ab
un
da
nc
e 
of
 th
e 
pr
ot
ei
n 
w
as
 c
om
pa
re
d 
be
tw
ee
n 
2 
gr
ou
ps
 (M
S 
vs
 m
on
op
ha
si
c 
A
D
S)
,
ex
pr
es
si
on
 o
f t
he
 id
en
tifi
ed
 p
ro
te
in
 s
ho
w
ed
 o
ve
rla
p 
w
ith
 o
ur
 s
tu
dy
; n
ot
 s
am
e 
tr
en
d 
5 
w
he
n 
ab
un
da
nc
e 
of
 p
ro
te
in
 w
as
 c
om
pa
re
d,
 e
xp
re
ss
io
n 
of
 th
e
id
en
tifi
ed
 p
ro
te
in
 d
id
 n
ot
 s
ho
w
 o
ve
rla
p 
w
ith
 o
ur
 s
tu
dy
.
AD
S 
= 
ac
qu
ire
d 
de
m
ye
lin
at
in
g 
sy
nd
ro
m
e;
 C
IS
 =
 c
lin
ic
al
ly
 is
ol
at
ed
 sy
nd
ro
m
e;
 M
S 
= 
m
ul
tip
le
 sc
le
ro
si
s; 
N
S 
= 
no
t s
ig
ni
fic
an
t; 
RR
M
S 
= 
re
la
ps
in
g 
re
m
itt
in
g 
M
S.
Chapter 9
136
(3/3), and protein diaphanous homolog 1 (2/2). The function of these 14 proteins and 
overlap with previous studies6, 13 are summarized in Table 9.3.
Among the 14 proteins with increased abundance in the MS, 12 were associated with 
CNS structure and functions (86%), especially to the gray matter (Table 9.3), compared 
to 17% of the total identified proteins related to CNS structure and functions. Seven 
proteins identified with decreased abundance in the MS (relative to monophasic ADS 
group) were components of the innate immune system and inflammation (Table 9.4).
For each peptide that passed (53 increased and 35 decreased in MS) all stringent 
criteria (as described in statistical analysis): the associated protein, database search 
identification details, p-value, fold expression difference, total number of peptides per 
protein, number of peptides identified below 0.01, median abundance, frequency/oc-
currence of identifications by MS/MS is shown in the supplementary Table e-2 and e-3. 
Proteins identified in the current study did not exhibit any myelin related proteins, for 
instance; myelin oligodendrocyte glycoprotein and myelin basic protein.
table 9.4 Function of proteins identified with decreased abundance in CSF samples of children with MS 
compared to samples of children with monophasic ADS.
Differential proteins (Accession 
number)
Functions Dhaunchak
et al.6
schutzer 
et al.13
Apolipoprotein B-100 (P04114) Innate immune related, not produced in CNS39 × ×
C4b-binding protein alpha chain 
(P04003)
Innate immune defense, involved in 
complement activity31
× ×
Haptoglobin (P00738) Innate immune defense29 × ×
Haptoglobin-related protein (P00739) Innate immune defense40 × ×
Leucine-rich alpha-2-glycoprotein 
(P02750)
Induced by inflammation and involved in 
cell adhesion, high expression in the deep 
cerebral cortex25, novel marker of granulocytic 
differentiation29
× ×
Monocyte differentiation antigen 
CD14 (P08571)
Main modulator of innate immune system32 × ×
Protein diaphanous homolog 1 
(O60610)
Coordinates cellular dynamics by regulating 
microfilament and microtubule function, role 
in cell–matrix adhesions, variant related to 
innate immune function34
× ×
Summary of the function of differentially abundant decreased protein markers in MS and their overlap 
with previous studies. Most of the proteins were assigned as either neuronal or immune-related molecules 
based on previous reports and database searches. The first column shows the name of the protein and 
Uniprot accession number. The second column shows the function of the proteins. The third column shows 
comparison with a previous study on children with MS (Dhaunchak et al.) using ADS-MS (n=8, mean age 12 
years) vs monophasic ADS (n=11, mean age 10 years). The fourth column shows overlap with the work of 
Schutzer et al., who used CIS-MS (n=9, age 18–42 years) and established MS and controls (n=6, age 31–54 
years).
ADS = acquired demyelinating syndrome; CIS = clinically isolated syndrome; MS = multiple sclerosis. × = Protein 
was not identified.
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We examined for the influence of age of onset on the 88 candidate peptides abun-
dances for children with MS and monophasic ADS by correlation analysis. We found a 
mean coefficient of determination (± SD) for MS 0.04 ± 0.06, and for monophasic ADS 
0.05 ± 0.05. Thus, by correlation analysis no significant correlation was found between 
age and peptide abundance for children with MS and monophasic ADS for all 88 pep-
tides.
Discussion
In the current study, we have used LC-MS proteomic approach to search for differences 
in CSF proteome between children with MS and monophasic ADS in children. Benefit of 
this Orbitrap technique is the possibility to identify relatively vast amounts of different 
peptides, and assess their abundances, in a small sample volume. We observed a striking 
difference between the two groups (children with monophasic ADS versus MS), using 
stringent statistical criteria. We searched for the known functions of the 88 peptides 
corresponding to 21 distinctive proteins (14 increased and 7 decreased in abundance 
in MS), using biological databases (www.geneontology.org and www.nextprot.org) and 
literature. Recently, two research groups6, 13 demonstrated the identification of axoglial 
and gray matter proteins using mass spectrometry in CSF of MS patients . Similar to our 
study, Dhaunchak and co-workers6 compared CSF of 8 children with MS with 11 children 
with monophasic ADS. The overlap of some proteins in the MS group is noticeable (e.g. 
carboxypeptidase E), despite clear differences in sample handling such as depletion of 
abundant proteins with possible carrier function for other proteins, and exclusion of 
proteins with less than 5 kDa weight (Table 9.3).
Our results show overlap with molecules identified in the CSF of adult acute onset MS 
cases by Schutzer et al.13, who performed the mass spectrometry analysis in CSF on CIS 
cases versus established relapsing remitting MS (RR-MS) and controls (Table 9.3). They 
showed proteins that distinguished these CIS patients from both established RR-MS 
and controls. For example, they showed a significant increase of kallikrein-6, dickkopf-
related protein 3 at first clinical onset in comparison to established RR-MS and controls 
(Table 9.3). They also showed a significant increase in contactin-2 (neuronal membrane 
protein) in first-attack MS patients relative to established RR-MS (Table 9.3).13
Our findings illustrate that the neurodegenerative arm of MS neuropathology is 
already active at the earliest stage of clinical disease, also in children. Consistent with 
the findings of others and our own previous studies6, 14-16, we again observed a striking 
lack of myelin proteins in these clear-cut cases of acute demyelination. This may not 
directly imply absence of such free proteins in this type of pathology, but rather it may 
reflect the specific physicochemical properties of the hydrophobic myelin components, 
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and perhaps different pathways of elimination from the CSF (e.g. via draining macro-
phages).17 In any case, we must be cautious in using the dominant presence of CNS gray 
matter over white matter proteins as proof that neurodegeneration is a primary event 
in MS and would precede demyelination. The presence of CNS gray matter may simply 
represent damage by inflammation, and the molecules identified may lead to a better 
understanding of this presumed inflammation induced neurodegeneration. It should 
be stressed that not all differentially abundant proteins were overrepresented in MS; 
some were underrepresented, pointing at more complex mechanisms, such as a pertur-
bation in the physiology of the axoglial apparatus (Table 2 and Tables e-2 and e-3).6 A 
confounding factor in our study could be the fact that, due to the skewed occurrence of 
monophasic disease at younger age, both groups were not matched according to age. 
We doubt, however whether this has influenced the results, as we did not see an age 
effect in our groups on the abundance of the 21 identified proteins.
Of 14 proteins with increased abundance in MS (Table 9.2 and 9.3), two were associ-
ated with the amyloid beta A4 protein family. Amyloid-like protein 2 is mainly concen-
trated at neuronal synapses18 and has a role in memory processes. While, amyloid beta 
A4 protein is associated with neurite growth, neuronal adhesion and axonogenesis 
(Table 9.3). Six (of 14) proteins: contactin-219, neurofascin20, neuronal growth regulator 
1, brevican core protein6, neuronal cell adhesion molecule19 and disintegrin and metal-
loproteinase domain-containing protein 2219 are shown to be located at the paranodal 
and, juxtaparanodal region of the CNS of myelinated axons (Table 9.3). Contactin-2 is 
axonal glycoprotein which is shown at juxtaparanodal domain of myelinated axons.13 
Neurofascin plays a role in the assembly of nodes of Ranvier in the CNS.21 Two isoforms 
of neurofascin are shown to interact with contactin-associated protein and contactin-1 
to form paranodal junction, that attaches the myelin loop to the axon; and helps to sepa-
rate voltage gated sodium channels at node and potassium channels at juxtparanodal 
region.20 Disruption of neurofascin localization shows early changes preceding demy-
elination and remyelination in MS.22 Interestingly, contactin-2 and neurofascin are previ-
ously reported as autoimmune targets in MS.20 Neuronal growth regulator 1 is shown 
to be located at paranodal region of CNS and play a role in axo-glia contact at the node 
of Ranvier. Identification of contactin-2 and neurofascin in CSF of children with MS is 
consistent with a previous study6 however, they did not found significant difference in 
CSF of children with MS and monophasic ADS (Table 9.2 and 9.3). Brevican core protein 
is known as CNS specific proteoglycan19 at the surface of neuroglial sheaths, where it is 
enriched in perisynaptic extracellular matrix.23
Among the proteins with increased abundance in MS (of 14), the proteases/peptidases 
protein named as carboxypeptidase E, plays a role in synthesis of most neuropeptides.24 
Next, disintegrin and metalloproteinase domain-containing protein 22 are highly ex-
pressed in brain and localized at juxtaparanode.19 This molecule presumed to be work 
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as a major neuronal receptor.25 Another brain related protease was kallikrein-6, which 
is a secreted serine protease13, and it is described to regulate early CNS demyelination 
in a viral model (expression in the brain and spinal cord of mice) of MS.26 Additionally 
CSF kallikrein-6 elevated level is reported in MS (adults) as compared to neurological 
controls (Table 9.3).27
Among other proteins with increased abundance in MS (of 14), tyrosine-protein 
phosphatase non-receptor type substrate 1, is implicated in the neurite outgrowth, 
glia-cell attachment and also shown to support adhesions of cerebellar neurons.28 Next 
the highest expression of dickkopf-related protein 3 is reported in the brain and spinal 
cord (Table 9.3).13 Thus the majority of proteins with increased abundance in our MS 
group (compared to monophasic ADS) were neuronal related with the exception of two 
immune function related proteins Ig gamma-1 chain C region and Ig kappa chain V-III 
region POM (Table 9.3).
Our study reports seven proteins with decreased abundance in pediatric-onset MS 
as compared to the monophasic ADS (Table 9.2 and supplementary Table e-3) group. 
Six of these seven proteins have previously been reported as a specific component of 
innate immune functions (Table 9.4). Haptoglobin, an acute phase protein29 was identi-
fied as the most distinctive one (18/29, 18 significant peptides for a total of 29 peptides) 
from those which were elevated in monophasic ADS children (compared to children 
with MS). Another study in adults showed increased haptoglobin concentration in NMO 
comparison to adult MS patients.30 C4b-binding protein alpha chain which is a crucial 
component of complement cascade and inhibits function of complement component.31 
Interestingly, we also found monocyte differentiation antigen CD14, which is shown to 
be mainly expressed on cells of monocytic lineage (macrophages and monocytes).32 
Higher CD14 levels might be linked with increased levels of cytokines triggering inflam-
matory processes in monophasic ADS children. Monocytic cells secrets soluble sCD14 
(activation product of activated monocytes), so this may affect the enormous macro-
phage activation during acute monophasic ADS.33 Among seven identified proteins, 
protein diaphanous homolog 1, has a role in cell adhesion, it is also expressed in brain 
and, its variant are shown to be required for innate immune response to gram-negative 
bacterial infection.34
Overall in the MS group we found a significant over-representation of proteins as-
sociated with changes in CNS gray matter, axons, synaptic regulation, node of Ranvier 
and brain proteases (Table 9.3). Several of these proteins are part of the axoglial ap-
paratus and may relate to disturbances in axo-glia interaction6 (Table 9.3). Two of them 
(contactin-2 and neurofascin) have been identified as possible axo-glial auto-antigens 
in MS.20 The overlap of proteins observed in previous studies6, 13 (Table 9.3) as part of 
the axo-glia apparatus and gray matter provides validation for these proteins. Further 
insight into the role of these proteins in early-onset MS can be useful for disease process 
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understanding and might be useful as a future tool to differentiate MS from monophasic 
ADS in children.
These pathologically relevant proteins (mostly CNS gray matter related), elevated 
in CSF of early-onset MS in children might be involved in early disease mechanisms. 
Further insight into the role of these proteins can be useful for disease process un-
derstanding. Moreover, such proteins might be useful as a future tool to differentiate 
children MS from children with monophasic ADS. In addition, knowing the start of MS 
could immediate an earlier treatment with disease modifying therapies. However, the 
current research is designated as discovery phase study, which serves as a base for the 
follow-up on verification and validation phase studies which can provide in clinically 
valuable biomarkers. In future, it would be interesting to further validate our findings 
with an independent technology more importantly in an independent sample group.
The data presented in this study indicate that monophasic ADS can be differentiated 
from MS in children primarily by CNS gray matter proteins and immune-related proteins. 
Our findings point to perturbed axoglial physiology as a hallmark of the earliest events 
of MS pathogenesis.
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Acquired demyelinating syndromes (ADS) cover a broad spectrum of inflammatory de-
myelinating syndromes of the CNS, of which multiple sclerosis (MS) is the most common 
subtype. This thesis focuses on two relatively rare clinical subtypes of ADS: neuromyelitis 
optica spectrum disorders (NMOSD) and childhood-onset ADS including MS. Awareness 
and recognition of uncommon ADS subtypes are of importance for clinicians, since those 
require a distinct diagnostic and therapeutic approach. In this thesis we aimed to reveal 
the spectrum of ADS by describing the clinical features of NMOSD and childhood-onset 
ADS, in order to improve the diagnostic process. Here, the most important findings from 
our studies are outlined and discussed in relation to other studies. Future directions and 
steps for further research are discussed.
PArt one: neuromyelitis oPticA sPectrum DisorDers
Demographic features of nmosD
NMOSD is a rare variant of CNS inflammation, previously often misdiagnosed as MS.1, 2 
However, treatment regimens and prognosis differ significantly between NMOSD and 
MS and therefore it is important to distinguish these diseases. Prior to our study, in-
cidence numbers of NMOSD in the Netherlands were unknown. Based on results of a 
national centralized NMO expert center, we could asses the mean nationwide incidence 
of AQP4-IgG seropositive NMOSD in the Netherlands is 0.09 per 100,000 people per year 
(chapter 2). The Dutch incidence is within the range of previous reported incidence 
rates which range from 0.05 – 0.4 per 100,000 people.3 It should be noted that these 
are minimum incidence figures, since mild cases and forme fruste types of the disease 
could have been missed. The incidence of NMOSD in the Netherlands is estimated more 
than twice as high in non-Caucasians. Africans seem to be more predisposed to NMOSD 
than whites.3-5 This is supported by a recently reported high incidence of AQP4-IgG sero-
positive NMOSD patients of 0.65 per 100,000 people in a population with 90% people of 
Afro-Caribbean origin.4 Moreover, Afro-Caribbean NMOSD patients are younger at dis-
ease onset, have more multifocal attacks and have a higher likelihood of visual disability 
than Caucasian patients.6 Differences in clinical features and outcomes between ethnic 
groups indicate the need for a future tailored treatment approach for individual groups.
The recently revised diagnostic criteria for NMOSD broaden the clinical spectrum of 
NMO.7 Most importantly, the new diagnostic criteria allow for an earlier NMOSD diagno-
sis8, 9 even under the assumption of an unknown AQP4-IgG status.8 Previously, patients 
had to have optic neuritis (ON) and transverse myelitis (TM) in order to fulfill definite 
NMO criteria.10 Now, AQP4-IgG seropositive patients can be diagnosed with NMOSD af-
ter one event of isolated ON, TM or area postrema syndrome.7 In patients without AQP4-
IgG, dissemination in space with two different core clinical characteristics (Table 1.1) 
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and exclusion of alternative diagnoses are required for NMOSD diagnosis. Recognition 
of NMOSD patients can be a diagnostic challenge since not all NMOSD patients present 
with classical bilateral ON and longitudinally extensive TM (LETM). Spinal cord lesions 
can be short in a minority of the NMOSD cases11, and sometimes even asymptomatic.12 
Clues to a NMOSD diagnosis are a non-Caucasian ethnicity, ON with severe vision loss 
and minimum response to steroids, preceding ON or brainstem syndrome, personal 
or serological evidence of autoimmunity and a brain MRI without MS lesions.12 More 
awareness and better recognition of the broadening clinical spectrum of NMOSD might 
increase the incidence of NMOSD in the future.
the search for new prognostic markers in nmosD
Despite the high specificity of AQP4-IgG for NMOSD, the antibody is present in ap-
proximately 77% of the NMO cases and lacks sensitivity to diagnose all patients with 
NMOSD.7, 13-15 Therefore, researchers focused on identifying new diagnostic and prog-
nostic biomarkers for the AQP4-IgG seronegative NMOSD patients.16, 17 In the past years, 
MOG autoantibodies were evaluated as a potential novel marker for NMOSD.18, 19 In the 
Dutch cohort we have confirmed the presence of MOG-IgG in 33% of the AQP4-IgG 
seronegative patients with a clinical NMOSD phenotype7, including limited forms as 
recurrent ON, bilateral ON and LETM1 (chapter 3). In addition to previous studies, we 
evaluated MRIs for NMO-specific cerebral lesions, which typically occur at sites with high 
aquaporin-4 expression.20, 21 NMO-specific cerebral lesions were absent in the MOG-
IgG seropositive patients which is likely explained by the different underlying disease 
mechanisms.16, 22 In general, MOG-IgG seropositive patients with a clinical NMOSD 
phenotype have a relative benign disease course, which is often monophasic, and if 
relapses occur those are less severe.23-25 However, MOG-IgG seropositive cases with a 
worse disease course including ongoing relapses and disability progression have been 
observed.24-27 At the NMO expert center at Erasmus MC, we follow a few MOG-IgG sero-
positive patients who suffered from frequent disabling relapses and required chronic 
immunosuppressant therapies. This demonstrates the importance of an individualized 
treatment approach and careful consideration of chronic treatment initiation in a sub-
group of MOG-IgG seropositive patients.
Reported MOG-IgG seropositivity rates as percentage of the AQP4-IgG seronegative 
NMOSD cases, including limited forms of NMO like recurrent ON or LETM, range between 
7-39%.23-35 Double seropositive cases (both AQP4-IgG and MOG-IgG) are extremely rare, 
limited to only a few cases.25, 28, 31, 35 Since study protocols and inclusion criteria differ 
between various cohorts, it is not easy to compare MOG-IgG seropositivity rates. At the 
NMO expert center at Erasmus MC we were also interested in limited forms of NMOSD 
and included patients with bilateral ON, recurrent ON and LETM. This and referral bias to 
expert clinics might contribute to differences in reported MOG-IgG seropositivity rates.
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PArt one: neuromyelitis oPticA sPectrum DisorDers
main findings
•  The incidence of AQP4-IgG seropositive NMOSD in the Netherlands is 0.09 per 100,000 people per year.
•  In approximately one-third of the Dutch AQP4-IgG seronegative patients with a clinical NMOSD phenotype 
MOG-IgG is detected.
•  MOG-IgG seropositive patients with a clinical NMOSD phenotype generally have a more favorable 
monophasic disease course than AQP4-IgG seropositive NMOSD patients.
clinical implications
•  MOG-IgG should be tested in AQP4-IgG seronegative patients with a clinical NMOSD phenotype as part of 
their standard diagnostic work up.
Future studies should collect serial serum samples to study if MOG-IgG persists in pa-
tients with a clinical NMOSD phenotype. Furthermore, MOG-IgG seropositive patients 
should be followed in order to investigate if they truly have a more favorable disease 
course than AQP4-IgG seropositive NMOSD patients. Collaborative international stud-
ies in search of new additional biomarkers for NMOSD diagnosis and for establishing 
the prognosis and therapeutic management of individual patients are promising.17, 36, 37 
Recently, it has been questioned whether MOG-IgG seropositivity justifies a diagnosis 
of NMOSD.22 Clinical phenotypes of MOG-IgG seropositive and AQP4-IgG seropositive 
patients overlap. However, there are important differences in their underlying disease 
mechanisms.16, 22 Neuromyelitis optica refers to the classical syndrome as first described 
by Eugene Devic in 1894.38 The old nomenclature became out-dated, since the spec-
trum of NMOSD is growing and includes limited forms of NMOSD as isolated ON, or 
isolated TM, or brainstem syndromes.1, 2, 7 Elevated creatine kinase (CK) levels39-41, and 
hypothalamic endocrinopathies, including symptoms as galactorrhoea42, are examples 
of rare features of NMOSD. Some have proposed the novel umbrella term autoimmune 
aquaporin-4 channelopathy as this term better suits the broad clinical spectrum, which 
includes more than inflammation of the optic nerve and spinal cord.2 In addition, this 
term clearly refers to the underlying disease mechanism. Major disadvantage of this 
term is that it excludes the AQP4-IgG seronegative NMOSD patients, who share clinical 
similarities with the AQP4-IgG seropositive NMOSD patients.43
PArt two: AcQuireD DemyelinAting synDromes in chilDren
Diagnosing childhood-onset ADs
In children with ADS, the most relevant risk parameters for MS can be found amongst 
MRI parameters, which can help to identify the children in whom an incident event of 
ADS represent the first attack of MS. In the past years, several MRI criteria have been 
developed for the diagnosis of ADS, including MS, in children and for the distinction 
from other diseases.44-46
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The current IPMSSG diagnostic definitions for childhood-onset MS, incorporate the 
2010 revised McDonald MRI criteria for MS.47, 48 Aims of the 2010 MRI criteria were to 
simplify the existing criteria49, 50, and to allow for an earlier definite MS diagnosis. Unique 
for the 2010 McDonald criteria is that MS can be diagnosed in patients who fulfill 
criteria for dissemination in time and space, already after a single attack based on a 
single baseline MRI.48 With the 2010 McDonald MRI criteria for relapsing-remitting MS, 
detection of CSF OCB is not obligatory to confirm MS diagnosis. However, in clinical 
practice CSF analysis is often performed in children presenting with CNS demyelination 
in order to exclude alternative diagnoses, most importantly infectious diseases, prior to 
the initiation of acute treatment with intravenous methylprednisolone. Previous studies 
reported the 2010 McDonald MRI criteria allow for an early MS diagnosis in children.51-55 
But the diagnostic accuracy is less when applied in young children and children with 
ADEM.51, 53 Therefore the 2012 IPMSSG stated the McDonald 2010 MRI criteria cannot be 
applied in children less than 12 years old and in children with ADEM at the first event.47 
In chapter 4 we evaluated the utility of the most recent MRI criteria, as per the 2012 
IPMSSG consensus definitions in a Dutch prospective cohort including children with the 
full spectrum of ADS. Here, we demonstrated the 2012 IPMSSG consensus definitions 
allow for an equally reliable but earlier MS diagnosis in all children (including children 
≤12) than with the 2007 IPMSSG definitions. This is beneficial for the adequate counsel-
ling of patients and parents, who face their lives with insecurity. In addition, an earlier 
MS diagnosis allows for earlier initiation of disease modifying therapy (DMT), which 
might be of long-term benefit.56-58
The IPMSSG 2012 definitions also include a revised definition of MS diagnosis after 
ADEM. However, using the IPMSSG definitions, a definite MS diagnosis is observed less 
often than previously reported59 in children initially presenting with ADEM (<10%).47, 60-62 
We endorse the IPMSSG panel’s advice not to apply the 2010 McDonald MRI criteria in 
children with a first event of ADEM. Children with ADEM usually have large and enhanc-
ing lesions47, 59, 60, 63, which could lead to false-positive MS diagnoses. Other MRI criteria 
are more useful to discriminate children with ADEM from those with MS.46 In the Dutch 
cohort it was confirmed that the Callen MS-ADEM criteria (i.e. fulfilling at least 2 out of 3: a) 
absence of a diffuse bilateral lesion pattern, b) presence of black holes and c) ≥2 periven-
tricular lesions) were the most useful criteria to differentiate MS from ADEM in children.64
The Canadian study group proposed new MRI parameters for the prediction of MS 
diagnosis in children with ADS.60 In their large-scale prospective cohort study including 
284 children with ADS, 14 MRI parameters were assessed for MS risk prediction using 
a multivariable prediction model. Here, 57 children were diagnosed with MS during 
follow-up. Two MRI parameters were associated with an increased likelihood of MS 
diagnosis: T1-hypointense lesions and periventricular lesions (Figure 10.1). MS risk was 
highest when both parameters were present. In collaboration with our Canadian col-
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leagues we validated these parameters in a large independent Dutch cohort of children 
with ADS (chapter 5).
Verhey MRI parameters60 were evaluated in both the Dutch retrospective65 and pro-
spective66 ADS cohorts. Overall, we found that the presence of ≥1 T2-periventricular 
and ≥1 T1-hypointense lesions reliably identify children with MS. We found a higher 
sensitivity of 93.3% and specificity 86.7% in the prospective group than in the retrospec-
tive group (66.7% and 85.2% respectively). The higher number of false negatives in the 
retrospective group might be explained by poorer quality of the images. In addition, 
we reported lower specificity in the prospective cohort, than in the original study (87% 
versus 93%).60 In our report we speculated this was caused by the fact that serial imaging 
was not standardly performed in the Dutch cohort and thus fulfillment of dissemination 
in time based on MRI for MS diagnosis might be underappreciated. Currently, one of the 
four children initially classified as false positive is diagnosed with MS during follow-up, 
increasing the specificity of the Verhey criteria to 90% in the prospective cohort.
Nowadays, serial imaging in children with ADS is performed on a more regular basis 
since its importance for early MS diagnosis, monitoring the effect of DMT and surveil-
lance for severe therapeutic side-effects including opportunistic infections such as 
progressive multifocal leukoencephalopathy (PML).67 In our opinion, serial imaging is 
only required in children in whom it might be of clinical relevance, since MRI scans are 
invasive for children. Moreover, an intravenous administration route is required, and 
in younger children there is the additional risk of narcosis. For example, children with 
isolated ON or TM with a normal cerebral MRI at onset have a very low risk for a future 
MS diagnosis61 and in these children continuing serial MRI scans seem not strictly neces-
a b
Figure 10.1 Example of periventricular lesions (arrows) (a) and T1-hypointense lesions (arrows)(b).
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sary. Clinical follow-up and surveillance for new symptoms are sufficient in this specific 
category of children who are at low risk for a future MS diagnosis.
This year novel MRI criteria for the diagnosis of MS were reported.68 The 2016 MS di-
agnostic MRI criteria include two new CNS sites which can contribute to dissemination 
in space: optic nerve lesions and cortical lesions. These criteria need to be validated 
in pediatric and adult cohorts of CNS demyelination. Furthermore, non-conventional 
imaging techniques as diffusion tensor imaging (DTI) should be further studied, as these 
images could be used as a prognostic marker in children presenting with ADS.69 Func-
tional MRI (fMRI) can provide insight into the adaptive and compensatory mechanisms 
in childhood-onset MS.70, 71 Combined with neuropsychological assessments, fMRI might 
provide relevant implications for counselling and rehabilitation strategies.
children versus adults: outcome and management
There are important differences in childhood-onset versus adulthood-onset MS. Chil-
dren with MS can present with a broad spectrum of demyelinating syndromes, includ-
ing ADEM.72 In addition, the differential diagnosis in children is far more complex.73-75 
Children with MS have more frequent and more severe attacks.76-78 Still, children with 
MS take longer to reach stages of progressive disability, but do so at a younger age.79-81 
However, these observations are based on studies conducted prior to the immuno-
modulatory treatment era in children.76, 79, 80 Current recommendation and use of DMT 
in children with MS, likely influences their disease course.82 In chapter 6 we compared 
the disease course in 383 children and adults presenting with CIS. Over 50 percent of 
the included patients were diagnosed with MS during follow-up. 11-16 year-old children 
had the highest rate of MS conversion and the shortest time to MS diagnosis. Overall 
we found a female predominance, but as in line with previous studies not in young 
children who were diagnosed with MS before puberty.83, 84 This suggests sex hormones 
might contribute to the onset of MS.85 Moreover, we found that children with MS more 
frequently had a non-Caucasian ethnicity than adults with MS. Previous studies reported 
a higher vulnerability for ADS and a future MS diagnosis in non-Caucasian children.66, 86-89 
The exact underlying mechanism is unclear, but it might be that those children lack 
certain protective genes since their ancestors were born in countries with a low preva-
lence of MS.66, 90 In addition, a higher load of certain environmental risk factors, as for 
example lower vitamin D levels in Afro-American children, might contribute to a higher 
MS vulnerability in non-Caucasian children. Moreover, non-Caucasian children with MS 
have a higher relapse rate and more severe relapses.91, 92 This indicates the need for fu-
ture tailored treatment protocols for individual groups based on their disease course. In 
chapter 6 we also validated a prediction rule for a future definite MS diagnosis and early 
first-line treatment initiation in 11-16 year-old children. In adult CIS patients with a high 
risk for a future MS diagnosis, it is already common practice to start with DMT at onset.93 
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In children long term effects of DMT are less well known and DMT is only prescribed to 
children with a definite MS diagnosis.82, 94 However, all children who fulfilled our predic-
tion rule had a definite MS diagnosis during follow-up. From an empirical point of view, 
it seems logical to start DMT in an as early as possible stage. However, the effect of DMT 
initiation in children with CIS who are at a high risk of MS needs to be established.
Prognostic markers in childhood-onset ADs
Prospective follow-up studies of children with ADS are of great interest to study the ge-
netic and environmental risk factors that contribute to MS, since any child presenting with 
ADS can be diagnosed with MS in the future. Studying children with ADS could identify 
new MS risk factors and underlying disease mechanisms. As in adults, genetic risk factors 
contribute to MS risk in children.95 The presence of one or both HLA-DRB1*15 alleles confer 
to MS susceptibility in children.61, 95, 96 In a Canadian cohort of 266 children with ADS, in-
cluding 64 children with MS, the increased risk of MS in children harbouring HLA-DRB1*15 
alleles was larger in children who reported a European ancestry (OR 3.3, p=0.001 versus OR 
2.0, p=0.15 in children with a non-European ancestry).95 Besides the major HLA-DRB1*15 
risk allele for MS, 200 SNPs with a relatively small effect on MS risk have been identified.97 
In chapter 7 we studied the effect of 57 MS risk SNPs98 (at that time known from a large-
scale international GWAS) in children with ADS in collaboration with the Canadian study 
group for childhood-onset ADS. Using a compound weighted genetic risk score, we found 
higher risk scores in children diagnosed with MS than in children with monophasic ADS. 
The genetic risk score of children with monophasic ADS was equal to the risk score of 
healthy controls. From this study we learned, genetic risk loci known from adults with 
MS also confer to increased MS susceptibility in childhood. The ability of the genetic risk 
score to discriminate between children with MS and monophasic ADS was moderate 
and comparable with the model for adult MS and controls. This risk model is of interest 
for studying genetic risk effects in groups of patients, but is not useful for prediction of 
the disease course in individual cases. Interestingly, the combined effect of 57 minor risk 
genes exceeded the effect of the major MS risk allele HLA-DRB1*15 alone. Whether the 
very same risk loci are involved in childhood-onset and adult-onset MS, and among vari-
ous ethnicities, remains to be elucidated. The identification of novel genetic risk factors in 
childhood-onset ADS might reveal new pathways for MS disease mechanisms and future 
therapeutic intervention strategies.99 However, future genetic studies are complicated by 
the requirement of large sample sizes. It would be interesting to study the effect of the 
currently 200 risk SNPs97 in a more complex prediction model for childhood-onset MS, in-
cluding HLA-DRB1*15, EBV serology and vitamin D levels. In a recent American prospective 
cohort study, no association was found between the compound genetic risk score of 110 
MS risk SNPs and relapse rate.100 However, only children with CIS and MS were included in 
this study, and not the full spectrum of childhood-onset ADS.
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Besides genetics, several environmental factors contribute to MS risk in childhood, 
including vitamin D level. In a Canadian cohort of 302 children with ADS every 10 nmol/L 
decrease in 25-hydroxyvitamin D levels led to an increased MS risk (HR 1.11, CI 1.0-1.25).61 
Furthermore, an increase in vitamin D levels was associated with decrease in relapse rate 
in a retrospective study of 110 children with CIS and MS.101 Recently is has been reported, 
this association is linked to children carrying at least one HLA-DRB1*15 allele.100 Whether 
vitamin D suppletion has a therapeutic effect on CNS demyelination is unknown.102 In 
the Netherlands vitamin D suppletion is recommended in healthy toddlers by the Dutch 
Health Council. At the outpatient clinic in Erasmus MC Sophia, vitamin D suppletion is 
started in children with 25-hydroxyvitamin D levels below the normal threshold (≤ 50 
nmol/L)103 for the purpose of their general health and normal bone growth. Remote EBV 
infection contributes to MS risk in adults and children.61, 104-107 This is recently confirmed 
in a prospective Canadian study including 247 children with ADS, of whom 58 were diag-
nosed with MS.108 Eighty-five percent of the children with MS, compared with 44% of the 
children with monophasic ADS, were seropositive for remote EBV infection (HR 3.6, CI 1.6 
– 7.9). Increased rates of EBV viral reactivation, as measured by monthly oral swabs, were 
found in children with MS (average detection rate 50.6% in patients with MS and 20.4% 
in controls, p=0.01).109 Suggesting a selective impairment in the immunological control 
of EBV in children with MS. On the other hand, MS risk is lower in children who had a 
previous CMV infection.107, 108 One American cohort study in 189 children with MS and 38 
controls reported higher levels of antibody response to EBNA-1 in HLA-DRB1*15 positive 
children.110 Their results demonstrate a possible gene-environment interaction in the 
disease mechanism of MS, in which genotype influences the humoral response to EBV. 
In adults, gene-environment interactions have been described between environmental 
factors as smoking and obesity and HLA-DRB1*15.102
mog-igg in childhood-onset ADs
MOG-IgG further elucidates the spectrum of childhood-onset ADS and is mainly detect-
ed in young children with an ADEM-like disease onset, including polyfocal symptoms 
and often encephalopathy.111-115 In the Dutch cohort we identified MOG-IgG in 21 out 
of 117 (18%) children with ADS (chapter 8). Most of the MOG-IgG seropositive children 
had a polyfocal disease onset (86%), of whom 10 children had encephalopathy, fulfilling 
2012 IPMSSG criteria for ADEM.47 In contrast, MOG-IgG was detected in only one of the 
adults with ADEM (3% versus 42% in children with ADEM), confirming that MOG-IgG is 
especially detected in young patients. In this study we reported 4 children with a rela-
tively new ADS phenotype of ADEM followed by recurrent optic neuritis (ADEM-ON).116 
Interestingly, all of the 4 children with ADEM-ON were MOG-IgG seropositive. Currently, 
we have included 7 children with ADEM-ON in the prospective ProudKids study. In one 
child MOG-IgG was not detected, nor was AQP4-IgG, despite sequential sampling and 
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sampling during relapse. In our experience, children with ADEM-ON can suffer from 
severe ON with fast progression of visual loss and frequent relapses. However, they seem 
to recover well with acute treatment with intravenous methylprednisolone. The chronic 
management of children with ADEM-ON is comparable with, and based on experience 
of, treatment of NMOSD.117 Six children with ADEM-ON who had an oral prednisone ta-
per, had relapses when the dose was reduced below 10 milligrams. Therefore we advise 
to decrease the prednisone taper very slowly, depending on the clinical features.
Further studies in international collaboration are needed, so that clinicians can share 
their experiences and study what are the best acute and chronic treatment strategies 
for MOG-IgG associated diseases, including ADEM-ON. Only one of the 21 MOG-IgG 
seropositive children was diagnosed with MS during follow-up. Low titers of MOG-IgG 
can be detected in young children with MS112-114, as was the case in this specific patient 
with MS. The presence of MOG-IgG pleads against MS, as MOG-IgG seropositive patients 
much more likely develop one of the various non-MS ADS subtypes (i.e. CIS, monophasic 
ADEM, multiphasic ADEM118, ADEM-ON or NMOSD). Similar results have been reported 
by the pediatric ADS study group from the United Kingdom.119 Furthermore, MOG-IgG 
has not been detected in adult MS patients at the outpatient clinic of Erasmus MC (un-
published data).
As in adults, MOG-IgG is detected in children with a NMOSD phenotype in whom 
AQP4-IgG was not detected.120 The optic nerve is a frequently involved location in MOG-
IgG seropositive patients.27, 31 MOG antibodies are specific for CNS demyelination and 
are not detected in other diseases.19 The diagnostic assays improved in the past years 
and the current CBA detecting full-length MOG-IgG reliably identify patients within the 
spectrum of CNS demyelinating disorders. However, the exact role of these antibodies 
is not clear yet. They might induce demyelination, or represent a bystander effect. It is 
unlikely that the antibodies solely reflect fulminant demyelination, since MOG-IgG is not 
detected in all patients with ADEM, or in patients with MS.119, 121 Loss of organisation 
of the cytoskeleton of oligodendrocytes incubated with purified MOG-IgG suggest a 
possible direct pathogenic effect of MOG-IgG.122 Recently, it has been reported that 
MOG-IgG was detected in 7 out of 35 patients (20%) with a symptomatic primary EBV 
infection and in none of the controls.123 This finding suggests EBV might be a possible 
trigger for MOG-IgG associated CNS demyelination. Further studies investigating the 
role of MOG-IgG and the pathogenesis of CNS inflammation are of interest, since those 
could shed light on new therapeutic interventions. However, MOG-IgG is already of 
relevance for clinicians, since the antibodies are specific for CNS demyelinating diseases 
and can aid in the diagnostic workup of patients by narrowing the differential diagnosis. 
Furthermore, detection of the antibody is of relevance for patient counselling, since the 
antibodies are present in a subgroup of ADS patients with generally a more favorable, 
non-MS, disease course.119-121
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search for novel biomarkers in childhood-onset ADs
Possible new biomarkers for CNS demyelination can be identified in the exciting field of 
proteomics. The large-scale study of proteins involved in ADS can provide further insight 
into the pathophysiology of MS. We studied the CSF proteome of 39 children with ADS, 
of whom 18 children were subsequently diagnosed with MS (chapter 9). In CSF collected 
at the first clinical event of CNS demyelination, we found peptides relating to 21 proteins 
to be differentially abundant in children with monophasic ADS and MS. Fourteen proteins 
had higher abundance in children with MS than in children with monophasic ADS. Of 
these proteins, 12 were linked to neuronal function and gray matter, illustrating neuro-
degeneration already occurs early in MS. This finding is supported by previous studies 
which reported an abundance of gray matter proteins in early MS.124 Furthermore, some 
of the identified proteins overlap with a previous study, including CSF of 8 children with 
MS and 11 children with monophasic ADS, in which axoglial proteins were detected in 
the children with MS.125 The presence of black holes on MRI at the first event46 and lim-
ited age-expected brain growth and brain atrophy in children with MS126 endorse neu-
rodegeneration occurs at an early stage. Seven proteins were abundant in children with 
monophasic ADS, of which 6 proteins have a role in innate immunity. This demonstrates 
a more innate inflammatory disease mechanism in children with monophasic ADS, which 
might be explained by the children with an ADEM-like onset in this group, who often have 
a monophasic event preceded by infections. Our discovery study of the CSF proteome in 
children with ADS indicates different underlying disease mechanisms in monophasic ADS 
and MS. Future larger-sample size studies, preferably in international collaboration, are 
needed in order to investigate whether certain proteins relate to clinical symptoms and if 
these proteins can predict the outcome of MS diagnosis and relapse rate.
PArt two: AcQuireD DemyelinAting synDromes in chilDren
main findings
•  In children with ADS, MOG-IgG identifies a subset of young children with an ADEM-like phenotype without a 
future MS diagnosis.
•  57 risk SNPs for adult-onset MS are associated with MS risk in children with ADS. The compound effect of 57 
minor risk alleles exceeded the effect of the major MS risk allele HLA-DRB1*15.
•  MRI is an important diagnostic tool in child-hood onset ADS. We found that the Verhey MRI criteria and 
IPMSSG 2012 consensus definitions reliably identify children with MS.
•  Children with CIS have a more inflammatory disease course than adults with CIS, apparent from a higher rate 
of future MS diagnoses and more frequent relapses.
clinical implications
•  MOG-IgG should be tested in children presenting with CNS inflammatory syndromes as part of their 
standard diagnostic work up.
•  The IPMSSG 2012 definitions for childhood-onset ADS, including MS, are validated.
•  We offer a clinical prediction rule, which has to be validated, for early DMT initiation in 11-16 year-old 
children with CIS who are at high risk for a future MS diagnosis.
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Future reseArch
In the past decade, a tremendous growth occurred in the knowledge of NMOSD and 
childhood-onset ADS. However, still questions remain concerning exact disease mecha-
nisms and early subtyping and prognosis of ADS. Currently, the cohorts of NMOSD and 
childhood-onset ADS are followed at Erasmus MC within the national NMO and pediatric 
ADS expert centers. As a result of the ongoing studies on NMOSD and childhood-onset 
ADS more epidemiological data in the Netherlands and long-term follow-up reports are 
expected. Specifi c recommendations for further studies regarding the results reported 
in the chapter 2 – 9 are described in the previous paragraphs of the general discus-
sion. The main goal of ADS research is summarized in Figure 10.2. In this model the ADS 
subtype and disease course are predicted for individual patients based on their clinical 
features, exposure to certain environmental factors, genetic profi le, biomarkers and 
MRI features. The aim of future research is to identify novel prognostic and diagnostic 
markers which can predict the ADS subtype and determine the prognosis of individual 
patients more precisely.
Future international collaborative studies are very welcome to gain more insight 
into the disease mechanisms of NMOSD and childhood-onset ADS. Such studies are of 
importance to increase the number of included patients to achieve suffi  cient statistical 
power. International collaborative studies are of interest to investigate if the outcome 
of ADS diff ers in various world regions127, and might reveal new environmental factors 
Clinical Features 
Gender, age at onset, encephalopathy 
Biomarkers 
MOG-IgG, AQP4-IgG, CSF OCB 
Novel antibodies  
MRI features 
Periventricular lesions, T1-hypointense 
lesions, LETM, DTI, fMRI 
Disease course 
ADS subtype 
Treatment response 
Genetic profile 
HLA-DRB1*15, 200 MS risk SNPs 
Epigenetics 
Environmental factors 
EBV, 25-hydroxyvitamin D  
Microbiome 
PREDICT  
Figure 10.2 This fi gure presents the main goal of ADS research: the accurate and early prediction for indi-
vidual patients of their ADS subtype and disease course based on their clinical features, prognostic markers 
and additional laboratory and MRI studies. In addition, possible novel prognostic and diagnostic markers 
are presented (black).
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involved in the pathogenesis of ADS. Ongoing prospective studies in NMOSD and 
childhood-onset ADS include the search for novel prognostic biomarkers and require 
large-scale standardized storage of blood and CSF samples (biobanking).128 Novel bio-
markers are needed to further specify the subtypes of ADS and determine the prognosis 
of individual patients. AQP4-IgG and MOG-IgG are useful markers in patients presenting 
with a first event of ADS and identify patients who are likely to have diseases distinct 
from MS.7, 19 However, AQP4-IgG and MOG-IgG lack sensitivity to accurately subtype all 
patients with ADS. Future serum and CSF immunohistochemistal studies might reveal 
novel antibodies associated with ADS.
An exciting new focus in MS research is the gut microbiome. The gut microbiome has 
an important role in normal immune function.129 The composition of the gut microbiota 
might represent a propagating factor for inflammatory signalling in MS.130 A recent Ger-
man study with a mouse model for human MS, presented at the 31st Congress of the Eu-
ropean Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), reported 
that mice who received a poop transplant from a monozygotic twin with MS got worse 
disease than mice who received a poop transplant from the healthy twin.131 These results 
suggest that the gut microbiome represent a propagating factor for MS rather than just 
a consequence of MS. American studies including relatively small sample sizes, already 
reported some microbiota stems are associated with pediatric MS and a higher relapse 
rate.132, 133 Further studies in this novel field, including children with a European diet, 
are exciting as those studies might identify novel (supportive) therapeutic strategies. 
Likewise, such studies would be interesting in other autoimmune diseases, including 
NMOSD.
Furthermore, international collaboration would allow for larger sample sizes and 
genome-wide association studies in patients with various ethnicities. Such large-scale 
genetic studies might reveal new specific risk genes for childhood-onset ADS and for 
NMOSD. In addition, international collaboration would allow discovering the field of 
epigenetics, which is the study of heritable changes in genome function without un-
derlying modifications in their nucleotide sequence.134 Epigenetic modifications are the 
crossroad between environmental and genetic modifications and might reveal future 
diagnostic and therapeutic targets in ADS patients.
Future prospective studies including a broader spectrum of CNS inflammation with 
ADS and other autoimmune diseases (for example sarcoidosis, vasculitis or SLE) would 
be of great interest to study early prognostic and diagnostic markers in patients pre-
senting with an incident event of CNS inflammation. Such an approach would resemble 
clinical practice, but is hampered by the rarity of these disorders.
Future research will focus on the improvement of treatment strategies. Novel thera-
peutic trials are underway both in the field of NMOSD and MS.2, 135-137 As the number 
of chronic treatment possibilities is growing, a future individual treatment approach is 
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encouraged.138 In this concept of personalized medicine the decision for chronic treat-
ment initiation is based on an individual risk benefit analysis. Genetic profiling might 
contribute tothis personalized medicine approach, since certain single-nucleotide 
polymorphisms are associated with treatment response to interferon-β.139 Moreover, 
FCGR3A genetic polymorphisms were associated with incomplete B-cell depletion and 
more than a 5-fold higher increased risk for relapses in NMOSD patients treated with 
rituximab.140
Future directions
•  Ongoing prospective long-term follow-up studies of NMOSD and childhood-onset ADS at Erasmus MC in 
order to determine epidemiological data and search for new potential risk factors.
•  Sequential serum sampling and follow-up of MOG-IgG seropositive patients in order to determine their 
long-term prognosis.
•  International collaborative studies in NMOSD and childhood-onset ADS for novel prognostic factors and 
diagnostic biomarkers including:
 - serum and CSF immunohistochemistal studies in search of possible novel antibodies.
 - exploring the gut microbiome as a possible propagating factor for CNS inflammation.
 - (epi)genetic studies.
•  Validation of the 2016 MS diagnostic MRI criteria in childhood-onset MS, plus studying non-conventional 
imaging techniques as potential diagnostic marker for ADS subtype and cognitive outcome.
•  Initiation of prospective studies including a broader spectrum of CNS inflammation with ADS and other 
autoimmune diseases to study early prognostic and diagnostic markers in patients presenting with an 
incident event of CNS inflammation.
•  International collaboration in order to optimize and study therapeutic treatment strategies in NMOSD and 
further evaluation of MS therapies in clinical trials in children.
•  The search for parameters which support a personalized medicine approach for individual patients should 
be further elaborated, as there is an urgent need for such parameters in clinical practice.
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summAry
Acquired demyelinating syndromes (ADS) are a group of immune mediated CNS inflam-
matory diseases, of which multiple sclerosis (MS) is the most common subtype. ADS 
cover a broad spectrum of clinical phenotypes with either a monophasic or relapsing 
disease course. These syndromes overlap and therefore can be difficult to recognize and 
distinguish. However, awareness and recognition of the various ADS subtypes are of 
importance for clinicians, since those require a distinct diagnostic and therapeutic ap-
proach. This thesis focuses on two relatively rare subtypes of ADS: neuromyelitis optica 
spectrum disorders (NMOSD) and childhood-onset MS. 
chapter 1 describes the heterogeneous spectrum of ADS, and the current knowledge 
of NMOSD and childhood-onset ADS respectively. NMOSD is a rare variant of MS, char-
acterized by optic neuritis and transverse myelitis. In the majority of NMOSD patients 
serum aquaporin-4 antibodies (AQP4-IgG) are present. Next to this, the clinical spectrum 
of ADS in children, as well as the risk factors for childhood-onset MS and its disease 
course are described. 
The first part of this thesis goes into NMOSD in the Netherlands. One of the goals of 
our research project was to gain epidemiological figures of NMOSD in the Netherlands. 
Here, AQP4-IgG is tested in one centralized Dutch NMO expert centre, which provides 
a unique change to assess a nationwide incidence figure. In chapter 2 we report ap-
proximately 15 AQP4-IgG seropositive NMOSD patients are detected per year in the 
Netherlands. The mean incidence of AQP4-IgG seropositive NMOSD was calculated at 
0.09 per 100,000 people, which is nearly one in a million. However, it is estimated that 
77% of the NMOSD patients are AQP4-IgG seropositive, meaning nearly one quarter of 
the NMOSD patients are not identified by AQP4-IgG testing. Another goal of our study 
was to identify new possible biomarkers for AQP4-IgG seronegative NMOSD patients. 
In chapter 3 we studied if antibodies directed to myelin oligodendrocyte glycoprotein 
(MOG-IgG) are a possible diagnostic and prognostic marker for AQP4-IgG seronegative 
NMOSD patients. We found that 20 patients out of 61 AQP4-IgG seronegative patients 
were MOG-IgG seropositive. MOG-IgG seropositive NMOSD patients more frequently 
were males and had a Caucasian ethnicity compared with AQP4-IgG seropositive 
NMOSD patients. In addition, MOG-IgG seropositive NMOSD patients more frequently 
had coincident optic neuritis and transverse myelitis, and in general had a more favor-
able monophasic disease course than AQP4-IgG seropositive NMOSD patients. 
The second part of this thesis describes the spectrum of ADS in children. The main goal 
of our studies on childhood-onset ADS is to find potential markers which can identify the 
children in whom an incident event of ADS represents the first attack of MS. In chapters 
4 and 5 the role of magnetic resonance imaging (MRI) was studied as a diagnostic and 
differentiating tool for children with ADS. We validated the 2012 revised diagnostic defi-
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nitions for childhood-onset ADS (chapter 4) and found that the new diagnostic criteria 
allow for a safe and early MS diagnosis, which is beneficial for patient counselling and 
early chronic treatment initiation. In addition, the Verhey MRI criteria (i.e. presence of 
T1-hypointese and/ or periventricular lesions) for the prediction of MS were validated in 
our large independent Dutch cohort of children with ADS. These criteria reliably identify 
children with MS (chapter 5). In chapter 6 the disease course after a first event of non-
encephalopathic CNS demyelination (CIS) was compared between children and adults. 
Children with CIS have a more inflammatory disease course than adults, appearing from 
the high rate of MS conversion and the shortest time to MS diagnosis, higher annualized 
relapse rates, higher MRI lesion load and a more inflammatory CSF profile. This could 
argue for early initiation of first-line disease modifying therapy in children with CIS who 
are at high risk for a future MS diagnosis in line with current clinical practice in adults. 
Therefore we offer a clinical prediction rule which might be used for early treatment 
initiation in future 11-16 year-old children with CIS who are at high risk for MS.
Genetic risk loci identified in adults with MS were studied in children with ADS in chap-
ter 7. Using a combined weighted genetic risk score we investigated if these genes are 
associated with a risk for childhood-onset MS, and if these genes can predict MS diagnosis. 
We found significant higher weighted genetic risk scores in children with MS than in chil-
dren with monophasic ADS. The 57 genetic risk loci alter small risk effects, however when 
combined they exceeded the effect of the major risk gene in MS HLA-DRB1*15. 
In chapter 8 we studied the ability of MOG-IgG to differentiate between ADS subtypes 
and found that MOG-IgG was present in 18% of the children with ADS. MOG-IgG was 
especially detected in young children with ADEM and in some children presenting with 
a clinical NMOSD phenotype, who were seronegative for AQP4-IgG. Here, we identified 
four MOG-IgG seropositive children with a newly recognized clinical entity of ADEM fol-
lowed by recurrent optic neuritis (ADEM-ON). Children with ADEM-ON have a relapsing 
disease course, however they do not fulfill diagnostic MS criteria and require a different 
chronic treatment strategy. MOG-IgG was detected in one child with MS who had his 
onset at a young age and had a very low MOG-IgG titer. In general, the presence of 
MOG-IgG is uncommon in MS and pleads against a future MS diagnosis.
We searched for new ADS biomarkers in cerebrospinal fluid (chapter 9) and found 
an increased abundance of CNS gray matter-related proteins in children with MS and 
an increased abundance of innate immunity-related proteins in children with mono-
phasic ADS. The different identified proteins indicate that distinct underlying disease 
mechanisms play a role in childhood-onset monophasic ADS and MS. The abundance of 
CNS gray matter-related proteins in children with MS demonstrate neurodegeneration 
occurs already early in the disease course. 
The main observations from our studies are summarized and discussed in chapter 10. 
Here recommendations for future research are described.
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sAmenVAtting
Verworven demyeliniserende syndromen (Acquired demyelinating syndromes, ADS) 
vormen een groep immuungemedieerde inflammatoire ziekten van het centrale ze-
nuwstelsel (CZS). Multipele sclerose (MS) is het meest bekende subtype en presenteert 
zich vaak op jong volwassen leeftijd. Daarnaast omvat ADS een breed spectrum aan 
klinische presentaties met een éénmalig of een recidiverend beloop. Het is van belang 
om de verschillende subtypes van ADS te kunnen herkennen, omdat dit consequenties 
heeft voor de behandeling. In dit proefschrift ligt het focus op twee relatief zeldzame 
subtypes van ADS: neuromyelitis optica (NMO) en MS op de kinderleeftijd. 
In hoofdstuk 1 wordt het heterogene spectrum van ADS beschreven. Tevens wordt de 
huidige kennis van NMO en MS op de kinderleeftijd samengevat. NMO is een zeldzame 
variant van MS en wordt gekenmerkt door vooral ontstekingen van de oogzenuw(en) en/
of het ruggenmerg. Het merendeel van de NMO patiënten heeft bijzondere antistoffen 
in het bloed (anti-aquaporine-4, anti-AQP4). Daarnaast wordt in dit hoofdstuk het hele 
spectrum van ADS op de kinderleeftijd beschreven, evenals de bekende risicofactoren 
voor MS en het ziektebeloop van MS bij kinderen. 
Het eerste deel van dit proefschrift gaat over NMO. Eén van de doelen van het 
onderzoek was het bepalen van de incidentie van NMO in Nederland. In Nederland 
wordt de antistoftest (anti-AQP4) bij NMO uitgevoerd in één landelijk gecentraliseerd 
laboratorium (Sanquin diagnostiek Amsterdam in samenwerking met het nationale 
NMO centrum in het Erasmus MC). Dit biedt de unieke mogelijkheid om een landelijke 
incidentie van NMO te bepalen. In hoofdstuk 2 rapporteren we dat er ongeveer 15 anti-
AQP4 positieve NMO patiënten per jaar worden gediagnostiseerd in heel Nederland. 
Daarmee hebben we de gemiddelde incidentie van anti-AQP4 positieve NMO berekend 
op 0.09 per 100,000 mensen, wat neerkomt op een kans van bijna 1 op de miljoen. 
Echter, naar schatting heeft ongeveer 77% van de NMO patiënten AQP4-antistoffen. Dit 
betekent dat nagenoeg een kwart van de NMO patiënten niet wordt geïdentificeerd 
door de anti-AQP4 test. Een ander doel van onze studie was om nieuwe biomarkers te 
onderzoeken voor anti-AQP4 negatieve NMO patiënten. 
In hoofdstuk 3 hebben we onderzocht of bijzondere antistoffen gericht tegen mye-
line oligodendrocyt glycoproteine (anti-MOG) kunnen fungeren als een diagnostische 
en prognostische marker in anti-AQP4 negatieve NMO patiënten. We hebben gevonden 
dat in 20 van de 61 anti-AQP4 negatieve NMO patiënten MOG-antistoffen aantoonbaar 
waren. Anti-MOG positieve NMO patiënten waren vaker man en hadden vaker een Kau-
kasische etniciteit in vergelijking met anti-AQP4 positieve NMO patiënten. Daarnaast 
hadden de anti-MOG positieve NMO patiënten vaker tegelijkertijd een oogzenuwont-
steking en ruggenmergontsteking. In het algemeen hebben de anti-MOG positieve 
NMO patiënten vaker een gunstiger en éénmalig ziektebeloop. 
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Het tweede deel van dit proefschrift beschrijft het spectrum van ADS bij kinderen. Het 
hoofddoel van het onderzoek naar ADS op de kinderleeftijd is het vinden van potentiële 
markers die vroeg in het ziektebeloop de kinderen met MS kunnen identificeren, het 
liefst al ten tijde van de eerste aanval. In hoofdstukken 4 en 5 wordt de rol van MRI 
bestudeerd om kinderen met verschillende vormen van ADS van elkaar te kunnen on-
derscheiden. In hoofdstuk 4 onderzochten we de in 2012 gereviseerde internationale 
diagnostische criteria voor ADS bij kinderen. Het blijkt dat deze nieuwe criteria een 
betrouwbare en snellere MS diagnose geven. Dit biedt voordelen voor adequate voor-
lichting van patiënten en hun families en biedt de mogelijkheid om vroeg te starten met 
onderhoudsbehandeling voor MS. Daarnaast, zijn de Verhey MRI criteria gevalideerd in 
het Nederlandse ADS cohort. Deze Verhey criteria identificeren nauwkeurig de kinderen 
met MS (hoofdstuk 5). In hoofdstuk 6 hebben we het ziektebeloop van kinderen met 
een eerste aanval van CZS demyelinisatie zonder encephalopathie (Clinically isolated 
syndrome, CIS) vergeleken met het beloop van volwassenen met CIS. Kinderen met CIS 
hebben een meer inflammatoir ziektebeloop dan volwassenen, wat blijkt uit het hoge 
aantal MS diagnoses, de korte tijd tot MS diagnose, hoge aanvalsfrequentie, de vele 
afwijkingen op de MRI en het ontstekingsbeeld in het hersenvocht bij kinderen. Dit zou 
een argument kunnen zijn om bij kinderen met CIS en een hoog risico op MS al vroeg 
te starten met ontstekingsremmende onderhoudsbehandeling, zoals momenteel al 
bij volwassen gebeurd. Daarom presenteren we een predictieregel die in de toekomst 
mogelijk gebruikt kan worden om de kinderen met CIS en een hoog risico op MS te 
identificeren.
Risicogenen voor MS, bekend uit het onderzoek bij volwassenen, zijn bestudeerd in 
hoofdstuk 7. Met behulp van een zogenaamde gecombineerde genetische risicoscore, 
die rekening houdt met het effect van de afzonderlijke genen, hebben we onderzocht 
of deze genen zijn geassocieerd met een risico op MS op de kinderleeftijd. We vonden 
significant hogere genetische risicoscores in kinderen met MS in vergelijking met de 
kinderen met éénmalige ADS. De 57 genetische MS risicovarianten hebben afzonderlijk 
een relatief klein effect, maar het gecombineerde effect is groter dan het effect van het 
bekendste en grootste MS risicogen HLA-DRB1*15. 
In hoofdstuk 8 hebben we onderzocht of anti-MOG kan helpen de verschillende ADS 
types bij kinderen te onderscheiden en vonden dat anti-MOG aanwezig is bij 18% van 
de kinderen met ADS. Anti-MOG wordt met name gevonden bij jonge kinderen met 
ADEM en ook bij een paar kinderen met anti-AQP4 negatieve NMO. In deze studie, heb-
ben we vier kinderen gevonden met een nieuwe klinische entiteit van ADEM gevolgd 
recidiverende oogzenuwontstekingen (ADEM-ON). Kinderen met ADEM-ON hebben 
een recidiverend ziektebeeld, maar voldoen niet aan de diagnostische criteria voor MS 
en hebben derhalve ook een andere behandeling nodig. Bij één kind met MS werd een 
laag positieve waarde van anti-MOG gevonden. Dit kind had het debuut van zijn ziekte 
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op zeer jonge leeftijd. In het algemeen, komt anti-MOG niet voor bij MS en pleit de 
aanwezigheid van anti-MOG tegen een toekomstige diagnose MS. 
We hebben gezocht naar nieuwe biomarkers in het hersenvocht van kinderen met 
MS (hoofdstuk 9) en vonden een overschot van eiwitten gerelateerd aan de grijze stof 
van het CZS in het hersenvocht van kinderen met MS. In het hersenvocht van kinderen 
met een éénmalige vorm van ADS hebben we een overschot gevonden van eiwitten 
die gerelateerd zijn aan het aangeboren afweersysteem. Deze verschillende geïdenti-
ficeerde eiwitten suggereren dat verschillende ziektemechanismen een rol spelen bij 
éénmalige ADS en MS op de kinderleeftijd. Het overschot van eiwitten gerelateerd aan 
de CZS grijze stof in het hersenvocht laat zien dat neurodegeneratie al vroeg in het 
ziektebeloop optreedt. 
De belangrijkste bevindingen uit onze studies worden samengevat en bediscussieerd 
in hoofdstuk 10. Hier worden ook aanbevelingen gedaan voor toekomstig onderzoek.
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Acquired 
Demyelinating 
Syndromes
 Focus on Neuromyelitis Optica 
 and childhood-onset Multiple Sclerosis
Acquired demyelinating syndromes (ADS) cover a broad spectrum 
of central nervous system (CNS) inflammatory demyelinating syn-
dromes, of which multiple sclerosis (MS) is the most common sub-
type. This thesis focuses on two relatively rare clinical subtypes 
of ADS: neuromyelitis optica spectrum disorders (NMOSD) and 
childhood-onset MS. Awareness and recognition of uncommon 
ADS subtypes are of importance for clinicians, since those require 
a distinct diagnostic and therapeutic approach. Here we aimed to 
reveal the spectrum of ADS by describing the clinical features of 
NMOSD and childhood-onset ADS, in order to improve the diag-
nostic process. In addition, we searched for prognostic and diag-
nostic biomarkers in ADS. 
